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Abstract 
 This thesis reports the use of NAL variants to catalyse the reaction between a 
range of aldehyde analogues and fluoropyruvate, generating two new stereogenic 
centres. These reactions were catalysed by variants of N-acetyl neuraminic acid lyase 
(NAL). Wild-type NAL catalyses the aldol reaction between pyruvate and N-acetyl 
mannosamine (ManNAc) to give N-acetylneuraminic acid (Neu5Ac) whereas the NAL 
variants were evolved to catalyse the aldol reaction between pyruvate and the 
aldehyde analogue DHOB ([2R,3S]‐2,3‐dihydroxy‐4‐oxo‐N,N‐dipropylbutanamide) to 
give DPAH ([5R,6R]‐7‐(dipropylamino)‐4,5,6‐trihydroxy‐2,7‐dioxoheptanoic acid). This 
work has sought to explore the effect on the activity and stereoselectivity of the NAL 
variants with a broader range of substrates. A major challenge was the identification of 
the products of the NAL variant catalysed reactions and to determine the selectivity of 
each NAL variant. 19F NMR spectroscopy was invaluable in aiding characterisation of 
the enzyme reaction products. 
Synthesis of the enzyme substrate where X=NHAc has been of particular focus within 
this work and has provided further insight into the potential importance of the N-
acetyl group in directing the binding of the aldehyde, therefore directing the 
diastereoselectivity. This work has also discovered that the introduction of fluorine 
may have an effect on the energy barrier to the transition state leading to the (4R) and 
(4S)-epimers of the products. However, in the case of more sterically demanding 
aldehydes, the diastereoselectivity is predominantly driven by the initial binding mode. 
This work has provided a more in-depth understanding of the effect of changing both 
the donor and acceptor substrates of the NAL-catalysed reaction. It has also evaluated 
the viability of using NAL variants in the synthesis of fluorinated analogues of N-acetyl 
neuraminic acid. 
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NAL 
N‐Acetylneuraminic acid lyase (unless specified - assume NAL refers to 
N‐acetylneuraminic acid lyase from Escherichia coli.) 
Neu5Ac N‐Acetylneuraminic acid 
NFSI N-Fluorobenzenesulfonimide 
NHAc N-acetyl 
NM Not measurable 
NMR Nuclear magnetic resonance 
NOE Nuclear overhauser effect 
Ns p-Benzylsulfonamide 
PCR Polymerase chain reaction 
PDB Protein data bank 
Petrol Petroleum ether b.p. 40 to 60 °C 
pyr Pyranose 
q Quartet 
QM/MM Quantum mechanic/molecular mechanic 
RT Room temperature 
s  Singlet 
saNAL Staphylococcus aureus N‐acetylneuraminic acid lyase 
SAX Strong anion exchange 
SCX Strong cation exchange 
SDS‐PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Selectfluor 
1-Chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane 
bis(tetrafluoroborate) 
t Triplet 
TBD Triazabicyclodecene 
TEMED N,N,N′,N′‐Tetramethylethylenediamine 
TFA Trifluoroacetic acid 
THB [2R,3R]‐2,3,4‐Trihydroxy‐N,N‐dipropylbutanamide 
TOCSY Total correlation spectroscopy 
Tris.HCl Tris(hydroxymethyl)aminomethane hydrochloride salt 
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Chapter 1 Introduction 
 Biocatalysis can be defined as the exploitation of enzymes in chemical 
reactions.1 Enzymes are fantastically well suited to use in performing chemical 
transformation, as their diverse and complex three-dimensional structures result in 
highly accelerated rates of reaction and often excellent stereoselectivity.2 Furthermore 
enzymes often operate at ambient temperatures under aqueous conditions and 
produce relatively little waste in comparison to traditional catalysts used in organic 
synthesis.3 It is therefore hardly surprising that enzymes have been increasingly used in 
industrial processes.4 Several classes of enzyme have been exploited in the preparation 
of pharmaceuticals and fine chemicals; examples include keto-reductases, lipases and 
aldolases.5 Synthetic applications include techniques such as dynamic kinetic 
resolution, for example in the preparation of chiral amines6 and tandem aldol 
reactions (DERA) used in the synthesis of statins.7 
As organic chemists, it is often necessary to carry out a chemical transformation with 
substrates that do not occur naturally. In order to use an enzyme in the synthesis of a 
non-natural product, it may be necessary to broaden or change the substrate 
specificity of an enzyme. This may be done using a rational design approach where 
certain residues are targeted for mutation; however this approach is only an option if 
the structure and mechanism of the enzyme is well understood.8 Alternatively, 
directed evolution may be employed in order to introduce random mutations, using 
the principle of Darwinian evolution to screen and select those variants that lead to 
the desired changes in selectivity.9,4 In order for an enzyme variant to be suitable for 
use in large scale reactions, it may be necessary to use directed evolution to identify 
variants with higher stability and tolerance to organic solvents.1 
The main focus of this thesis is to investigate the application of enzyme variants in the 
stereoselective synthesis of chiral fluorinated compounds, in particular, fluorinated 
analogues of N-acetyl neuraminic acid. Fluorine is an atom scarcely found in natural 
products.10 Over 130 000 unique natural products have been characterised however 
only five have been identified containing a carbon-fluorine bond.11 Consequently, 
there are very few examples of enzymes that use fluorine;12, 13 one of the rare 
examples is a fluorinase found in Streptomyces cattleya11 which catalysed a 
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substitution reaction in which a fluoride ion displaces L-methionine, forming a C-F 
bond.14, 15 There is evidence that, although Nature did not evolve many enzymes that 
use fluorinated ligands, some naturally occurring enzymes may also turn over a 
fluorinated analogue of their natural substrates.16 While fluorinated natural products 
are rare, fluorinated drugs are very common due to several benefits observed by the 
introduction of fluorine into biologically active molecules.17,18 Considering both the 
trend towards incorporation of fluorine into drugs and the growing use of biocatalysis 
in the synthesis of fine chemicals and pharmaceuticals; combining the two and 
exploiting biocatalysis in the synthesis of fluorinated molecules is a potentially exciting 
area of research. 
The following Sections outline a number of themes that are directly relevant to this 
thesis. First, the value of fluorinated N-acetyl neuraminic acid analogues is described 
(Section 1.1). Secondly, traditional chemical methods for the synthesis of fluorinated 
small molecules is considered (Section 1.2). Finally, an overview of the development 
and application of N-acetyl neuraminic acid lyase (NAL) variants (which have been 
engineered using a combination of rational design and directed evolution) is provided 
in Section 1.3 and 1.4. 
1.1 Relevance of fluorinated sialic acid analogues in medicinal chemistry 
1.1.1 Biological activity and applications of sialic acid analogues 
 Sialic acids are a family of around 50 monosaccharides, including among others, 
N-acetylneuraminic acid (Neu5Ac).19 Neu5Ac is synthesised by N-acetylneuraminic acid 
lyase (NAL), which catalyses both the aldol (forward) and retro-aldol (cleavage) 
reaction between N-acetyl mannosamine (ManNAc) and pyruvate (Scheme 1.1)*. The 
reversibility of the reaction is important in preventing accumulation of toxic levels of 
sialic acid in the cell. Sialic acid plays several important roles in cell biology; however 
increased levels of sialic acid on the surface of cells, which occurs in some cancers, is 
believed to be a contributing factor to the detachment of cells from tumours, resulting 
in metastasis.20 
                                                     
*
 The mechanism of this reaction is discussed in greater detail in Section 1.3.1. 
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Scheme 1.1 - Biosynthesis of N-acetyl neuraminic acid (Neu5Ac) from N-acetyl mannosamine 
(ManNAc) and pyruvate, catalysed by N-acetyl neuraminic acid lyase (NAL). 
The most important application of analogues of sialic acid is in the treatment of 
influenza. Influenza neuraminidase cleaves the terminal sialic acid from 
glycoconjugates preventing viral aggregation so that the virus is consequently released 
from infected cells.21 It is also believed that neuraminidase may affect respiratory tract 
mucus in such a way as to increase viral penetration into epithelial cells.22 Inhibition of 
neuraminidase has therefore become a widely employed approach for the treatment 
of influenza. 
Several sialic acid analogues have been shown to inhibit influenza neuraminidase. Well 
known drugs such as Zanamivir (Relenza™)21,22,23 and Oseltamivir (Tamiflu™)24,25 are 
potent influenza neuraminidase inhibitors (Figure 1.1). Oseltamivir is a pro-drug; the 
active compound (Figure 1.1b), known as GS4071,25 was discovered to be a potent 
inhibitor of influenza A and B neuraminidase. 
 
 
Figure 1.1 - Structure of inhibitors of influenza neuraminidase. a) Zanamivir (Relenza™). b) Oseltamivir 
(Tamiflu™). Oseltamivir is activated in vivo by hydrolysis of the ester to give GS4071. 
 
In 1998, a new series of carboxamide type neuraminidase inhibitors containing an 
amide group at C-6 was discovered (Figure 1.2). Structure–activity relationships of the 
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carboxamide compounds revealed that tertiary amides were more potent inhibitors 
than secondary amides.26, 27 These analogues inspired research into the engineering of 
NAL to accept a broader variety of substrates;28 and this work will be covered in 
greater detail in Section 1.4. 
 
Figure 1.2 – Carboxamide influenza neuraminidase inhibitors 
1.1.2 The importance of fluorine in medicinal chemistry 
 It was first demonstrated in 1954 that introduction of fluorine into the drug 
cortisol, improved its therapeutic properties. Since then, the popularity of introducing 
fluorine into biologically active compounds has grown rapidly and now fluorine is 
found in around 15-20% of new drugs licensed.17,18 A review of the top selling drugs in 
201229 revealed several examples containing fluorine, including Crestor (Figure 1.3a), 
and Lipitor (Figure 1.3b) (generic name atorvastatin), this has been a top selling drug 
for several years and was ranked top in terms of sales (in US$) in 200818 and 2011.30 
Table 1.1 outlines the fluorine-containing drugs in the top 50 of all pharmaceuticals 
(based on US sales in 2012).29 
 
Figure 1.3 - Examples of two top selling fluorinated pharmaceuticals, both used in the treatment of 
high cholesterol a) Crestor and b) Lipitor 
 
Chapter 1 - Introduction 
 
5 
 
Table 1.1 - Top selling organofluorine pharmaceuticals based on US sales in US$ in 2012
29
 
 
Position in sales (2012) 
relative to all drugs 
Name US sales in 2012 
/$ × 10
9
 
3 Crestor 4.8 
4 Advair Diskus 4.6 
13 Atripla
a 
2.8 
18 Januvla 2.5 
20 Truvada
a 
2.2 
21 atorvastatin
b 
2.1 
26 Celebrex 1.9 
31 Lipitor
b 
Not available 
39 Zetia 1.4 
a) Name for a combined therapy incorporating the fluorinated pharmaceutical emtricitabine along with 
other molecules. b) Atorvastatin is the generic name for Lipitor, the statistics report the sales of the 
generic drug and the brand named drug separately. 
The popularity of incorporating fluorine into biologically active compounds is as a 
result of the enhanced properties of fluorine-containing drugs.31 The introduction of 
fluorine into drug molecules has an effect on several aspects of the drug’s properties, 
such as binding, absorption through the membrane and bioavailability, distribution, 
metabolism, pharmacokinetic, pharmacodynamic and excretion.32 There are several 
cases where fluorine or trifluoromethyl groups, for example, have been used to 
replace other groups of similar size. The introduction of fluorine usually leads to 
increased lipophilicity, which can improve transport into the active site. Also, fluorine 
can modulate the pKa of neighbouring groups.32 
Fluorine exists naturally as the 19F isotope. This isotope is spin-active and therefore 
fluorine incorporation can be viewed easily by NMR spectroscopy.33 There is a second 
isotope of fluorine; 18F, which is positron–emitting, and can be incorporated into drug 
molecules and used as a diagnostic tool to visualise uptake, transport and excretion of 
a drug.31 
1.1.3 The gauche effect in organo-fluorine molecules 
 One of the properties of fluorine which makes it interesting to study is its effect 
on the conformation of small molecules. Gauche effects, where vicinal groups 
preferentially adopt a gauche conformation over an anti conformation, are widely 
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reported in organo-fluorine compounds where a carbon-fluorine bond is vicinal to a 
second carbon-fluorine bond (Figure 1.4).34 The energy difference between the gauche 
and anti conformations has been calculated to be in the region of 2-4.2 kJmol-1 and the 
preference appears to dominate over the lone-pair repulsion between fluorine 
atoms.34  
 
Figure 1.4 - The gauche effect in 1,2-difluoro ethane  
The gauche preference is also observed between carbon-fluorine and a vicinal 
polarised bonds, such as carbon-oxygen or carbon-nitrogen bonds. DFT calculations 
have been used in order to evaluate the gauche preference in 2-fluoroethylamine and 
2-fluoroethanol and the observations are summarised in Figure 1.5.35 Rotating around 
the carbon-heteroatom bond reveals that when a lone-pair is pointing towards the 
fluorine, these conformations are less stabilised by the gauche effect compared to the 
conformation in which a proton is pointing towards the fluorine. In the corresponding 
ammonium and oxonium ions, the stabilisation as a result of the gauche effect is 
predicted to be greater. 
 
Figure 1.5 - Gauche preference of different conformations of 2-fluoroethylamine and 2-fluoroethanol. 
The scale refers to the relative stabilisation of the gauche conformation compared to the anti 
conformation. 
1.1.4 Potential value of fluorinated sialic acid analogues 
 It is rare to encounter a drug with a chiral sp3 hybridised carbon attached to a 
fluorine atom. (The only example in Table 1.1 is the steroid derivative Advair Diskus.) 
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Most of the sialic acid analogues discussed previously contained several sp3 hybridised 
carbons and multiple chiral centres. The lack of fluorine-bearing chiral centres in 
pharmaceuticals is most likely due to the difficulty presented by stereoselectively 
introducing a fluorine atom into a molecule. Development of a novel method utilising 
enzyme variants for introducing a fluorine-bearing chiral centre with high levels of 
stereocontrol into sialic acid analogues may provide a new route to interesting, highly-
chiral and potentially biologically active small molecules bearing multiple chiral 
centres. 
1.2 Chemical methods for the synthesis of organo-fluorine molecules 
1.2.1 Aldol reactions of -fluoro ketones 
 NAL, the enzyme responsible for the biosynthesis of sialic acid is an aldolase 
enzyme. In the NAL active-site, the aldol reaction is accelerated by a catalytic lysine 
residue which forms a Schiff-base then an enamine in the active-site of the enzyme 
(see Section 1.3.1). This method of enamine catalysis of aldol reactions has been 
mimicked using chemical methods by exploiting amine catalysts.  
The aldol reaction between aryl aldehydes and fluoroacetone has been evaluated with 
different catalysts. The diastereoselectivity of an aldol reaction is governed by both the 
enamine geometry and the facial selectivity. It is possible that the gauche effect may 
be a contributing factor in controlling the enamine geometry of -fluoro-ketones (see 
Section 1.1.3). Catalyst 3a36 and 3b37, 38 are derived from L-proline and selectively give 
anti-diastereoselectivity whereas catalyst 3c37 is a primary amine and gives syn-
diastereoselectivity (Figure 1.6). The diastereoselectivity of the aldol reactions of 
fluoroacetone are presented in Table 1.1. By way of comparison, the 
diastereoselectivity observed for catalyst 3c with pentan-3-one has been presented as 
the gauche effect in this case will have no impact on the enamine geometry, therefore 
diastereoselectivity. 
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Figure 1.6 - Catalysts of asymmetric aldol reactions of aryl aldehydes and fluoroacetone (see Table 
1.2) 
 
Table 1.2 - Diastereoselectivity of the reaction between aryl aldehydes and fluoroacetone with a 
selection of catalysts
36,37, 38
 
 
Entry Aryl X R Catalyst Yield % d.r. (anti:syn) ee % 
1 p-NO2 F CH3 3a (33 mol%) 82 70:30 84 
2 p-NO2 F CH3 3b (20 mol%) 96 67:33 95 
3 p-NO2 F CH3 3c (20 mol%) 45 7:93 99 
4 o-NO2 F CH3 3c (20 mol%) 82 <6:>94 98 
5 m-NO2 Me Et 3c (20 mol%) 82 20:80 80 
 
The catalyst has a profound effect on the diastereoselectivity, which can be 
rationalised by considering the organisation of the possible transition states (Figure 
1.7). The prolinol catalyst 3a is predicted to react via a chair-like transition state where 
the facial selectivity is governed by hydrogen bonding between the hydroxyl proton 
and the aldehyde. The aryl and the fluorine both adopt a pseudo-equatorial position in 
order to reduce 1,3-steric interactions (Figure 1.7a).36 Catalysts 3b and 3c are proposed 
to direct the facial selectivity via hydrogen bonding interactions between the side 
chain and the aldehyde. In the case of the secondary amine catalyst 3b it is predicted 
that the (E)-enamine is preferred in order to reduce the steric clash between the 
fluorine and the protons of the pyrrolidine ring (Figure 1.7b)38 whereas in the case of 
the primary amine catalyst 3c, the (Z)-enamine is preferred in order to reduce steric 
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interaction between the fluorine and the methyl group (Figure 1.7c).37 However, the 
gauche effect may be used to explain the large difference in diastereoselectivity 
between the reaction of fluoroacetone (Entries 3 and 4) and pentan-3-one (Entry 5). 
 
Figure 1.7 - Transition state diagrams to rationalise the diastereoselectivity of amine catalysed aldol 
reaction of fluoroacetone. a) Prolinol catalyst 3a is predicted to give anti diastereoselectivity therefore 
both the aryl group and the fluorine will be in the pseudo-equatorial positions in the chair-like transition 
state. b) Secondary amine catalyst 3b is also predicted to give anti diastereoselectivity via the (E)-
enamine in order to reduce steric interaction with the protons of the pyrrolidine. c) Primary amine 
catalyst 3c is predicted to give syn diastereoselectivity via the (Z)-enamine, which may be driven by 
steric clash with the methyl group plus the preference for fluorine to adopt a gauche conformation 
relative to a vicinal polarised bond. 
 
1.2.2 Carbon-fluorine bond forming reactions 
 There are two main classes of reagents used for making carbon-fluorine bonds 
referred to as nucleophilic and electrophilic fluorinating reagents. There are several 
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methods in the literature that exploit nucleophilic reagents for the introduction of 
fluorine functionality;39,40 one such example is in the enantioselective synthesis of a all-
syn four vicinal fluorine motif by a series of carefully controlled SN2 reactions with 
nucleophilic fluorine sources.41  Nucleophilic fluorinating reagents are important for 
the introduction of radioactive 18F into molecules for radio-labelling studies.42 
However, the main drawback of nucleophilic fluorinating chemistry is it does not seem 
to be able to provide much in the way of methods of synthesis of fluorine-bearing 
chiral centres from achiral starting materials. In order to look into stereoselective 
methods of fluorination, it is necessary to consider electrophilic fluorinating reagents.  
The two most widely used electrophilic fluorinating reagents are N-
fluorobenzenesulfonimide (NFSI) 7 and 1-alkyl-4-fluor-1,4-diazoniabicyclo- 
[2.2.2]octane salts (Selectfluor) 8 (Figure 1.8).43,44 NFSI and Selectfluor have been used 
in conjunction with catalysts which are able to induce stereoselectivity in order to 
carry out asymmetric fluorination reactions.44-49 
 
Figure 1.8 – N-fluorobenzenesulfonimide (NFSI) 7 and general structure of 1-alkyl-4-fluor-1,4-
diazoniabicyclo[2.2.2]octane salts (Selectfluor) 8 
Asymmetric catalysis methods have taken many forms and include both metal catalyst 
with chiral ligands,46 organocatalysts48 as well as some more unusual methods 
including using DNA in catalysis.43 An example of a metal catalysed electrophilic 
fluorination is the use of the palladium catalyst 10  which can be used in conjunction 
with NFSI 7 in order to yield chiral fluorinated products from -keto phosphonate 9 
starting materials (Scheme 1.2).46 
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Scheme 1.2 – Enantioselective palladium-catalysed fluorination of a -keto phosphate. (Absolute 
configuration was not stated.) 
Organocatalysts can also be used to control highly enantioselective fluorination 
reactions. A chiral amine catalyst 13 (a proline derivative) has been used in the 
asymmetric fluorination of achiral aldehydes 12 via an enamine intermediate, which 
then underwent electrophilic fluorination (Scheme 1.3). This method has yielded chiral 
aldehydes 14 with enantiomeric excess of up to 97%.48 
 
Scheme 1.3 – Organocatalysed asymmetric fluorination of aldehydes. 
Organosilanes, in particular allylsilanes have attracted interest in the field of 
electrophilic fluorination chemistry. Allylsilanes are able to undergo regioselective 
fluorination resulting in desilylation and translocation of the double bond (Figure 1.9). 
Regioselectivity is achieved as the carbocation is stabilised by hyperconjugation with 
silicon.44 There are several examples in the literature of asymmetric fluorination using 
allylsilanes. Stereocontrol at the fluorine-bearing chiral centre in the reaction of a 
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terminal organosilane may be achieved by the use of a chiral auxilary,50 or a chiral 
catalyst.51 
 
Figure 1.9 - General scheme for fluorodesilylation of allylsilanes 
Secondary organosilanes may be used in the diastereoselective synthesis of fluorinated 
molecules. One such example is the synthesis of fluorinated carbohydrate analogues 
17a, 17b and 17c (Scheme 1.4). The configuration of the carbohydrate product is 
determined by the configuration of the allylsilane and exploits the preference for 
fluorination to occur anti to the silyl group.45 
Scheme 1.4 - Diastereoselective synthesis of fluorinated analogues of D-glucitol 17a and L-glucitol 17b 
and D-mannitol 17c 
The synthesis of 3-fluoro-sialic acid has been achieved using an electrophilic 
fluorination approach (Scheme 1.5).52 Selectfluor 8 was reacted with the protected 
intermediate 18 in a one-pot fluorination procedure, which is highly diastereoselective, 
giving only the C-3 axial fluorine epimer (controlled by steric effects of the ring). Later 
(Section 1.3.2.2), an alternative route will be discuss which demonstrates that NAL may 
be used in a one-step synthesis of 3-fluoro-sialic acid, avoiding the multi-step synthesis 
of the protected sialic acid analogue 18. 
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Scheme 1.5 – Electrophilic fluorination synthesis of protected 3-fluoro sialic acid 19 from protected 
sialic acid alkene 18. 
1.3 Wild type N-Acetyl-neuraminate lyase (NAL)  
1.3.1 Mechanism of wild-type NAL 
 N-Acetyl-neuraminate lyase (NAL) is a Class I aldolase enzyme which catalyses 
the reversible aldol reaction between N-acetyl-D-mannosamine (ManNAc) and 
pyruvate to give N-acetylneuraminic acid (Neu5Ac) (Scheme 1.6a). This reaction sets 
up one new stereocentre at C-4 and wild-type NAL is highly selective for the (4S)-
epimer. In solution, the -anomer is predominant, but the α-anomer is the substrate 
for the reverse aldolase reaction (Scheme 1.6b).53  
 
Scheme 1.6 - Wild-type NAL-catalysed reaction of ManNAc and pyruvate. The sugars are drawn in 
open form for clarity, which will be the standard format throughout this thesis a) The NAL catalysed 
aldol reaction between ManNAc and pyruvate to give Neu5Ac as the (4S)-epimer. b) In solution, the -
Neu5Ac is in equilibrium with -Neu5Ac. 
 
 There are two types of aldolase enzymes: Class I and Class II, which are characterised 
according to the mechanism by which the aldol reaction is catalysed. Class I aldolases, 
such as NAL, catalyse aldol reactions via formation of a Schiff-base, involving a lysine 
residue in the active site, to form an enamine intermediate.54 Class II aldolases form an 
enolate intermediate stabilised by a metal cofactor (e.g. Zn2+) (Figure 1.10).55  
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Figure 1.10 - Comparison of Class I and Class II aldolases (examples shown are DHAP-dependent 
aldolases). a) Class I aldolases have a catalytic lysine residue in the active site which forms a Schiff-base 
with the donor. b) Class II aldolases incorporate a metal cofactor (zinc in this example) into the active 
site, which forms an enolate with the donor. 
 
The active site of NAL contains three residues, Glu192, Asp191 and Ser208, which form 
hydrogen bonding interactions with the triol chain of ManNAc/Neu5Ac while Lys165 
forms the Schiff-base. This can be seen in the crystal structure of NAL from H. 
influenzae in complex with the 4-oxo-sialic acid inhibitor 20 shown in Figure 1.11.55, 56  
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Figure 1.11  – Representations of key binding interactions between ManNAc/Neu5Ac in the active site 
of NAL, taken from the crystal structure of the 4-oxo-sialic acid inhibitor 20 in complex with NAL from 
H. influenzae. (PDB 1F7B)
56
 (Residues are numbered according to the E. coli. NAL) a) Schematic 
representation of the active site showing the residues which may form hydrogen bonds with the triol 
side-chain of ManNac/Neu5Ac. b) Surface view of the binding pocket in wild-type NAL. c) Hydrogen 
bond distances (Å) between residues important in recognition and the triol of ManNac/Neu5Ac.  
 
As mentioned previously, wild-type NAL is highly diastereoselective, giving only the 
(4S)-epimer of Neu5Ac. Computational QM/MM (Quantum Mechanic/Molecular 
Mechanic) studies have gained information about the origin of this observed 
diastereoselectivity.57 The configuration is determined not only by the relative 
positions into which the pyruvate and the aldehyde bind in the NAL active-site, but 
also by the catalytic residue which is responsible for delivering a proton in the forward 
reaction and removing the proton in the cleavage reaction. QM/MM modelling 
suggests that the residue important in transferring the proton is Y137. The modelling 
studies also suggest that the phenolate anion is stabilised by hydrogen bonding 
interactions with S47 and Y110’ (a tyrosine from a neighbouring subunit). The 
c) 
Glu192 
Lys165 
Ser208 
Asp191 
b) 
Glu192 
Lys165 
Ser208 
Asp191 
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calculated transition state is shown in Figure 1.12a. Replacement of Y137 or S47 with 
alanine was highly detrimental to activity, although the Y110’ was found to be less 
critical. In order for Y137 to be close enough to perform its role in catalysis, ManNAc 
has to bind in such a way that the si-face is presented towards the Schiff base, which is 
consistent with the observed stereoselectivity. It has also been postulated that T167 
forms a hydrogen bond with the aldehyde of ManNAc,58 further directing the position 
of the substrate in the active-site. Additionally, steric interactions between the N-
acetyl group of ManNAc and F252 and hydrogen bonding interactions between the 
terminal alcohol groups of ManNAc and E192 limit the number of possible binding 
modes of ManNAc, resulting in high levels of stereocontrol. A schematic 
representation of the important interactions in the transition state is shown in Figure 
1.12b. 
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Figure 1.12 - Representation of the transition state of the NAL catalysed reaction of ManNAc and 
pyruvate to give Neu5Ac, based on predictions from QM/MM modelling. a) Transition state diagram 
(modified from reference).
57
 b) Schematic representation of forward and retro aldol reactions of Neu5Ac 
catalysed by NAL. Y137 (green) mediates transfers of a proton to the aldehyde in the forward reaction 
and abstracts a proton from the alcohol in the cleavage reaction. The negative charge on Y137 (green) is 
stabilised by S47 (purple) and Y110’ (grey). Hydrogen bonding between the aldehyde oxygen with T167 
(cyan), as well as a steric clash between F252 (lilac) and the N-acetyl group and hydrogen bonding 
between E192 (red) and the terminal alcohol groups help limit the number of binding modes and direct 
the si-face of the aldehyde towards the Schiff base.  
F252 
S47 
T167 
Y137 
K165 
a) 
T48 
Y110’ 
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1.3.2 Substrate specificity of NAL 
1.3.2.1 Acceptors 
 Several substrate studies have been carried out on wild-type NAL and it has 
been found that it will accept a variety of different sugars in place of ManNAc. 
Substitutions at C-2, C-4 and C-6 can be tolerated so long as the absolute configuration 
at these positions is not changed. A summary of some of the accepted substrates and 
relative rates of reaction compared to ManNAc (Entry 1) are given in Table 1.3.54 
Modification to the triol (Entries 2, 3, 4 and 6) has a moderately detrimental effect on 
rate of reaction, which is consistent with the structural evidence (Figure 1.11) which 
indicates that the triol is important in binding. Exchanging the NHAc at C-2 for an OH 
(Entry 5) and replacing the C-2 NHAc with a proton (Entry 7) both slightly improve the 
rate. However, inverting the configuration at C-2 (Entry 8) is extremely detrimental to 
the rate of reaction. The crystal structure shows that the C-2 substituent points out 
into solvent, so inverting the configuration would mean the C-2 substituent would 
instead potentially be pointing back towards the backbone, which may result in an 
unfavourable steric clash. 
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Table 1.3 – Aldehydes accepted by wild-type NAL
54
 
 
Entry R
1
 R
2 
R
3 
R
4 
R
5 
Relative Rate
a 
1 AcNH H OH H CH2OH 1 
2 AcNH H OH H CH2OAc 0.2 
3 AcNH H OH H CH2N3 0.6 
4 AcNH H OH H CH2F 0.6 
5 OH H OH H CH2OH 2 
6 OH H OH H H 0.1 
7 H H OH H CH2OH 1.3 
8 H OH OH H CH2OH 0.07 
a) The rates given are relative to the rate of the wild-type reaction (Entry 1) 
1.3.2.2 Donors 
 There has been some contradiction over whether or not 3-fluoropyruvate can 
be accepted in place of pyruvate by NAL in reaction with ManNAc. In 1996, one group 
concluded that 3-fluoropyruvate is not a viable substrate for wild-type NAL and 
therefore cannot be used to synthesise 3-fluoro-N-acetyl neuraminic acid (3-fluoro 
Neu5Ac, 21)59, while another group claimed that fluoropyruvate acts as a competitive 
inhibitor of NAL.60 The vast majority of evidence however demonstrates that 3-
fluoropyruvate is a viable substrate for wild-type NAL and the reaction between 3-
fluoropyruvate and ManNAc will result in the production of 3-fluoro Neu5Ac 21 
(Scheme 1.7).16, 57, 61, 62 
NAL, in reaction with ManNAc and pyruvate, is highly selective towards the (4S)-
epimer. The NAL-catalysed reaction between ManNAc and 3-fluoropyruvate is further 
complicated because the reaction creates two new stereocentres at C-3 and C-4. All 
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previous studies seem to be in agreement that NAL retains its C-4 stereoselectivity* 
and the two (4S)-epimers of 3-fluoro-Neu5Ac 21 are not observed.16, 57, 61, 62 
 
Scheme 1.7 - Wild-type NAL-catalysed reaction between 3-fluoropyruvate and ManNAc. The reaction 
sets up two new stereocentres so there is the possibility of forming one or more of 4 diastereomers. 
Previous studies have shown that only the two (4R)-epimers (3R,4R)-21 and (3S,4R)-21 are observed. 
There is however disagreement over the control of the configuration at C-3 and several 
studies have reported different ratios of products under various reaction conditions.16, 
61, 62 The work that directly precedes this thesis found that when using ManNAc in a 5-
fold excess over 3-fluoropyruvate, after a reaction time of approximately 500 minutes 
(the time taken for all of the 3-fluoropyruvate to be consumed) that the ratio of 
products was 90:10 in favour of the product (3R,4R)-21. When the reaction was left for 
a prolonged period of time (approximately 5 weeks) with regular addition of enzyme, 
the ratio of products switches to 70:30 in favour of the product (3S,4R)-21.57 This 
result suggests that the product (3R,4R)-21 is the kinetic product and the product 
(3S,4R)-21 is thermodynamically favoured. 
The kinetic parameters of the wild-type NAL catalysed cleavage of the two 3-fluoro-
Neu5Ac diastereomers were evaluated and compared to Neu5Ac (Table 1.4). The kcat 
of the the reacton with (3R,4R)-21 was found to be 500-fold lower than Neu5Ac and 
the KM four-fold higher, therefore showing that 3-fluoro-Neu5Ac 21 is a very poor 
substrate for NAL.57 This data may explain why a previous study concluded that 3-
fluoro-Neu5Ac 21 wasn't a substrate for NAL.59 The product (3S,4R)-21 was a very poor 
substrate, and it was not possible to determine kcat or KM. This was consistent with the 
                                                     
*
 In 3-fluoro-Neu5Ac, the priority of the groups surrounding C-4 changes so that the same relative 
configuration which for Neu5Ac would be called (4S), in 3-fluoro-Neu5Ac is called (4R). 
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observed switch in selectivity over prolonged reaction times, suggesting that only the 
product (3R,4R)-21 is able to undergo the cleavage reaction so the product (3S,4R)-21 
accumulated over time. 
Table 1.4 - Kinetic parameters of wild-type NAL for the cleavage of Neu5Ac, (3R,4R)-21 and (3S,4R)-21. 
Determined using a standard LDH-coupled assay (see Section 1.4.1) at 30 °C.
57
 
NAL substrate kcat /min
-1 KM /mM kcat/ KM /min
-1mM-1 
Neu5Ac 510 ± 11 2.0 ± 0.1 260 
(3R,4R)-21 0.91 ± 0.03 8.4 ± 0.7 0.11 
(3S,4R)-21 -a -a -a 
a) Not measurable under the conditions 
The observed diastereoselectivity of the wild-type NAL-catalysed reactions between 
ManNAc and fluoropyruvate indicate that the preferred enamine geometry is the (Z)-
enamine. This may be related to the gauche effect discussed in Section 1.1.3. Previous 
gas phase computational modelling studies of 3-fluoropyruvate forming a Schiff-base 
with a truncated lysine have shown that there is a preference of 35.3 kJ mol-1 for 
fluorine to adopt a gauche configuration, resulting in a preference for the (Z)-enamine 
(Figure 1.13a).57 Since then, a crystal structure of fluoropyruvate bound in the active-
site of wild-type NAL from S. aureus has shown that the fluorine does adopt a gauche 
configuration (Figure 1.13b).63  
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Figure 1.13 - Configuration of the enamine of fluoropyruvate a) Gas phase optimised calculated relative 
energies of the (E) and (Z)-fluoroenamines form of the complex between 3-fluoropyruvate and a 
truncated lysine reside. b) Crystal structure of 3-fluoropyruvate bound to K165 of NAL from S. aureus 
showing the fluorine atom adopting a gauche relationship relative to the carbon-nitrogen bond.
63
 
Section 1.2.2 describes an alternative method in which a protected precursor 19 of 3-
fluoro-sialic acid 21 is synthesised chemically in a multi-step procedure. The 
application of wild-type NAL may provide a viable alternative to this chemical method 
as it allows access to fluorinated sialic acid 21 in a single step from commercially 
available materials. 
1.4 Protein engineering of NAL E192N variants 
 Mutagenesis methods have previously been used to engineer variants of NAL 
with high specificity for C-6 amide sialic acid analogues.64 The NAL variants to stem 
from mutagenesis studies have also been shown to be useful in the parallel synthesis 
of sialic acid analogues, with a range of different amides.28 The following Section will 
outline the methodology by which NAL variants with modified substrate specificity 
were identified and optimised. In addition, the evolution of a pair of complementary 
NAL variants with opposing stereoselectivity is discussed. 
b) 
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1.4.1 Engineering of NAL variants with modified activity 
 Engineering of NAL variants aimed to identify an NAL variant capable of 
catalysing the reaction between the dipropylamide aldehyde DHOB 
([2R,3S]‐2,3‐dihydroxy‐4‐oxo‐N,N ‐dipropylbutanamide) and pyruvate. In order to 
screen for desired activity, it was necessary to synthesise chemically DPAH 
([5R,6R]‐7‐(dipropylamino)‐4,5,6‐trihydroxy‐2,7‐ dioxoheptanoic acid) which is the 
product of the reaction between DHOB and pyruvate (Scheme 1.8).65 In solution, the 
open chain of DPAH cyclises to give a mixture of four equilibrium species.* 
 
Scheme 1.8 - Screening substrate DPAH used in the discovery of E192N. DPAH can be synthesised by 
the aldol reaction between DHOB and pyruvate. DPAH exists as a mixture of the 6 member ring 
(pyranose) and 5 member rings (furanose), each of which can exist as the - or -anomer. 
 
In order to alter the substrate specificity of NAL, Glu192, Asp191 and Ser208 were 
chosen targets for saturation mutagenesis, as these residues were known to form 
hydrogen bonding interactions with the triol of ManNAc/Neu5Ac.64 Variants with 
modified specificity were identified by using a standard coupled assay in which the rate 
of the retro-aldol reaction was measured. The standard coupled assay works by 
                                                     
*
 - and -anomers of furanose and pyranose rings. 
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indirectly measuring the rate of pyruvate formation in the retro-aldol reaction. 
(Scheme 1.9).64  
 
Scheme 1.9 – Principle of the standard coupled assay for determining the rate of the retro-aldol 
reaction by an NAL variant. 
1.4.2 Identification of the NAL E192N variant and substrate specificity 
After saturation mutagenesis and screening, mutants with substitutions at each 
of the target residues were evaluated. In the case of Asp191 substitution, very low 
activity with sialic acid was observed and little improved selectivity for DPAH was 
observed. Substitutions of Ser208 also showed decreased activity with sialic acid and 
little improvement in selectivity for DPAH. However, substitution of Glu192 with 
asparagine did yield a mutant enzyme (E192N) with 640-fold greater selectivity for 
DPAH than for sialic acid (Table 1.5).28 
Table 1.5 - Steady-state kinetic parameters for wild-type NAL compared to the E192N variant
28
 
 Wild-type NAL NAL E192N 
NAL 
substrate 
kcat  
/min
-1
 
KM  
/mM 
kcat/ KM  
/min
-1
mM
-1
 
kcat  
/min
-1
 
KM  
/mM 
kcat/ KM  
/min
-1
mM
-1
 
Neu5Ac 260 ± 6 4.4 ± 0.3 74 ± 4 170 ± 10 38 ± 5 4.4 ± 0.6 
DPAH 11 ± 1 6.9 ± 1.0 6.9 ± 1.0 130 ± 3 0.39 ± 0.04 340 ± 30 
 
The drastic change in substrate specificity can be explained by examining the crystal 
structures of the closely related NAL from H. influenzae bound to the 4-oxo-sialic acid 
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inhibitor 20 (Figure 1.14a)56 compared to E. coli NAL E192N bound to the THB 
([2R,3R]‐2,3,4‐trihydroxy‐N,N‐dipropylbutanamide) inhibitor, which is closely related 
to DHOB (Figure 1.14b and c).66 The glutamic acid at position 192 forms a hydrogen 
bonding interaction with the triol of Neu5Ac, whereas when the glutamic acid is 
exchanged for an asparagine, hydrogen bonding with the triol of Neu5Ac is no longer 
possible. The hydrophobic pocket created by this mutation is instead able to 
accommodate the hydrocarbon chains of the greasy dipropylamide group. 
The NAL E192N variant, unlike the wild-type NAL was found to exhibit poor 
diastereoselectivity at the newly formed chiral centre, giving a 74:26 mixture of the 
(4S) and (4R)-epimers of DPAH.67 The crystal structure of the THB inhibitor in complex 
with NAL E192N revealed two different binding modes, the major binding mode where 
the hydroxyl group of C-3 was orientated towards the core of the enzyme (Figure 
1.14b) and the minor binding mode where the same hydroxyl group is pointing 
towards the bulk solvent (Figure 1.14c).66 The crystal structure of the THB inhibitor in 
complex with NAL E192N was used as a starting point for QM/MM studies to 
understand the observed ratio of epimers in the NAL E192N catalysed reaction of 
DHOB and pyruvate (Section 1.4.3).57 
Chapter 1 - Introduction 
 
26 
 
 
  
Figure 1.14 - Comparison of active-sites of wild-type NAL and the NAL E192N variant a) Wild-type NAL 
from H.influenza bound to the 4-oxo-sialic acid inhibitor 20 (PDB 1F7B)
56
 and b) E. coli NAL E192N bound 
to the THB inhibitor in the major binding orientation observed in subunits A, C and D (PDB 2WPB).  c) E. 
coli NAL E192N bound to the THB inhibitor in the minor binding orientation observed in subunit B (PDB 
2WPB)
66
 
 In order to examine the modified specificity of E192N towards other amide sialic acid 
analogues 22a-22g, a further series of amides was synthesised and evaluated using the 
standard coupled assay (Scheme 1.9) in order to determine the scope of substrates 
NAL E192N would accept. It was found that NAL E192N had greater catalytic activity 
for more hydrophobic derivatives and the rate of turnover of dibutylamide derivative 
was even faster than DPAH (22a). Figure 1.15 shows the amides screened in order of 
catalytic activity with E192N. The pyrrolidine derivative, which was amongst the most 
polar, is positioned on the far left as the rate of the retro-aldol reaction by NAL E192N 
was slowest. The dibutylamide derivative, which is the least polar, is positioned on the 
far right as the rate of the retro-aldol reaction by NAL E192N was fastest.64 
a)  
E192  
K165 
b)  
N192  
K165 
c)  
N192  
K165 
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Figure 1.15 – Amide derivatives accepted by NAL E192N in order of slowest to be turned over to 
fastest to be turned over. (Catalysis determined in terms of kcat/Km) 
1.4.3 Quantum mechanical/molecular mechanical studies of the active-site of NAL 
E192N 
 In order to understand the poor diastereoselectivity exhibited by the NAL 
E192N variant, a series of QM/MM modelling studies were undertaken.57 Initial in silico 
energy-minimised structures of DHOB in complex with NAL E192N revealed that DHOB 
is predicted to adopt a similar pair of binding modes as those observed 
crystalographically for the THB inhibitor (see Figure 1.14 in Section 1.4.2). Umbrella 
sampling simulations of the reaction between DHOB and pyruvate in the two binding 
modes resulted in the identification of the reaction profiles with the lowest energy 
barriers. The starting structures for umbrella samples were produced by molecular 
dynamic simulations from the two binding modes. For each binding mode, the lowest 
energy reaction profiles resulting in (4S) and (4R) selectivity were selected and 
compared using two-dimensional potential energy surfaces (2D-PESs). It was found 
that, from the major binding mode, the energy barrier to the transition state of the 
(4R) pathway was 21 kJmol-1 lower than the energy barrier to the transition state of 
the (4S) pathway. From the minor binding mode, the energy barrier to the (4R) 
pathway was found to be 21 kJmol-1 higher than the energy barrier to the transition 
state of the (4S) pathway. Consequentially, it was postulated that the major binding 
mode leads to the (4R)-epimer of DPAH whereas the minor binding mode leads to the 
(4S)-epimer (Figure 1.16).57 
Chapter 1 - Introduction 
 
28 
 
  
  
  
  
Figure 1.16 - Summary of the results of QM/MM modelling of the NAL E192N catalysed reaction 
between DHOB (green) and pyruvate (grey). As in wild-type NAL, Y137 acts as a base to transfer the 
proton to the aldehyde of DHOB and the negative charge is stabilised by S47 and Y110'  
Left pane: Starting structure for umbrella sampling of DHOB in the major (top left) and minor (bottom 
left) binding mode  
Right pane: Approximate transition states structures of the lowest energy reaction pathways. The 
transition state for the major binding mode (top right) is organised to give the (4R)-epimer of DPAH and 
the minor binding mode (bottom right) is organised to give the (4S)-epimer of DPAH. (Figure adapted 
from reference)
57
 
1.4.4 Discovery of a complementary pair of stereoselective enzymes 
 As mentioned previously (Section 1.4.2), the NAL E192N exhibits poor 
diastereoselectivity at the newly formed chiral centre of DPAH, therefore further 
mutagenesis studies were carried out in order to engineer a complementary pair of 
NAL E192N variants with high levels of stereoselectivity at C-4.67 Screening substrates 
Starting structure: Major binding mode 
T167 
T167 
N192 
S47 
Y137 Y137 
K165 K165 
Y110' 
T167 
S47 
Y137 
K165 
Y110' 
N192 
T167 
K165 
Y137 
Transition state: Major binding mode 
Starting structure: Minor binding mode Transition state: Minor binding mode 
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DPAH-a and DPAH-b were synthesised to be used in the standard coupled assay as 
described previously (Figure 1.17).65  
 
Figure 1.17 – DPAH screening substrates used in the discovery of NAL mutants with modified C-4 
selectivity.  
At the time the diastereoselective NAL variants were evolved, the mechanism by which 
the C-4 configuration is controlled was not understood; so error prone PCR (EP-PCR) 
was used to randomly introduce mutations.67 Mutant libraries from EP-PCR were 
screened using the standard coupled assay as described previously (Section 1.4.1). 
Mutants that showed enhanced selectivity towards one or other diastereomer were 
screened using substrates DPAH-a and DPAH-b, identifying a series of potentially 
important residues. Site-directed mutagenesis experiments were then carried out in 
order to identify which residues were most important in determining the configuration 
of the product. It was discovered that three residues, Ala10, Thr48 and Ser208, all of 
which are in direct contact with the substrate when it is bound in the active site were 
the most important. In addition, Thr167 was reasoned to also be important as the 
corresponding residue in another aldolase (2-keto-3-deoxygluconate aldolase) makes a 
hydrogen bond to the C-4 hydroxyl of its product68 (and it has since been found that 
this hydrogen bonding interaction is also found in NAL.)57 The NAL variant 
E192N/T167G was found to be highly selective for the (4S)-epimer and the NAL variant 
E192N/T167V/S208Vwas found to be highly selective for the (4R)-epimer. The kinetic 
parameters for the (4S) and (4R)-selective variants are outlined in Table 1.6.  These 
enzymes can be used in synthesis of C-6 amide-substituted sialic acid analogues with 
the desired configuration at C-4 with high diastereoselectivity.67 
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Table 1.6 - Kinetic parameters of NAL variants towards (4S) and (4R)-dipropylamide screening 
substrates DPAH-a and DPAH-b. 
 
NAL 
Wild-type 
NAL  
E192N 
NAL 
E192N/T167V/S208V 
NAL 
E192N/T167G 
DPAH-a 
kcat /min
-1
 230 ± 6 450 ± 14 0.1 ± 0.003 5 ± 1 
KM /mM 12 ± 1 0.8 ± 0.07 8.5 ± 0.4 0.5 ± 0.03 
kcat/KM 
/min
-1 
mM
-1
 
19 563 0.012 10 
DPAH-b 
kcat /min
-1
 73 ± 4 130 ± 3 1.1 ± 0.04 -
a 
KM /mM 11 ± 2 0.4 ± 0.04 1.9 ± 0.2 -
a 
kcat/KM 
/min
-1 
mM
-1
 
6.6 325 0.58 < 0.2 
 Ratio of kcat/KM 
(4S):(4R) 
74:26 63:37 2:98 >98:<2 
a) Not measurable under the conditions 
1.5 Thesis overview 
 The primary aim of this thesis is to study the NAL-catalysed reaction between 
fluoropyruvate and a series of aldehyde substrates in order to access fluorinated 
analogues of sialic acid. NAL E192N was engineered to be highly active towards DPAH, 
however it was found to exhibit poor stereocontrol, which lead to the evolution of the 
diastereoselective variants NAL E192N/T167V/S208V and E192N/T167G. This work 
aims to evaluate these NAL variants in greater detail, to discover whether the activity 
and diastereoselectivity they were designed to exhibit is retained when the donor and 
acceptor are changed. 
These aims were achieved initially by the development of a new synthetic route 
towards the synthesis of a broader range of potential enzyme substrates, as outlined in 
Chapter 2. The main priority was the synthesis of an enzyme substrate in which the N-
acetyl functionality present in ManNAc was retained. Chapter 3 compares the new 
aldehyde analogues with the previously studied enzyme substrate DHOB in the NAL 
variant-catalysed reaction with pyruvate. The QM/MM modelling studies, outlined in 
Section 1.4.3, have been invaluable in rationalising the outcomes of the NAL-catalysed 
reactions of the new aldehyde substrates. Significantly, the QM/MM modelling studies 
indicate a link between the initial binding mode and the energy barrier of the two 
possible pathways leading to the two C-4 epimer. This link may be validated by higher 
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levels of stereocontrol in the NAL-catalysed reactions of aldehydes bearing a sterically 
demanding group which directs the binding. 
Chapter 4 describes the NAL-catalysed reaction of aldehyde analogues with 
fluoropyruvate, in the synthesis of fluorinated sialic acid analogues. This added an 
extra level of complexity because two stereocentres are formed in the reaction. It was 
therefore necessary to understand the factors that controlled the selectivity at both 
positions. The underlying reason for the diastereoselectivity of the NAL variants 
E192N/T167V/S208V and E192N/T167G was not fully understood; therefore it was 
unclear whether these variants would retain their diastereoselectivity with 
fluoropyruvate as the donor. The aim was to discover whether fluorine was merely a 
bystander or if it was somehow directing the diastereoselectivity at both positions.   
Finally, the potential scope of using NAL variants in the synthesis of fluorinated 
analogues of sialic acid has been considered. In order for the NAL variants to be 
synthetically useful, it is important that they exhibit both high levels of selectivity as 
well as activity. The NAL variants identified with both of these qualities may be used as 
a starting point for further optimisation. 
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Chapter 2 Synthesis of Enzyme Substrates 
2.1. Substrate Design 
 Wild-type NAL is known to catalyse the reaction between ManNAc and 
fluoropyruvate.16 The initial aim of this thesis was to determine whether the NAL 
variants (E192N, E192N/T167V/S208V and E192N/T167G), which were evolved to 
catalyse the reaction DHOB ([2R,3S]-2,3-dihydroxy-4-oxo-N,N-dipropylbutanamide) 
with pyruvate to give DPAH ([5R,6R]-7-(dipropylamino)-4,5,6-trihydroxy-2,7-
dioxoheptanoic acid) (see Section 1.4), will also accept fluoropyruvate as an alternative 
donor to give the fluorinated product 23 (Scheme 2.1). In extension to this, further 
potential acceptor substrates were studied to further probe the activity and selectivity 
of the NAL variants; the synthesis of which will be discussed within the following 
Sections. The reaction between DHOB and pyruvate results in the formation of one 
new stereocentre, whereas the reaction between DHOB and fluoropyruvate results in 
the formation of two new stereocentres. This work has sought to evaluate both the 
activity of the NAL variants towards alternative donors and acceptor substrates, and 
also the diastereoselectivity exhibited by the NAL variants. 
 
Scheme 2.1 - Enzyme-catalysed reaction between DHOB ([2R,3S]-2,3-dihydroxy-4-oxo-N,N-
dipropylbutanamide) and pyruvate and DHOB and fluoropyruvate to give DPAH ([5R,6R]-7-
(dipropylamino)-4,5,6-trihydroxy-2,7-dioxoheptanoic acid) and the fluorinated product 23 
In order to further probe the promiscuity of the NAL variants, along with DHOB, a 
series potential acceptor substrates were designed which were used in the NAL-
catalysed reaction with fluoropyruvate (Figure 2.1). The substrates were chosen 
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because it was proposed that they would provide interesting insight into the 
mechanism and selectivity of the NAL variants. 
It had previously been shown that NAL variants catalyse the reaction between ent-
DHOB and pyruvate.69 In the case of E192N and E192N/T167G the activity of ent-DHOB 
compared to DHOB was reduced 10 to 20-fold, however in the case of 
E192N/T167V/S208V the rate was increased 6-fold compared to DHOB. These results 
have demonstrated that it is important to consider both enantiomeric series when 
designing potential enzyme substrates. Previous work has not considered the 
combined effect of changing both the donor substrate and the  enantiomeric series of 
the acceptor substrate. 
E192N, E192N/T167V/S208V and E192N/T167G have all been evolved to have 
optimised activity where the acceptor is DHOB. Analogues of DHOB have since been 
studied, including the 3-deoxy analogue,70 which exhibited diminished enzyme activity 
and stereocontrol. ManNAc bears an N-acetyl group adjacent to the aldehyde group, 
and this functional group combination is replicated in the potential substrate AHOB 
([2R,3S]-3-acetamido-2-hydroxy-4-oxo-N,N-dipropylbutanamide). Until now it has not 
been possible to study AHOB as no suitable synthetic route had been developed. 
AHOB was considered an important substrate to study due to its structural similarity to 
ManNAc and AHOB has provided information about the significance of the N-acetyl 
functionality in controlling the relative configuration of the product (to be discussed in 
Section 3.3). Furthermore, the introduction of a nitrogen atom provides a synthetic 
handle for further modification and diversification. 
 
Figure 2.1 - Potential acceptor substrates of the NAL variant-catalysed reaction with fluoropyruvate. 
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The following Sections will describe only the synthesis of stable precursors of the 
enzyme substrate DHOB, ent-DHOB, AHOB and ent-AHOB. The aldehydes themselves 
decompose within days, therefore for reasons of practicality, the enzyme substrates 
were stored as alkene precursors of the type 24 and 25 (Figure 2.2), which were 
converted to the corresponding aldehyde by ozonolysis when required and used 
immediately (Section 3.1.1). 
 
Figure 2.2 - Stable alkene precursors of the potential NAL substrates of DHOB/ent-DHOB (24/ent-24) 
and AHOB/ent-AHOB (25/ent-25). 
2.2. Synthesis of the stable alkene precursor of DHOB 
The DHOB precursor 24 was synthesised in 6 steps from D-ribonolactone 26 in 
an overall yield of 24% using a previously established method (Scheme 2.2).65 The 
secondary alcohols of D-ribonolactone 26 were protected by acetonide formation to 
give 27. The primary alcohol of 27 was then reacted with triphenylphosphine, 
imidazole and iodine, to yield the corresponding iodide 28, which was then eliminated 
and the lactone opened under Lewis-acidic conditions to give the corresponding 
carboxylic acid 29. The carboxylic acid 29 was then activated for amide coupling by 
HOBt and EDC, to give the acetonide protected dipropylamide 30 which, after acid-
mediated cleavage of the acetonide protecting group gave the DHOB precursor 24. 
ent-DHOB can be synthesised by an analogous method starting from D-lyxose,71 
although for this work, a sample of the ent-DHOB precursor ent-24 was kindly 
provided by Thomas Harman.69 
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Scheme 2.2 – Synthesis of DHOB precursor 24 from D-ribonolactone 26 
 
2.3. Synthesis of a stable precursors of AHOB and ent-AHOB 
2.3.1. Retrosynthetic analysis of the stable precursors of AHOB/ent-AHOB 
Several methods were considered for the synthesis of the stable alkene 
precursors of AHOB and ent-AHOB. The method needed to be reliable to allow the 
synthesis of multiple grams of substrate, preferably in both enantiomeric series. 
Scheme 2.3 outlines the different routes considered.  
Route 1 would utilise a Petasis reaction to construct intermediate 31. It was envisioned 
that the primary alcohol of intermediate 31 could be selectively oxidised, followed by 
amide coupling and finally functional group interconversion to give the AHOB 
precursor 32. The absolute configuration could be controlled by the use of a single 
enantiomer of glyceraldehyde for the Petasis reaction.  
Route 2 would exploit the lactone 33 as a key intermediate in the synthesis. The 
lactone 33 could be synthesised in three steps from a single enantiomer of 
chloropropane diol by a previously well-established method.72 Both enantiomers of 
chloropropane diol are commercially available so both enantiomers of the lactone 33 
can be accessed by analogous routes. The lactone 33 would then be exploited in a 
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Mannich reaction to give the lactone 35 which, on opening with dipropylamine and 
introduction of an acetyl group, would give the AHOB precursor 25.  
 
 
Scheme 2.3 – Retrosynthetic analysis of AHOB. Two routes were considered; route 1 would utilise the 
Petasis reaction to construct intermediate 31 diastereoselectively and route 2 would utilise the 
lactone 33 as a key intermediate. 
2.3.2. Synthesis of AHOB utilising the Petasis reaction 
 The Petasis reaction is a three component reaction between an aldehyde, vinyl 
or aryl boronic acid and an amine to give an allyl or phenyl amine.73 When a chiral  -
hydroxy-aldehyde is used, the reaction is diastereoselective in favour of the product 
with an anti-relationship between the -hydroxyl group and the amine. Scheme 2.4 
shows the proposed mechanism of the Petasis reaction between an -hydroxy 
aldehyde and a vinyl boronic acid. The mechanism is based on DFT calculations74 which 
predicted that the rate-determining step was C-C bond formation, which occurs by an 
intramolecular transfer of the vinyl group from a tetra-coordinated borate 
intermediate. The borate is coordinated to the top face of the imine (as drawn), 
therefore the vinyl group is delivered to the top face of the imine. 
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Scheme 2.4  – Mechanism of the Petasis reaction and the role of the -hydroxyl group in control of 
the diastereoselectivity 
Two amines were considered, the primary amine 36a,75 (see Appendix 1 for synthesis), 
and the commercially available diallylamine 36b76 (Figure 2.3). Both amines had 
previously been shown to be suitable substrates for the Petasis reaction.75, 76  Previous 
reaction development studies have shown that secondary amines tend to give higher 
yields than primary amines.77 In addition, studies have shown that using 
hexafluoroisopropanol (HFIP) as a co-solvent with dichloromethane leads to faster 
reaction times, especially with secondary amines.78 When the Petasis reaction was 
originally reported,73 a boronic acid was used, however it was found that vinyl boronic 
acid is unstable75 so therefore the corresponding dialkyl ester was used. The boronic 
ester had to be activated by addition of water to the reaction solvent and required 
elevated reaction temperatures (24 °C up to 50 °C) and longer reaction times (up to 72 
h). 
 
Figure 2.3 - Primary amine 36a and secondary amine 36b used in optimisation of the Petasis reaction. 
For the purpose of reaction development, the racemic aldehyde 37 was used. Several 
conditions for the Petasis reaction (Scheme 2.5) were screened in order to optimise 
the synthesis of the diol 39 and these conditions are outlined in Table 2.1. Entries 1-3 
outline the conditions screened for the primary amine 36a. The crude product, 31a, of 
the Petasis reaction was converted directly into the diol 39 by removal of the bis-p-
methoxyphenyl protecting group under acidic conditions followed by acetylation.79 The 
yields quoted in Table 2.1 are based on the quantity of the diol 39 obtained (Scheme 
2.5a). Entries 4-7 outline the conditions screened for the secondary amine 36b. In this 
case, the intermediate amine 31b was purified by flash column chromatography so the 
yields quoted in Table 2.1 are based on the yield of the diallylamine 31b. The 
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diallylamine 31b  was converted into the diol 39 by deprotection with N,N'-
dimethylbarbituric acid and catalytic tetrakistriphenylphosphine palladium(0) in 
dichloromethane, followed by reaction with acetic anhydride in refluxing methanol to 
give the diol 39 in a 70% yield over 2 steps from the diallylamine 31b (Scheme 2.5b). 
In Entry 1, the literature conditions were replicated however the reported yield of 
60%79 was not found to be reproducible. Despite increasing the reaction temperature, 
the best yield achieved with ethanolwater as the solvent was 9% (Entry 2). Switching 
to 9:1 dichloromethaneHFIP improved the yield to 38% (Entry 3). 
After the mixed success with primary amine 36a, diallylamine 36b was considered as 
an alternative (Entries 4-7). As observed previously, using HFIP as a co-solvent greatly 
improved the yield (Entries 6 and 7). However, when the scale was increased, the yield 
decreased significantly and the product became more difficult to purify (Entry 7). 
 
Scheme 2.5 – Petasis reaction optimisation varying amine 36, solvent, reaction temperature, reaction 
time and relative equivalents of DL-glyceraldehyde 37, amine 36 and vinyl boronic acid 38 a) Reactions 
of primary amine 36a (Table 2.1, Entries 1-3). Yield of the diol 39 (based on the limiting reagent) is 
reported. b) Reactions of the secondary amine 36b (Table 2.1, Entries 4-7). Yield of diallylamine 31b 
(based on the limiting reagent) is reported. 
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Table 2.1 – Optimisation of the Petasis reaction 
Entry Amine Solvent Temp 
Scale 
/mmol 37 
Equivalents 
37:36:38 
Reaction 
time 
/day 
Yield % 
(d.r.)
a
 
1 36a 
EtOH–H2O 
(4:1) 
50 °C 5 1:1:2 4 
6
b 
(>98:<2) 
2 36a 
EtOH–H2O 
(4:1) 
70 °C 3.3 1.5:1.5:1 4 
9
b 
(>98:<2) 
3 36a 
CH2Cl2–HFIP 
(9:1) 
Reflux 3 1.5:1.5:1 3 
38
b 
(>98:<2) 
4 36b 
EtOH–H2O 
(4:1) 
Reflux 5.55 1.5:1.5:1 1 
20
c 
(>98:<2) 
5 36b 
EtOH–H2O 
(4:1) 
RT 5.55 1.5:1.5:1 7 
36
c 
(>98:<2) 
6 36b 
CH2Cl2–HFIP 
(9:1) 
Reflux 5.55 1.5:1.5:1 1 
71
c 
(>98:<2) 
7 36b 
CH2Cl2–HFIP 
(9:1) 
Reflux 11.1 1.5:1.5:1 1 
36
c 
(>98:<2) 
a) Diastereomeric ratio determined by 500 MHz 
1
H NMR spectroscopy b) Yield of the diol 39 c) Yield of 
the diallylamine 31b 
The next stage was to oxidise the primary alcohol of the diol 39 to the corresponding 
carboxylic acid. There are very few methods for selective oxidation of a primary 
alcohol, particularly a 1,2-diol. It was decided to investigate a protocol which had 
previously been successful76 in which sodium hypochlorite and catalytic TEMPO in 
dichloromethane at 0 °C were expected to selectively oxidise the primary alcohol to 
the corresponding aldehyde 40 (Scheme 2.6). Unfortunately after several attempts, no 
reaction was observed. 
Chapter 2 - Synthesis of Enzyme Substrates 
 
40 
 
 
Scheme 2.6 – Unsuccessful TEMPO catalysed oxidation of the diol 39 to the corresponding aldehyde 
40. 
After the lack of success selectively oxidising the primary alcohol of the diol 39, the 
secondary alcohol was selectively protected by formation of an oxazolidinone 42 so 
only the primary alcohol was available for reaction. The diallylamine 31b was 
deprotected as described previously with N,N'-dimethylbarbituric acid and catalytic 
tetrakistriphenylphosphine palladium(0) in dichloromethane, however the primary 
amine intermediate 41 was purified by SCX ion exchange and was isolated in a 69% 
yield. The primary amine 41 was then successfully converted in a 74% yield into the 
oxazolidinone 42 by reaction with p-nitrophenol chloroformate (Scheme 2.7). 
 
Scheme 2.7 – Conversion of allyl amine 31b into oxazolidone 42. 
The oxazolidone 42 was subjected to two sets of oxidation conditions. The first oxidant 
investigated was Dess–Martin periodinane in dichloromethane at room temperature, 
however no product was observed despite the starting material being consumed. The 
same problem occurred under a one-pot direct oxidation to the acid, in which it was 
expected that the oxazolidinone 42 would be oxidised to the aldehyde by sodium 
hypochlorite and catalytic TEMPO, immediately followed by a second oxidation to the 
corresponding acid with sodium chlorite and 2-methyl-2-butene in monosodium 
phosphate buffered aqueous solution at pH 6 to 7.   
The route was abandoned as suitable oxidation conditions for the diol 39 or the 
oxazolidinone 42 could not be found. This, along with the problems encountered with 
yield and purification on scale-up of the Petasis reaction, resulted in the conclusion 
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that this route was unsuitable. Further problems were encountered when trying to 
find a reputable source of single enantiomers of glyceraldehyde, which would be 
necessary if the route had been optimised. Consequently, the second route considered 
for the synthesis of AHOB was investigated. 
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2.3.3. Reactions of the lactone intermediate 33 
The lactone 33 was synthesised in 3 steps from chloropropane diol 43.72 (S)-
Chloropropane diol (S)-43 was first reacted with butanedione and 
trimethylorthoformate in methanol with catalytic camphorsulfonic acid to give the 
chlorolactone 44 in a 41% isolated yield after chromatography. Upon treatment with 
potassium tert-butoxide in refluxing THF, the chlorolactone 44 underwent elimination 
to the corresponding exocyclic alkene 45a. Over prolonged reaction times, 
isomerisation to the endocyclic alkene 45b occurred. The alkene 45a was then 
ozonolysed to give the lactone 33 in a 38% yield and an overall yield of 16% over 3 
steps (Scheme 2.8). By telescoping all three steps and only carrying out purification by 
chromatography after the ozonolysis reaction, the overall yield was improved to up to 
25% over 3 steps. 
 
Scheme 2.8 – Synthesis of the lactone 33 from (S)-chloropropane diol (S)-43 
It was envisioned that the lactone 33 could be used as a key intermediate in the 
synthesis of the AHOB precursor 25. A range of reactions of the lactone 33 were 
investigated and are summarised in Table 2.2. The general protocol was to generate 
the enolate by deprotonation with lithium hexamethyldisilazide (LiHMDS) in THF at –
78 °C, followed by addition of one of the following electrophiles: an aldehyde (aldol 
reaction),80 an acid-chloride (Claisen-type reaction)80 or an imine (Mannich-type 
reaction)81 followed by filtration through silica and purification by column 
chromatography.  
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Entry 1 shows the reaction between the lactone 33 and the allyl aldehyde 46 to give 
the lactone 49. The lactone 49 could be opened with dipropylamine to give an anti-1,2-
diol similar to the DHOB precursor 24 described in Section 2.2. Although the aldol 
reaction proceeded successfully, it was not considered a practical intermediate for the 
synthesis of AHOB as a double inversion of the configuration of the alcohol group of 
the lactone 49 would be required to give the correct relative configuration for the 
conversion into AHOB.  
Entries 2 and 3 show a Claisen-type condensation of the lactone 33 with an acid 
chloride. It was previously shown that for bulky alkyl acid chlorides, a single 
condensation would occur to give an enol, which would then undergo reduction by 
tetrabutylammonium borohydride to give the epimer of the product 49.80 The acid 
chlorides 47 (Entry 2) and 48 (Entry 3) were both investigated.* Reaction with the acid 
chloride 47 installed the required alkene functionality directly whereas selenide-ethers 
have previously been shown to act as "masked" double bonds.82 Both acid chlorides 47 
and 48 underwent a Claisen-type reaction to give the corresponding enol 
intermediates 50 and 51 respectively however the isolated yields were poor. 
Furthermore the carbon-selenium bond of the enol 51 was not very stable, leading to 
rapid decomposition. Suitable conditions for the reduction of the enol intermediates 
50 and 51 were not found. Despite screening several different conditions (see 
Appendix 2), in all cases either conjugate reduction products were observed, or the 
enol was seen to decompose and a complex mixture was observed. 
Entry 4 shows a Mannich type reaction between the sulfonyl-imine 34 (for synthesis, 
see Appendix 1) and the lactone 33. This installed the amine group directly without the 
requirement for substitution and inversion. The lactone 35 was chosen as a suitable 
intermediate in the synthesis of AHOB. 
  
                                                     
*
 The synthesis of the none commercially available acid chloride 48 is discussed in Appendix 1 
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Table 2.2 - Reactions of lactone 33 
 
Entry Reaction partner 
Reaction 
Time 
Product 
Yield % 
(d.r.) 
1 
 
5 min 
 
85 
(d.r. >98:<2)
b 
2 
 
1 hr 
 
37 
3 
 
1 hr 
 
65 
~50:50 enol:keto 
4 
 
2 hr 
 
78 
(d.r. 83:17)
c 
a) Not commercially available, see Appendix 1 and experimental Section 6.3 for synthesis b) 
Configuration was proven by comparison with the previously reported data. c) Absolute configuration 
was confirmed by analysis of downstream products (Section 3.1.3). 
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The aldol reaction (Entry 1) and the Mannich reaction (Entry 4) both result in the 
formation of two new stereocentres (therefore four possible diastereomers could be 
observed) and the products 49 and 35 drawn in Table 2.2 were observed as the major 
diastereomers. The aldol reaction was diastereoselective (d.r. >98:<2)* whereas the 
Mannich-type reaction gave an 83:17 mixture of diastereomers. Rationalisation for the 
observed stereocontrol of both reactions is shown in Figure 2.4. In both cases, the pair 
of diastereomers in which the electrophile attacks into the axial position of the lactone 
33 would be highly unfavoured due to a 1,3-steric clash with the methoxy group 
(Figure 2.4a). The aldol reaction (Figure 2.4b) is likely to proceed via a chair-like 
transition state with the lithium coordinating to the negative charge of the oxygen on 
the lactone 33 and the lone pair of the aldehyde 46 oxygen. The electrophile attacks in 
the equatorial position of the lactone 33 and the bulkiest group is positioned in a 
pseudo-equatorial position in the transition state, with the hydrogen occupying the 
pseudo-axial position in order to minimise steric interaction with the methoxy groups 
of the lactone.80 In the case of the Mannich reaction (Figure 2.4c), in order for the 
nitrogen lone pair to be available to interact with the lithium and the reaction to 
proceed via a chair-like transition state, the imine 34 would have to adopt the (Z) 
configuration to give the observed major diastereomer of the lactone 35.81 It is likely 
however that the imine adopts the (E) congifuration predominantly, therefore it may 
also be possible that the reaction proceeds via an open transition state to give the 
observed major diastereomer of the lactone 35. The (E)-imine would be unlikely to 
react via a chair-like transition state due to unfavourable steric interactions between 
the phenyl group of imine 34 and the methoxy groups of the lactone 33. This added 
level of complexity may account for the reduction in diastereoselectivity observed in 
the Mannich-type reaction. 
                                                     
*
 Within the error of NMR integral measurements 
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Figure 2.4 - Transition state comparisons for the aldol and Mannich reactions of the lactone 33 a) 
Unfavoured attack of the electrophile into the axial position of the lactone b) The aldol reaction 
between the aldehyde 46 and the lactone 33 and c) The Mannich reaction between the sulfonyl-imine 
34 and the lactone 33. 
2.3.4. Conversion of the lactone intermediate 35 into AHOB. 
In order to convert the intermediate 35 into the AHOB precursor 25, the 
following synthetic steps were necessary: opening of the lactone 35, the introduction 
of the dipropylamide functionality and conversion of the sulfonylamide into an 
acetylamide. The acetyl group was introduce in the last step so that it would be 
possible to add different functional groups to the amine if required in the future, 
without having to redesign the synthesis. 
The step which proved to be most challenging was the opening of the lactone 35 and 
the conditions investigated are outlined in Table 2.3. The protected intermediate 52 
was difficult to purify due to its instability on silica, however it was necessary to ensure 
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removal of all unreacted dipropylamine as any contaminating dipropylamine in the 
acetal cleavage reaction resulted in poor or no conversion to the deprotected 
sulfonylamide 53.  
Entries 1-3 use dipropylamine as the solvent, making its subsequent removal very 
difficult. Under these conditions, it was found to also be necessary to use a catalyst, as 
the uncatalysed reaction (Entry 1) resulted in no reaction taking place. Both TBD and 
DMAP at 30 mol% loading, heating to 75 °C (Entries 2 and 3) gave a similar yield with 
no epimerisation (the d.r. of the lactone 35 is 83:17) but significant elimination of p-
benzenesulfonamide as a by-product was observed.* The mechanism of this 
elimination is unclear as no lactone-containing by-product partner was isolated. 
Despite careful removal of the of p-benzenesulfonamide by-product,† the yields of 
isolated product were disappointing at only 22%. 
Amines activated by forming the aluminium salt have previously been shown to open 
lactones under milder conditions.83, 84 Two aluminium sources were considered, 
trimethylaluminium in dichloromethane at 40 °C (Entries 4 and 6)83 and DIBAL in THF at 
room temperature (Entry 5).84 Activating with aluminium allowed for much lower 
dipropylamine loadings to be used; therefore removal of dipropylamine simply by 
aqueous extraction became possible. It was found by crude NMR that under the DIBAL 
activated conditions (Entry 5) that significant epimerisation had occurred, with the d.r. 
reduced from 83:17 to 67:33, however the yield was improved to 52% of the protected 
intermediate 52 after chromatography. Under the trimethylaluminium activated 
conditions (Entry 4), the crude NMR showed little to no epimerisation had taken place, 
however the yield after chromatography was reduced to only 28%. However, 
examination of the 500MHz 1H NMR spectrum of the unpurified product 52, after an 
aqueous work-up, contained very little unreacted dipropylamine or other impurities. 
The crude product was dissolved in acetonitrile–water (1:1) and the O-acetal 
protecting group was hydrolysed by the addition of trifluoroacetic acid. The 
sulfonylamide 53 was isolated in a much improved 68% yield over 2 steps with little to 
                                                     
*
 By careful removal of the p-nitrobenzensulfonamide after the Mannich reaction, it was found that the 
p-nitrobenzenesulfonamide was being eliminated during opening of the lactone 35 under the conditions 
outlined in Table 2.3, Entries 2 and 3 rather than being carried through the synthesis. 
†
 The p-nitrobenzensulfonamide by-product could be removed by dissolving the contaminated product 
in chloroform after chromatography, followed by removal of the p-benzenesulfonamide by filtration. 
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no epimerisation observed and with the reaction time of the lactone opening reaction 
reduced to only 2 hours (Entry 6). 
Table 2.3 – Optimisation of condition for opening of the lactone 35 
 
Entry Solvent 
Catalyst/ 
Lewis acid 
Eq. HNPr2 
Temp. 
/°C 
Time 
/h 
Yield of 52 % 
(d.r) 
Yield of 53 
% 
1 HNPr2 - >20 100 - No reaction - 
2 HNPr2 
TBD  
(30 mol%) 
>20 75 2 22 (83:17) 36 
3 HNPr2 
DMAP  
(30 mol%) 
>20 75 2 22 (83:17) - 
4 CH2Cl2 Me3Al 1 40 24 28 (83:17) - 
5 THF DIBAL 2.5 RT 24 52 (67:33) - 
6 CH2Cl2 Me3Al 2 40 2 Not isolated 
68 
(2 steps) 
 
The final synthetic route employed for the latter stages of a multi-gram synthesis of 
the AHOB precursor 25 is outlined in Scheme 2.9. The lactone 35 was opened under 
the optimised conditions described previously to give the protected dipropylamide 53, 
which is then deprotected in over 90% yield with thiophenol and DBU at room 
temperature in acetonitrile. The resulting primary amine 54 was reacted with acetic 
anhydride in refluxing methanol to give the AHOB precursor 25 as a single enantiomer 
in a 10% overall yield from the commercially available (S)-chloropropane diol (S)-43. 
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Scheme 2.9 – Conversion of the lactone 35 into the AHOB precursor 25 by aluminium mediated 
lactone opening, followed by deprotection and N-acetylation. 
The enantiomeric precursor, ent-25, was synthesised by an analogues route starting 
from (R)-chloropropane diol (R)-43 (Scheme 2.10). The yields obtained at each stage 
were similar to those observed for the enantiomeric series. 
 
Scheme 2.10 – Synthesis of the ent-AHOB precursor ent-25 from (R)-chloropropane diol (R)-43. 
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In summary, stable alkene precursors of the four potential NAL substrates discussed in 
Section 2.1 have been successfully synthesised in sufficient quantities for use in the 
enzyme catalysed reaction between NAL and pyruvate or fluoropyruvate. The method 
for synthesis of the DHOB precursor 24 was successfully replicated and a new synthetic 
route for accessing different potential NAL substrates has been established. 
The Petasis reaction proved to be unsuccessful due to problems with selective 
oxidation of the primary alcohol 39 or the oxazolidinone 42. Furthermore, the yield of 
the Petasis reaction appeared to decrease when the scale was increased, and the 
purification became more challenging. Furthermore, the intermediates formed in the 
Petasis route are limiting in terms of the potential to introduce further diversity or 
adapt the route to access a greater range of potential enzyme substrates. 
The method developed utilising the lactone 33 is not only a very reliable route to 
access the AHOB precursor 25, the lactone 33 may be used in other types of reaction 
to produce several other synthetically useful intermediates. The route that has been 
developed could be easily adapted to access further substrates to probe the NAL active 
site.
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Chapter 3 NAL-catalysed reactions of aldehyde analogues and 
pyruvate 
3.1 NAL E192N variants in the preparation of N-acetyl neuraminic acid 
analogues 
 The analysis of the NAL variant-catalysed reactions has been separated into 
two sections; the reactions of pyruvate and the reactions of fluoropyruvate. This 
Chapter focuses only on the NAL-catalysed reaction of pyruvate, in which one new 
stereocentre is formed in the reaction. The reaction of DHOB and ent-DHOB with 
pyruvate have previously been studied in detail67, 69 so this Chapter will only evaluate 
the NAL variant-catalysed reactions of the aldehyde substrate AHOB ([2R,3S]‐3-
acetamido‐2-hydroxy‐4‐oxo‐N,N‐dipropylbutanamide) and its enantiomer ent-AHOB. 
The main objective of this study was to determine whether the NAL variants (E192N, 
E192N/T167V/S208V and E192N/T167G) would tolerate the introduction of an N-
acetyl group and what the effect would be on the diastereoselectivity of the reaction. 
3.1.1 Preparation of NAL variants and aldehyde substrates 
His6-tagged NAL variants were expressed in E. coli grown in 2×TY media from 
glycerol stocks prepared previously.57 The NAL variants were obtained by collecting the 
pellet, lysing the cells, centrifugation to remove the cell debris and purification from 
the supernatant using nickel affinity chromatography. Figure 3.1 shows a typical 
example of an SDS-PAGE gel analysing the purification process. The second lane shows 
the crude cell extract with a very intense band at 33.5 kDa, which corresponds to the 
molecular weight of His-tagged NAL.85  
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Figure 3.1 - SDS-PAGE during NAL E192N purification. From left to right, lane 1 corresponds to the 
molecular weight marker, lane 2 shows the crude cell extract, clearly showing the large band 
corresponding to over-expression of NAL. Wash 1-4 corresponds to washing contaminated proteins 
off the nickel resin while NAL was bound to the resin. Elution 1 and 2 correspond to purified NAL after 
being eluted from the nickel resin with imidazole. 
The previous Chapter outlined the development of a synthetic route to a series of 
stable precursors of potential substrates of the NAL variants.  The potential substrates 
were stored as their corresponding alkene precursors 24 and 25, which were 
converted into the aldehyde substrates by ozonolysis as they were required (Scheme 
3.1).65 The methodologies for preparation of NAL variants and aldehyde substrates 
described within this Section were applied throughout. 
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Scheme 3.1 - Conversion of stable alkene precursors 24 and 25 into the corresponding aldehydes 
DHOB/ent-DHOB and AHOB/ent-AHOB by ozonolysis. 
3.1.2 Preparative scale enzyme catalysed reactions of AHOB with pyruvate 
 AHOB and ent-AHOB were subjected to reaction with pyruvate, catalysed by 
the NAL variants E192N, E192N/T167V/S208V and E192N/T167G. Typically, the NAL-
catalysed reactions were carried out in 50 mM Tris.HCl at pH 7.4, followed by addition 
of formic acid after 16 hours in order to denature the NAL variant and stop the 
reaction. The pH was then returned to 7.4 and Bakers' yeast was added in order to 
break down excess pyruvate to acetaldehyde. Initial purification was carried out by 
Dowex® ion exchange. Table 3.1 outlines the isolate yields and observed 
diastereoselectivity (measured by 500 MHz 1H NMR; Section 3.1.3 and Appendix 3) of 
the NAL variant-catalysed reactions. The NAL E192N/T167V/S208V variant was found 
to be completely inactive towards AHOB under the reaction conditions (Entry 2). The 
NAL E192N-catalysed reaction of AHOB and pyruvate (Entry 1) gave a single 
diastereomer, 55a, which did not require further purification. The NAL E192N/T167G 
variant also gave product 55a selectively (Entry 3). The NAL E192N-catalysed reaction 
of ent-AHOB gave a 76:24 mixture of ent-55b and ent-55a (Entry 4). The products 55a 
and the mixture of ent-55a and ent-55b were further purified by mass-directed 
reverse-phase HPLC. 
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Table 3.1 - Reactions of the NAL variants with AHOB/ent-AHOB and pyruvate under preparative 
conditions. 
 
Entry Aldehyde NAL variant 
Equivalents of 
aldehyde:pyruvate 
Yield % d.r 
1 AHOB E192N 1:2 41
a
 
>98:<2 
55a 
2 AHOB 
E192N/T167V/
S208V 
1:2 0 - 
3 AHOB E192N/T167G 1:2 11
b
 
>98:<2 
55a 
4 ent-AHOB E192N 1:2 9
b
 
24:76 
ent-55a:ent-55b 
a) Yield after ion exchange chromatography b) Yield after mass-directed reverse-phase HPLC purification 
3.1.3 Identification and characterisation of AHOB enzyme catalysed reaction 
products 
 The reaction between AHOB/ent-AHOB and pyruvate sets up one new 
stereocentre; therefore there are two possible products in the reaction, resulting from 
re or si-face attack of the aldehyde. Figure 3.2a is a 500 MHz 1H NMR spectrum of the 
HPLC purified product 55a. Figure 3.2b shows the 500 MHz 1H NMR spectrum of the 
mixture of isolated products ent-55b and ent-55a (76:24).  
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Figure 3.2 - Diagnostic region of the 500 MHz 
1
H NMR spectra of the mass-directed reverse-phase 
HPLC purified products of the NAL variant-catalysed reaction of AHOB/ent-AHOB and pyruvate. a) 
HPLC purified product 55a b) HPLC purified 76:24 mixture of products ent-55b and ent-55a.
*
 
The diagnostic peaks in the 500 MHz 1H NMR spectrum of the products 55a and ent-
55b were analysed and characterised (Table 3.2). The configuration of the products 
was assigned by careful analysis of the signals corresponding to 5-H. Due to the 
configuration of the starting materials, and the preference for the largest substituents 
to adopt the equatorial positions of a pyranose ring, 5-H and 6-H will always be axial. 
The structure of product 55a was confirmed because the signal for 5-H appeared as a 
triplet with a coupling constant of 10.2 Hz, indicating that H-4, H-5 and H-6 are all axial 
in a pyranose ring. The structure of product ent-55b was confirmed because 5-H 
appeared as a doublet of doublets with a coupling constant to 6-H of 10.6 Hz and a 
coupling constant to 4-H of 3.1 Hz, indicating that 5-H and 6-H were axial and H-4 was 
equatorial in a pyranose ring. 
                                                     
*
 The NMR spectra were recorded without suppression of the water peak, as suppression resulted in 
diminished resolution of signals close to the water peak, and in some cases disappearance of signals. 
a) 
b) 
6-H55a 
6-Hent-55b 
5-H55a 
4-H55a 
6-Hent-55a 
5-Hent-55b 
4-Hent-55b 
4-Hent-55a 
5-Hent-55a 
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Table 3.2 - Characterisation of the products 55a and ent-55b by 500 MHz 
1
H NMR spectroscopy. 
 
Product H (500 MHz, 
D2O) /ppm 
Multiplicity 
3
J  /Hz Identity Configuration 
at C-4 
55a 
4.83 d 10.3 6-H  
4.11 td 11.2, 10.9 and 4.5 4-H (S) 
4.00 t 10.2 5-H  
ent-55b 
5.03 d 9.6 6-H  
4.23 dd 10.6 and 3.1 5-H (S) 
4.12 t 3.0 4-H  
 
3.1.4 Measuring activity of the cleavage of the products of enzyme catalysed 
reactions 
 The activity of the NAL variants in the cleavage of the products 55 and ent-55 
was analysed in comparison to the cleavage of DPAH (the product of the NAL variant-
catalysed reaction of DHOB and pyruvate) using the coupled assay* (Scheme 3.2). Due 
to only small quantities of material being available, single concentration kinetic 
measurements were taken at low concentrations (1 mM of substrate with 0.06 mg/ml 
of NAL) of products 55, ent-55 and DPAH. At low substrate concentrations, the enzyme 
is unlikely to be saturated therefore the observed rates are likely to correlate with 
kcat/KM.
85 Chart 3.1 shows the activity of the NAL variants recorded as the decrease in 
absorbance at 340 nm per minute for each of the NAL variants and substrates. 
                                                     
*
 For more details of the standard coupled assay, see Section 1.4.1 and the experimental Section 6.1.6 
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Compound 55a was evaluated as a single diastereomer, whereas ent-55 and DPAH 
were tested as a mixture of diastereomers. 
 
Scheme 3.2 – Principle of the standard coupled assay for determining the rate of the retro-aldol 
reaction of the NAL variant 
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Chart 3.1 - Single point kinetic measurements of the NAL variants against the products of the NAL 
E192N-catalysed reactions (1 mM of substrate with 0.06 mg/ml of NAL); DPAH (blue), which was used 
as a 74:24 mixture of (4S) and (4R)-epimers, 55a (red) and ent-55 (green), which was used in a 76:24 
mixture of (4S) and (4R)-epimers. Insert shows an enlargement of the lower level activity 
measurements. 
DPAH was found to be by far the most active in the cleavage direction for all the NAL 
variants. The NAL E192N variant is over 20 times more active towards the cleavage of 
DPAH compared to the cleavage of the product 55a. As discussed in the previous 
Section, NAL E192N/T167V/S208V was inactive towards AHOB, therefore it was not 
surprising to find that it was also inactive in the cleavage of the product 55a. 
The NAL E192N/T167V/S208V and E192N/T167G variants are both poorly active 
towards cleavage of ent-55. NAL E192N is known from previous studies to be 20 times 
less active towards the enatiomeric form of DPAH,64 and is also seen to be less active 
towards ent-55 compared to 55. However, as observed for the enantiomeric series of 
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DPAH, NAL E192N/T167V/S208V was found to be more active towards ent-55 
compared to 55.69 
3.2 Monitoring enzyme catalysed reactions of AHOB by 500 MHz 1H NMR 
spectroscopy 
3.2.1 Comparison of activities and kinetic selectivity of enzyme catalysed reactions of 
AHOB 
 The forward reactions, catalysed by the NAL variants, with AHOB/ent-AHOB 
were monitored by 500 MHz 1H NMR spectroscopy in order to evaluate the kinetic 
selectivity of the enzyme-catalysed reactions. Figure 3.3 shows a selection of the time 
points of the NAL E192N-catalysed reaction between AHOB and pyruvate. The peaks 
highlighted in red, which correspond to AHOB, disappear and the peaks corresponding 
to diastereomer 55a, highlighted in blue, appear over time.* The areas highlighted in 
green correspond to the regions of the spectra where the peaks corresponding to 55b 
would appear. It was found that the product 55b (the (4R)-epimer of the product of 
the reaction of AHOB and pyruvate) was not observed under the conditions 
investigated. Chart 3.2 shows a plot of the appearance of the product 55a and the 
disappearance of AHOB over time.  
 
                                                     
*
 Due to deuterium incorporation as a result of keto-enol tautomerisation of pyruvate, the chemical 
shifts and multiplicities of the peaks change compared to the preparative scale reaction. 
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Figure 3.3 – 500 MHz 
1
H NMR spectroscopy time-course of the NAL E192N-catalysed reaction of AHOB 
and pyruvate. AHOB (red) 55a (blue) region of the spectra where 55b would appear (green). 
(Conditions for time-course: 0.1 mmol of aldehyde, 0.2 mmol of pyruvate and 0.56 mg of NAL in 0.7 ml 
of deuterated sodium phosphate buffer, pH 7.4)  
 
Chart 3.2 - Representation of the percentage disappearance of AHOB and the percentage appearance 
of product 55a over the full reaction time. 
The selectivity data of the kinetically controlled reactions is shown in Table 3.3, along 
with the known selectivities of the NAL-catalysed reaction of DHOB and ent-DHOB.69 
This data is further illustrated in Chart 3.3. The most remarkable result is that 
regardless of the enantiomer of AHOB, the NAL E192N variant exhibits high levels of C-
4 selectivity, which is in direct contrast with the selectivity observed for DHOB/ent-
DHOB, where the C-4 selectivity is very poor.69 The NAL E192N/T167G-catalysed 
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reaction of AHOB was also found to be selective for the (4S)-epimer, product 55a. At 
the time NAL E192N/T167V/S208V and E192N/T167G were evolved, very little was 
known about the different reaction pathways leading to the two diastereomers of 
DPAH in the NAL E192N-catalysed reaction.67 
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Table 3.3 – Kinetic ratio of the NAL variants towards the aldehyde analogues calculated from the 500 
MHz 
1
H NMR spectra. (Conditions for time-course: 0.1 mmol of aldehyde, 0.2 mmol of pyruvate and 
0.56 mg of NAL in 0.7 ml of deuterated sodium phosphate buffer) 
 
Aldehyde NAL variant 
Ratio of products 
a:b 
Ratio of products by 
configuration at C-4 
(4R):(4S) 
DHOB
a
 
E192N 79:21 79:21 
E192N/T167V/S208V >13:<87 >13:<87 
E192N/T167G <95:>5 <95:>5 
ent-DHOB
a
 
E192N 57:43 43:57 
E192N/T167V/S208V <83:>17 >17:<83 
E192N/T167G 64:36 36:64 
AHOB 
E192N >98:<2 >98:<2 
E192N/T167V/S208V - - 
E192N/T167G >98:<2
b 
>98:<2
b 
ent-AHOB 
E192N <2:>98
b 
>98:<2
b 
E192N/T167V/S208V - - 
E192N/T167G NM NM 
a) Reported from previously recorded experiments
69
 for the purpose of comparison. b) See Appendix 3 
for time course data used to calculate kinetic ratios. 
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Chart 3.3 – Kinetic ratio of the NAL variants towards the aldehyde analogues calculated from the 500 
MHz 
1
H NMR spectra. Expressed in terms of the absolute configuration at C-4. 
3.3 Rationalisation of the observed outcomes of enzyme catalysed reactions 
of AHOB 
NAL E192N has previously been shown to exhibit poor diastereoselectivity with 
DHOB, however it was found to be highly selective for AHOB, giving only the product 
resulting from attack of the si-face of the aldehyde, product 55a. Unfortunately, NAL 
E192N was found to be significantly less active towards AHOB and the NAL 
E192N/T167V/S208V variant was completely inactive towards AHOB. The following 
Section aims to discuss the possible reason for this improved diastereoselectivity but 
loss of activity. The QM/MM modelling studies into the mechanism of facial selectivity 
in NAL E192N57 has been used to form the basis of the rationalisation presented within 
this Section. 
3.3.1 Proposed modified binding mode of AHOB compared to DHOB 
 Predictions with regards the binding of AHOB* were based upon analysis of the 
crystal structure of NAL E192N in complex with the inhibitor THB (which is closely 
related to DHOB)66 since there is no crystal structure of an analogue of AHOB in 
complex with NAL. It has previously been shown that DHOB has two possible binding 
modes. The major binding mode, in which the C-3 hydroxyl group is pointing back 
towards the core of the enzyme, and the minor binding mode, where the C-3 hydroxyl 
                                                     
*
 There are no crystal structures for the enantiomeric series of the aldehyde substrates so it is not 
possible to analyse the potential binding modes of ent-AHOB. 
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group is pointing out into the solvent.66 It has also been predicted using QM/MM 
modelling that the major binding mode preferentially leads to re-face attack of the 
aldehyde and that the minor binding mode preferentially leads to si-face attack of the 
aldehyde (see Section 1.4.3).57 In the reactions of AHOB and ent-AHOB, the reaction 
products have (4S)-configuration, which means that the si-face of the aldehyde is 
attacked. 
In order to gain understanding of how AHOB may bind in the NAL active-site, the 
crystal structure of the THB inhibitor in complex with the NAL E192N variant was 
computationally modified so that the C-3 hydroxyl group was exchanged for an N-
acetyl group using the building function of Accelrys Discovery Studio Visualizer 3.0. 
This was done without changing the position of any of the residues or the inhibitor, 
with the aim of understanding whether AHOB could potentially adopt similar binding 
modes in the NAL E192N variant active site as is predicted for DHOB. The N-acetyl 
group was built into both the major and minor binding modes (Figure 3.4). The N-
acetyl group is much larger than the hydroxyl group that it replaces; when the N-acetyl 
group was built into the major binding mode of THB (Figure 3.4a), the N-acetyl group 
came into close contact with the tyrosine residue at position 190. This potential steric 
clash led to the conclusion that AHOB would be unlikely to bind in the NAL E192N 
active-site in this way. When the N-acetyl group was built into the minor binding mode 
(Figure 3.4b), this steric clash was removed and the N-acetyl group was in a space 
where it was not obviously clashing with any of the residues around the active-site. It is 
therefore predicted that the minor binding mode of the THB inhibitor is a closer 
representation of the true binding mode of AHOB than the major binding mode of the 
THB inhibitor. The minor binding mode of DHOB is predicted to favour the pathway 
leading to si-face attack of the aldehyde57 so if AHOB is binding in a manner similar to 
the minor binding mode of DHOB, this may explain why the product resulting from the 
si-face attack of AHOB is observed predominantly. 
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Figure 3.4 - N-acetyl group built onto the C-3 hydroxyl group of the THB inhibitor in the major and 
minor binding modes. In the major binding mode, there is predicted to be a steric clash between the 
N-acetyl group and Y190 (red) (PDB 2WPB)
66
. a) Computation modified inhibitor 56 in the major binding 
mode of THB, surface view shows (left) shows the N-acetyl comes into close contact with the density 
surrounding the Y190 residue, which is further illustrated with the surface removed (right). b) 
Computation modified inhibitor 56 in the minor binding mode of THB, surface view (left) shows that the 
N-acetyl group is now pointing out into solvent and with the surface removed (right), the N-acetyl group 
is clearly seen rotated away from the Y190 residue. 
ManNAc, the natural substrate of NAL, has an N-acetyl group in the same position 
relative to the aldehyde as AHOB. Considering the region of the NAL active-site 
occupied by the N-acetyl group of ManNAc gave some indication as to whether the 
predicted binding mode of AHOB was a reasonable estimation of the true binding 
mode. The computationally modified inhibitor 56 (green), in the minor binding mode 
in the NAL E192N active site 66 has been overlaid with the crystal structure of the 
inhibitor 20 (pink) in complex with the NAL from H. influenza56  (Figure 3.5). The 
carbon chain does not line up as the THB inhibitor sits slightly higher than the inhibitor 
20. However, looking just at the position of the N-acetyl group in both inhibitors, it 
Y190 
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Y137 
N192 K165 
K165 
T167 
S208 
N192 
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points out into the same area of solvent but the N-acetyl group of the inhibitor 20 is 
rotated out and away from the K165 residue. The true binding mode of AHOB is likely 
to be somewhere in between the minor binding mode of DHOB and the binding mode 
of ManNAc. 
 
 
Figure 3.5 - Computationally modified inhibitor 56 (green) in the minor binding mode of THB in the 
active site of NAL E192N in complex with pyruvate overlaid with the 4-oxo-sialic acid inhibitor 20 
(pink) in complex with the NAL from H. influenza  (1F7B).
56
 The surface corresponds to the surface of 
the NAL E192N crystal structure (PDB 2WPB).
66
 
To summarise, the wild-type NAL reaction between ManNAc and pyruvate results in 
attack of the si-face of the aldehyde (therefore the new stereocentre has the (S)-
configuration). The reaction between AHOB and pyruvate also only resulted in attack 
of the si-face of the aldehyde. In order to reduce unfavourable steric interactions, 
AHOB is predicted to bind similarly to the minor binding mode of DHOB, which means 
that the N-acetyl group will point out into solvent, similarly to the N-acetyl group of 
ManNAc/Neu5Ac. It is predicted from QM/MM modelling studies that the minor 
binding mode of DHOB favours attack of the si-face of the aldehyde and it is known 
experimentally that the si-face of ManNAc is attacked in the wild-type reaction. This 
evidence together provides justification for the observed stereoselectivity in the 
reactions between AHOB and pyruvate, catalysed by the NAL variants. 
N-acetyl of 56 
N-acetyl of 20 
K165 
Chapter 3 - NAL-catalysed reactions of aldehyde analogues and pyruvate 
 
67 
 
3.3.2 Rationalisation of complete loss of activity of NAL E192N/T167V/S208V with 
AHOB 
 It is not clear why the NAL E192N/T167V/S208V, under the reaction conditions, 
is inactive towards AHOB. In the reaction with DHOB, the NAL E192N/T167V/S208V 
preferentially forms the product resulting from attack of the re-face of the aldehyde, 
therefore suggesting that NAL E192N/T167V/S208V may direct DHOB into the major 
binding mode. However the mechanism by which this occurs is unknown.57 It has 
already been postulated that AHOB cannot adopt the major binding mode of DHOB, 
which was the justification of the selectivity observed in NAL E192N (Section 3.3.1). 
This proposal however does not fully explain why AHOB is not a substrate for NAL 
E192N/T167V/S208V. 
The mutation which may hold the most clues about why the NAL E192N/T167V/S208V 
variant is inactive is the mutation at position 208. In the wild-type reaction, residue 
S208 forms a hydrogen bond with the C-7 hydroxyl group of Neu5Ac over a distance of 
2.7 Å (Figure 3.6a).56 In the THB inhibitor, the equivalent C-7 hydrogen-bond acceptor 
is the amide oxygen. In both the major and minor binding modes of the THB inhibitor, 
the distance between the S208 residue and the amide-oxygen is too long for a 
hydrogen bond interaction at 6.4 Å and 5.5 Å respectively (Figure 3.6b and c).66 The 
distance is shorter in the minor binding mode, which is the binding mode predicted to 
most closely resemble the true binding mode of AHOB. Since the binding mode of 
AHOB is not exactly known, it is possible that in the true binding mode of AHOB that 
this distance is short enough that hydrogen bonding between S208 and the amide-
oxygen occurs. Therefore, when this interaction is not possible, as in the NAL 
E192N/T167V/S208V variant, no measurable activity is observed. 
The NAL E192N/T167G variant also has very poor activity towards AHOB compared to 
the NAL E192N variant, so it is possible that both the T167 and S208 residues are 
important in binding AHOB. Removing the hydrogen bond donors from just the 167 
position is very detrimental to activity, and removing both hydrogen bond donors is so 
detrimental to binding that the activity is completely lost. 
Chapter 3 - NAL-catalysed reactions of aldehyde analogues and pyruvate 
 
68 
 
 
 
Figure 3.6 - Distances between the mutated residues in the diastereoselective NAL variants 
E192N/T167V/S208V and E192N/T167G and the bound enzyme substrates. a) Wild-type NAL from H. 
influenza in complex with the 4-oxo-sialic acid analogue 20 (PDB 1F7B).
56
 b) Major binding mode of the 
THB inhibitor bound in the active site of NAL E192N in complex with pyruvate. c) Major binding mode of 
the THB inhibitor bound in the active site of NAL E192N in complex with pyruvate (PDB 2WPB).
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In conclusion, in the true binding mode of AHOB, it is possible that the amide-oxygen 
forms a hydrogen bond with S208; consequently S208 plays a more important role in 
directing the binding of AHOB compared to DHOB. If this is the case, the NAL variant 
E192N/T167V/S208V, in which the serine at 208 is replaced with a valine, cannot form 
a hydrogen bond with the amide-oxygen of AHOB, which may be the cause for the 
insignificant activity of this variant. There are multiple binding modes in the NAL 
active-site and the lowest energy binding mode is most likely controlled by a 
combination of the substrate conformation and the active site residues (i.e. the 
sequence of amino acids of the NAL variant) and their conformation. Consequently, it 
is difficult to predict which changes to the substrate may be tolerated by the enzyme 
variants. This Chapter has however highlighted some of the subtleties that need to be 
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understood before protein engineers can truely claim to be able to rationally design 
enzymes. 
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Chapter 4 NAL-catalysed reactions of aldehyde analogues and 
fluoropyruvate 
4.1 Understanding and interpreting the diastereoselectivity of reactions of 
NAL variants with fluoropyruvate 
 The previous Chapter described the NAL-catalysed reactions of AHOB and 
pyruvate. In these reactions only one new stereocentre was formed, hence only two 
diastereomers were possible. In the reaction between the aldehyde analogues and 
fluoropyruvate, two stereocentres are formed, adding an extra level of complexity 
both to identifying and characterising enzyme reaction products and to understanding 
what the results mean in terms of the mechanism of the enzyme. These challenges 
presented in characterisation of enzyme reaction products were overcome by 
exploiting 19F NMR spectroscopy and the mechanistic understanding gained from the 
QM/MM modelling studies carried out previously.57 19F NMR spectroscopy is a very 
useful diagnostic tool and was used to gain information about the disastereoselectivity 
of the NAL variants. The insights gained through computational modelling studies have 
been used to rationalise the diastereoselectivity at the fluorine-bearing chiral centre of 
the products of the NAL catalysed reactions. 
4.1.1 19F NMR spectroscopy as a diagnostic tool 
In order to evaluate the diastereoselectivity of the NAL variants, it must be 
possible to identify which diastereoisomers are formed in each NAL-catalysed reaction. 
In the NAL-catalysed reaction between the aldehyde analogues and fluoropyruvate, 
four diastereomers are possible. However, the reaction products may cyclise in 
solution. In the simple case of AHOB, where X=NHAc, it is only possible to get pyranose 
species; however both - and -anomers are possible (Figure 4.1b). In the case of 
DHOB, where X=OH, the analysis is further complicated by the additional possibility of 
- and -furanose species* (Figure 4.1a). 
                                                     
*
 Throughout this Chapter, “products” refers to the diastereomeric outcomes of the NAL-catalysed 
reaction of the aldehyde variants and fluoropyruvate and “species” refers to the equilibrium ring forms 
of the “products”. 
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Figure 4.1 - Ring forms of the products of the NAL E192N catalysed reactions between aldehyde 
substrate DHOB or AHOB and fluoropyruvate. a) Pyranose and furanose ring forms of the products of 
the NAL variant-catalysed reaction DHOB and fluoropyruvate. The example given here is product 23a b) 
Pyranose only ring forms of the products of the NAL variant-catalysed reactions of AHOB and 
fluoropyruvate. The example given here is product 57a. 
If the NAL variant is unselective, or the position of the equilibrium does not favour one 
ring form, the 1H NMR spectrum of the enzyme reaction product(s) would be very 
complicated. However, each product contains one fluorine atom, therefore there will 
only be one peak in the fluorine NMR spectrum per equilibrium species. 19F NMR 
proved to be an extremely useful diagnostic tool for identifying and characterising the 
enzyme reaction products. Each of the individual species of the products of the 
enzyme-catalysed reactions between the aldehyde analogues and fluoropyruvate are 
characterised by a doublet of doublets in the 19F NMR spectrum. The two coupling 
constants correspond to a proton-fluorine geminal coupling and a proton-fluorine 
vicinal coupling, each of which is characteristic of the species.  
The geminal proton-fluorine coupling constant provides information about whether 
the carbon attached to fluorine is part of a five or a six-membered ring. The geminal 
coupling for a five-membered ring is 3-4 Hz larger than the geminal coupling in a six-
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membered ring, which is around 49 Hz. The chemical shift also provides information 
about whether the fluorine is in the axial or equatorial position of a six-membered 
ring, an axial fluorine has a chemical shift upfield from an equatorial fluorine (Figure 
4.2).33 
 
Figure 4.2 - Geminal proton-fluorine coupling constants in six-membered rings are generally slightly 
smaller than five-membered rings
33
 
Just as for vicinal proton-proton coupling constants, vicinal proton-fluorine coupling 
constants can be described by the Karplus relationship, which defines the relationship 
between the dihedral angle between vicinal subsituents and the coupling constant.86 
This relationship serves as a guide to predict the coupling constants of the pyranose 
forms of each of the possible products. Coupling constants in six-membered rings are 
generally well defined and can therefore be used to evaluate the relationship between 
vicinal substituents. Proton-fluorine coupling constant are typically much larger than 
proton-proton coupling constants as outlined in Table 4.1, which shows the range of 
expected vicinal proton-proton and proton-fluorine coupling constants in six 
membered rings. 
Table 4.1 - Typical proton-proton and proton-fluorine vicinal coupling constants in six-membered 
rings
33, 87
 
Vicinal 
proton  
 
Range of 
3
JHH  
X=H /Hz 
Range of 
3
JHF  
X=F /Hz 
Range of 
3
JHH  
X=H /Hz 
Range of 
3
JHF  
X=F /Hz 
H-axial 8-11 25-35 3-6 10-25 
H-equatorial 3-6 10-25 0-4 0-10 
 
An understanding of the Karplus relationship was applied to predict ranges of the 
diagnostic vicinal proton-fluorine and proton-proton coupling constants for a pyranose 
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ring form each of the four possible diastereomers of the enzyme reaction products, as 
shown in Figure 4.3. The pyranose ring forms of the products 23/57a will have the 3-F 
and 4-H in the axial position and will have the largest proton-fluorine vicinal coupling 
constant. The products 23/57b, which have an equatorial 3-F and an equatorial 4-H, 
will have the smallest proton-fluorine vicinal coupling constant. The products 23/57c 
and 23/57d cannot be distinguished from the proton-fluorine coupling constant alone, 
as they may be similar, and can only be distinguished by the proton-proton vicinal 
coupling constants. The 5-H of 23/57 will always be axial in a pyranose ring due to the 
structure of the starting material and a preference for the largest substituents to be in 
the equatorial positions, therefore the vicinal coupling constant between the 4-H and 
5-H is very diagnostic. This coupling constant will be largest when the 4-H is axial, as in 
product 23/57d, and smaller when the 4-H is equatorial, as in product 23/57c. 
 
Figure 4.3 - Schematic representation of relative proton-fluorine and proton-proton vicinal coupling 
constants of the pyranose rings in each of the four possible diastereomeric products from the reaction 
between DHOB/AHOB and fluoropyruvate. 
4.1.2 Prediction of the enzyme reaction products based on QM/MM modelling 
studies 
 In the reaction between the aldehyde analogues and fluoropyruvate, catalysed 
by the NAL variants, there are three factors to consider: the face of the enamine which 
attacks the aldehyde, the face of the aldehyde which is attacked and the geometry of 
the enamine. For the purpose of simplifying the explanation of the diastereoselectivity, 
the faces of the enamine will be referred to as the "top" and "bottom", which means, if 
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the enamine is orientated so that the lysine residue is in the back right quadrant, "top" 
refers to the aldehyde coming in from above and "bottom" refers to the aldehyde 
coming in from below (as the enamine is drawn in Figure 4.4). 
 
Figure 4.4 - Illustration of nomenclature for describing the two faces of the fluoro-enamine 
The Y137 residue is believed to transfer the proton to the aldehyde.57 In order for Y137 
to be close enough to the substrate to carry out the proton transfer, it is predicted that 
the aldehyde has to be attacked from the "top" face of the enamine. Furthermore, it is 
known from the crystal structure of fluoropyruvate in complex with NAL from S. 
aureus63 that the fluoroenamine adopts the (Z)-configuration in complex with K165 
(Figure 4.5a)  This observation was consistent with the modelling studies carried out 
on the complex between n-butylamine and fluoropyruvate, which predicted the (Z)-
configuration to be 35.2 kJ mol-1 lower in energy than the (E)-configuration57 (Figure 
4.5b). 
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Figure 4.5 - The enamine complex between K165 and fluoropyruvate in the NAL active-site 
preferentially adopts the (Z)-configuration and the attack on the aldehyde comes from the “top” face 
of the enamine. a) Y137 (gold) is positioned above the "top" face of the (Z)-fluoroenamine, therefore it 
is predicted that the aldehyde can only be protonated from the "top" face of the (Z)-enamine.
63
 b) The 
(Z)-configuration was calculated to be 35.2 kJmol
-1
 lower in energy thant the (E)-configuration.
57
 
The "top" face of the (Z)-enamine can attack either the si or re-face of the aldehyde, 
which is illustrated using Newman projections in Figure 4.6. This mode of attack can 
lead to only the two diastereomers with the (3R)-configuration. The two diastereomers 
with the (S)-configuration at C-3 can only be accessed by either attack from the 
"bottom" face of the (Z)-enamine or attack from the "top" face of the (E)-enamine, 
both of which are predicted to be unfavoured. It was hypothesised that the 
diastereomers with (3R,4R) and (3R,4S)-configurations would be observed most 
frequently in the NAL variant-catalysed reactions of the aldehyde analogues and 
fluoropyruvate. In Section 4.5.1, this hypothesis is evaluated along with further 
discussion into the diastereoselectivity of NAL variants towards reactions of 
fluoropyruvate. 
a) 
+ 35.2 kJmol-1                                0 kJmol-1 
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Figure 4.6 - Newman projections of the "top" face of the (Z)-enamine attacking the re or si-face of the 
aldehyde, leading to the formations of diastereomers with (3R)-configuration. 
4.2 NAL E192N variants in the preparation of 3-fluoro-N-acetyl neuraminic 
acid analogues from AHOB 
4.2.1 Conditions for the enzyme catalysed reaction between 3-fluoropyruvate and 
AHOB 
 AHOB and ent-AHOB were generated by ozonolysis of the alkene precursors 25 
and ent-25 as described previously (Section 3.1.1) and used immediately without 
purification. The conditions used for the preparative scale reaction between 
fluoropyruvate and AHOB were different from those for the reaction between 
pyruvate and AHOB (Section 3.1.2). In the reactions of fluoropyruvate, the aldehyde 
was generally used either in excess or equimolar equivalents and Bakers’ yeast was not 
used. The conditions were altered because there is evidence that fluoropyruvate may 
act as an inhibitor to NAL60 and it has previously been found that using excess 
fluoropyruvate results in formation of several by-products.57 
The preparative scale reactions between fluoropyurvate and AHOB/ent-AHOB are 
summarised in Table 4.2. Carrying out the reaction with fluoropyruvate as the limiting 
reagent made it possible to estimate the conversion by measuring the relative 
integrals of fluoropyruvate and product peaks in the 296 MHz 19F NMR spectrum 
before HPLC purification. It was therefore possible to ascertain whether low yields 
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were due to low conversions or difficulty in purification. The products were purified 
initially by Dowex® ion exchange and in the cases where sufficiently high conversion 
was observed, reverse-phase mass-directed HPLC was used to remove the unreacted 
fluoropyruvate. In all cases, the conversions and yields were very low and only the 
reaction between AHOB and fluoropyruvate, catalysed by NAL E192N (Entry 1), gave 
enough product to warrant HPLC purification. In order to find out if the reaction could 
be carried out with an excess of fluoropyruvate, five equivalents of fluoropyruvate 
were used in the NAL E192N catalysed reaction of AHOB (Entry 2), however although 
the conversion was estimated to be improved, the yield after HPLC purification was 
not significantly increased. NAL E192N/T167V/S208V, as previously, was found to be 
inactive towards both enantiomers of AHOB. Some of the reactions were left for more 
than two days (Entries 2, 6 and 7), in the hope of improving the yield however AHOB is 
not very stable and decomposes over the course of two days, so it is unlikely that 
longer reaction times would lead to an improvement in the overall conversion/yield. 
Remarkably, the reactions were all highly selective and the following Sections outline 
how the relative configurations of the products were assigned. 
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Table 4.2 - Conditions, estimated conversion and yield after reverse-phase HPLC purification of the 
reactions between AHOB and ent-AHOB with fluoropyruvate, catalysed by NAL variants. 
 
Entry Aldehyde 
NAL 
variant 
Equivalents of 
aldehyde: 
F-pyruvate 
Reaction 
time 
/days 
Conversion
a
 % 
Yield 
after 
HPLC % 
Products 
observed 
1 AHOB E192N 1:1 2 21 5 
57a and 
57d 
(98:2) 
2 AHOB E192N 1:5 5 50
b
 7 
57a and 
57d 
(98:2) 
3 AHOB 
E192N/ 
T167V/ 
S208V 
1:0.75 2 0 - - 
4 AHOB 
E192N/ 
T167G 
1:0.75 2 0.3 c 
57a 
(>98:<2) 
5 ent-AHOB E192N 1:0.75 2 5.6 c 
ent-57d 
(>98:<2) 
6 ent-AHOB 
E192N/ 
T167V/ 
S208V 
1:1 7 0 - - 
7 ent-AHOB 
E192N/ 
T167G 
1:1 7 4.7 c 
ent-57a 
(>98:<2) 
a) Conversions were calculated by measuring the relative integrals in the 296 MHz 
19
F NMR of the 
products after purification by ion exchange. b) Fluoropyruvate was used in excess so estimating the 
conversion from 296 MHZ 
19
F NMR integrals would have had a much larger error. c) HPLC purification 
was not carried out due to low conversion. 
 
 
Chapter 4 - NAL-catalysed reactions of aldehyde analogues and fluoropyruvate 
 
79 
 
4.2.2 Identification and characterisation of diastereomers of enzyme catalysed 
reactions of AHOB and fluoropyruvate 
The 296 MHz 19F NMR spectra of the NAL variant-catalysed reactions of 
AHOB/ent-AHOB and fluoropyruvate were recorded (see Appendix 4) and the 19F NMR 
spectrum of the HPLC purified product 57a is shown in Figure 4.7 as an example. The 
chemical shifts and coupling constants of the peaks observed by 19F NMR were 
measured and the configurations at C-3 and C-4 were assigned (Table 4.3). The peaks 
at –207.8 ppm and –218.5 ppm had vicinal coupling constants of 29.1 Hz and 28.8 Hz 
respectively, which was within the range expected for the diastereomer where the 3-F 
and 4-H are both axial, therefore this product was proposed to be 57a. The two peaks 
correspond to the major and minor anomers, which were observed in a ratio of 98:2. 
The product 57d/ent-57d was characterised by a peak at –199.2 ppm with a vicinal 
coupling constant 10.4 Hz, which is at the bottom end of the range of predicted 
coupling constants for an axial-equatorial relationship between the fluorine and the 
vicinal proton. Unfortunately, due to low conversion, it was not possible to acquire a 
good 1H NMR spectrum of the product ent-57d. The configuration was assigned by 
correlation of the data with a compound with the same configuration which was 
purified (see characterisation of product ent –23d in Section 4.3.2.1). 
 
Figure 4.7 - 296 MHz 
19
F NMR of the mass-directed reverse-phase HPLC purified product 57a. 
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Table 4.3 - Chemical shifts and coupling constants from the 296 MHz 
19
F NMR of the observed 
products of the NAL variant-catalysed reactions of AHOB/ent-AHOB and fluoropyruvate. 
 
Product 
F (295 MHz, 
D2O) /ppm 
J /Hz 
Predicted 
ring form 
Ratio of 
equilibrium 
species 
Configuration at C-3 
and C-4 
57a 
–207.8 49.0 and 29.1 Pyranose 
98:2 
(3R,4R) 
[(3S,4S) - ent-57a] –218.5 50.2 and 28.8 Pyranose 
57d –199.2 49.3 and 10.4 Pyranose >98:<2 
(3S,4R) 
[(3R,4S) - ent-57d] 
 
In order to further confirm the configuration of the product 57a, the 500 MHz 1H NMR 
spectrum of the mass-directed reverse-phase HPLC purified material was recorded. 
The 500 MHz 1H NMR spectrum (Figure 4.8), provided all of the proton-proton 
diagnostic coupling constant around the pyranose ring, which are recorded and 
characterised in Table 4.4. The large coupling constant of 10.0 Hz between 5-H and 4-H 
and the smaller coupling constant of 2.2 Hz between 4-H and 3-H are consistent with 
the expected coupling constants of the product 57a. 
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Figure 4.8 - 500 MHz 
1
H NMR spectrum of the product 57a. The product was purified by mass-directed 
reverse-phase HPLC in order to remove excess fluoropyruvate  
 
Table 4.4 - Characteristic chemical shifts and coupling constant of the protons of the pyranose ring of 
the product 57a. 
 
H (500 MHz, 
D2O) /ppm 
Multiplicity 
2
JHF /Hz 
3
JHF /Hz 
3
JHH /Hz Identity 
4.90 dd 49.2 - 2.2 3-H 
4.83 d - - 10.0 6-H 
4.23 t - - 9.9 5-H 
4.16 ddd - 29.1 10.9 and 2.2 4-H 
 
The overall selectivity of NAL E192N and E192N/T167G towards AHOB and ent-AHOB 
in the reaction with fluoropyruvate is summarised in Table 4.5. Generally, as predicted 
in Section 4.1.2, the (3R)-epimer is almost exclusively preferred and the only exception 
is the NAL E192N/T167G-catalysed reaction of ent-AHOB, which appears to give a 
product with (3S)-configuration but the conversion in this reaction was very low (4.7% 
conversion) and will be discussed later (Section 4.5.1). 
6-H 
5-H 4-H 
3-H 
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Table 4.5 - Summary of the products of the reactions between AHOB/ent-AHOB with fluoropyruvate 
catalysed by NAL variants. 
 
Aldehyde NAL variant 
Products 
observed 
Ratio of 
products 
a:b:c:d 
Ratio of products by 
configuration at C-3 and C-4 
(3R,4R):(3S,4S): 
(3R,4S):(3S,4R): 
AHOB 
E192N 57a and 57d 98:0:0:2 98:0:0:2 
E192N/T176G 57a 100:0:0:0 100:0:0:0 
ent-AHOB 
E192N ent-57d 0:0:0:100 0:0:100:0 
E192N/T176G ent-57a 100:0:0:0 0:100:0:0 
 
4.3 NAL variants in the preparation of 3-fluoro-N-acetyl neuraminic acid 
analogues from DHOB 
4.3.1 Challenges presented in the characterisation of products derived from DHOB 
DHOB and ent-DHOB were generated by ozonolysis from the alkene precursors 
24 and ent-24 as described previously (Section 3.1.1) and used immediately without 
further purification. The reactions between DHOB/ent-DHOB and fluoropyruvate 
catalysed by the NAL variants were carried out in much the same way as the reactions 
of AHOB, with equimolar equivalents of aldehyde and fluoropyruvate or an excess of 
aldehyde. The conversions and yields achieved in the reactions were considerably 
higher compared to AHOB and the conditions and conversions are given in Table 4.6. 
The reactions were carried out in aqueous 50 mM Tris.HCl buffer at pH 7.4, since 
neither the buffer nor the solvent contain any fluorine atoms, it was possible to 
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perform 19F NMR on the reaction mixtures rather than on purified product. It was 
therefore possible to analyse the conversion and diastereoselectivity of the enzyme 
reactions without the need to purify the products of every reaction. For the reactions 
that were not purified the conversion is given but not the yield. While the yields were 
higher compared to the reactions of AHOB, the selectivity was greatly reduced in the 
case of NAL E192N and E192N/T167G, which led to greater difficulty in identifying and 
characterising the reaction products. Notably, product 23a, the minor product of the 
NAL E192N-catalysed reaction of DHOB and fluoropyruvate, was only ever observed in 
a mixture with 23c. 
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Table 4.6 - Conditions, estimated conversion and yield after reverse-phase HPLC purification of the 
reactions between DHOB and ent-DHOB with fluoropyruvate, catalysed by NAL variants. 
 
Entry Aldehyde NAL variant 
Equivalents 
of aldehyde: 
F-pyruvate 
Reaction 
time 
/days 
Conversion 
% 
Yield
a
 
% 
Products 
observed
d 
1 DHOB E192N 2:1 2 >99 53 
23a and 23c 
(40:60) 
2 DHOB 
E192N/T167V/
S208V 
2:1 2 94 41 
23c 
(>98:<2) 
3 DHOB E192N/T167G 1:1 6
 b
 79 - 
23a, 23c and 
23d 
(28:70:2) 
4 ent-DHOB E192N 1:1 6
 b
 45 - 
ent-23a and 
ent-23d 
(8:92) 
5 ent-DHOB 
E192N/T167V/
S208V 
1:1 1 NM
c
 52 
23d 
(>98:<2) 
6 ent-DHOB E192N/T167G 1:1 6
b
 38 - 
ent-23a and 
ent-23d 
(10:90) 
a) Yield after purification by ion exchange b) Reaction mixture was not purified. The reactions were 
monitored by 
19
F NMR and the conversions given were after 6 days of reaction. c) NM = Not measured 
d) Products observed by 395 MHz 
19
F NMR of purified products (where products were purified) and 
crude products (where products were not purified). 
Figure 4.9 shows the 395 MHz 19F NMR spectra of the reactions between DHOB and 
fluoropyruvate catalysed by NAL E192N (Figure 4.9a), E192N/T167V/S208V (Figure 
4.9b) and E192N/T167G (Figure 4.9c). In the NAL E192N-catalysed reaction of DHOB, 
two different diastereomers are observed. The minor diastereomer, identified as 
product 23a (indicated in red), existed predominantly as one ring form characterised 
by the peak at –206.0 ppm, with a small amount of the minor ring form characterised 
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by the peak at –216.8 ppm. This same diastereomer, product 23a, is also observed as 
the minor product in the NAL E192N/T167G catalysed reaction. In all three reactions, 
the product identified as 23c (indicated in blue) is always observed as the major 
diastereomer. Product 23c exists as a complex mixture of four equilibrium species in a 
ratio of 37:23:29:11. In the NAL E192N/T167V/S208V-catalysed reaction of DHOB, the 
product 23c is the only diastereomer observed. Finally, there is a very small amount of 
the product identified as 23d (indicated in green), characterised by a peak at –199.8 
ppm, which under the reaction conditions, is only observed as a product of the NAL 
E192N/T167G-catalysed reaction. 
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Figure 4.9 - 395 MHz 
19
F NMR of products isolated after ion exchange of the reactions between 
fluoropyruvate and DHOB catalysed by NAL variants. Product peaks are indicated in blue (product 
23c), red (product 23a) and green (product 23d). The multiplets observed at –193.8 ppm and –201.0 
ppm were found to correspond to a by-product which was removed upon further purification. a) 
E192N catalysed reaction between DHOB and fluoropyruvate b) E192N/T167V/S208V catalysed reaction 
of DHOB and fluoropyruvate c) E192N/T167G catalysed reaction of DHOB and fluoropyruvate. The 
spectrum of the E192N/T167G was recorded on the un-purified reaction mixture, so some of the 
chemical shifts are slightly different due to a difference in pH and the presence of salts from the reaction 
buffer, however the coupling constants are consistent across all three experiments. 
The reactions of ent-DHOB are rather more selective and the 395 MHz 19F NMR 
spectra of each the products are shown in Figure 4.10. All three NAL variants give one 
major diastereomer, identified as product ent-23d (indicated in green), which is 
characterised by a peak at –199.8 ppm. NAL E192N/T167V/S208V, in the reaction with 
ent-DHOB, appears to be completely selective (Figure 4.10b). NAL E192N (Figure 
4.10a) and E192N/T167G (Figure 4.10c) both gave a small amount of the diastereomer 
characterised by a peak at –206.0 ppm, identified as ent-23a (highlighted in red). 
a) 
b) 
c) 
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Figure 4.10 - 395 MHz 
19
F NMR of products isolated after ion exchange of the reactions between 
fluoropyruvate and ent-DHOB catalysed by NAL variants. a) E192N catalysed reaction between ent-
DHOB and fluoropyruvate b) E192N/T167V/S208V catalysed reaction of ent-DHOB and fluoropyruvate c) 
E192N/T167G catalysed reaction of ent-DHOB and fluoropyruvate 
4.3.2 Characterisation of the products of the NAL variant-catalysed reactions of 
DHOB and fluoropyruvate 
Table 4.7 outlines the peaks and coupling constants which correspond to each of the 
observed products of the NAL variant-catalysed reactions of DHOB/ent-DHOB and 
fluoropyruvate. This highlights a second challenge in the characterisation of products 
of the reactions of DHOB/ent-DHOB; the product 23c exists as a complex mixture of 
equilibrium species. This is compounded by the problem identified previously that the 
product 23a is only observed in a mixture of diastereomers with 23c. The following 
sections explain how each of the diastereomers were individually characterised by 
exploiting further purification techniques and advanced NMR experiments. 
a) 
b) 
c) 
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Table 4.7 - Characterisation by 395 MHz 
19
F NMR spectroscopy of diastereomers from the NAL 
catalysed reactions of DHOB and ent-DHOB with fluoropyruvate 
 
Products 
observed 
F (395 MHz, 
D2O) /ppm 
J /Hz 
Predicted 
ring form 
Ratio of 
equilibrium 
species 
Configuration at C-
3 and C-4 
23a 
–206.0 
49.9 and 
32.5 
Pyranose 
92:8 
(3R,4R) 
[(3S,4S) – ent-23a] 
–216.8 
51.4 and 
32.8 
Pyranose 
23c 
–190.5 
50.5 and 
24.0 
Pyranose 
37:23:29:11 (3R,4S) 
–194.5 43.7 and 4.7 Furanose 
–201.9 
53.1 and 
18.7 
Pyranose 
–207.4 
48.5 and 
10.1 
Furanose 
23d –199.8 
49.3 and 
13.3 
Pyranose >98:<2 
(3S,4R) 
[(3R,4S) – ent-23d] 
 
4.3.2.1 Characterisation of the product of the NAL E192N/T167V/S208V-catalysed 
reaction of ent-AHOB and fluoropyruvate 
 The product of the NAL E192N/T167V/S208V catalysed reaction of ent-DHOB 
and fluoropyruvate is characterised by a peak in the 19F NMR at –199.8 ppm and has 
been identified as the product ent-23d. The enantiomer of this product (23d) is also 
observed in the NAL E192N/T167G catalysed-reaction of DHOB and pyruvate. Since 
this product could be isolated without the need to separate mixtures of diastereomer 
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and existed predominantly as one ring form, it was characterised without need for 
further purification or advanced analytical techniques. The 500 MHz 1H NMR spectrum 
was recorded (Figure 4.11) and the structure was confirmed by careful analysis of the 
coupling constants of the protons attached to the carbons in the pyranose ring (Table 
4.8). The coupling constant between the 5-H and 4-H is 9.5 Hz and the 5-H appears as a 
triplet, which indicated that the 4-H, 5-H and 6-H were all axial. Furthermore, the 
coupling constant between 4-H and 3-H is 9.3 Hz, which indicated that both of these 
protons are axial, which means that the fluorine must be equatorial, therefore 
confirming the identity of this product as ent-23d. 
 
Figure 4.11 – Expansion of the 500 MHz 
1
H NMR spectrum of the product ent-23d 
Table 4.8 - Diagnostic chemical shifts and coupling constants from the 500 MHz 
1
H NMR of the product 
23d 
 
H (500 MHz, 
D2O) /ppm 
Multiplicity 
2
JHF /Hz 
3
JHF /Hz 
3
JHH /Hz Identity 
4.62 d - - 9.7 6-H 
4.60 dd 49.3 - 9.3 3-H 
3.95 dt - 13.3 9.4 4-H 
3.78 t - - 9.5 5-H 
 
6-H 
5-H 
4-H 
3-H 
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The characterisation of ent-23d has assumed that the major equilibrium species of this 
diastereomers is a pyranose ring. This was confirmed by recording an NOE spectrum. 
The peak at 3.95 ppm (corresponding to 4-H) was irradiated and correlation was 
observed with the peak at 4.62 ppm, which corresponds to 6-H (Figure 4.12). 
 
Figure 4.12 - NOE spectrum of ent-23d provided evidence that the major equilibrium species was a 
pyranose ring. Predicted to be observed as a positive NOE due formation of non-covalent polymerised 
lattices resulting in slower tumbling. 
4.3.2.2 Separation of mixtures of diastereomers 
In the NAL E192N catalysed reaction of DHOB and fluoropyruvate, a mixture of 
two diastereomeric products was observed, products 23a and 23c. The mixture was 
difficult to separate, however it was possible to prepare a small quantity of each of the 
diastereomers by semi-preparative reverse-phase HPLC (Figure 4.13a). Product 23a 
was eluted after 28.7 minutes (Figure 4.13b), was confirmed to exist predominantly as 
one equilibrium species, which is characterised by a peak at –206.0 ppm. While the 
vicinal proton-fluorine coupling constant indicated that this peak corresponded to the 
diastereomer in which the 3-F and 4-H were axial, in order to be sure it was necessary 
to acquire a 1H NMR spectrum. Product 23c was eluted after 31.0 minutes (Figure 
6-H 5-H 
4-H - irradiated 
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4.13c) and was observed as a complex mixture of equilibrium species and the 
characterisation of this diasteromer will be discussed in Section 4.3.2.3. 
 
  
Figure 4.13 – Separation of the products of the NAL E192N catalysed reaction of DHOB and 
fluoropyruvate by reverse-phase HPLC a) UV-Vis trace 210 nm from the reverse-phase HPLC 
purification. Two peaks are observed at 28.7 minutes and 31.0 minutes. b) 395 MHz 
19
F NMR spectrum 
of the product 23a was eluted after 28.7 minutes c) 395 MHz 
19
F NMR spectrum of product 23c was 
eluted after 31.0 minutes. Some contamination from the product 23c can still be observed in the 
spectrum of product 23a. 
Having separated the mixture of diastereomers, it was possible to obtain a 500 MHz 1H 
NMR spectrum (Figure 4.14) and confirm the structure of product 23a. The 
configuration of product 23a was confirmed by careful analysis of the coupling 
constants of the protons attached to the carbons in the pyranose ring (Table 4.9). Most 
importantly, the vicinal coupling constant between the 4-H and 5-H was measured to 
be 9.7 Hz, which indicated that both of these protons are axial in a pyranose ring. It 
was therefore concluded that the minor diastereomer of the NAL E192N-catalysed 
reaction between DHOB and fluoropyruvate was the product 23a. 
28.7 min 
31.0 min 
a) b) 
c) 
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Figure 4.14 – Expansion of the 500 MHz 
1
H NMR spectrum of the product 23a 
 
Table 4.9 - Diagnostic chemical shifts and coupling constants from the 500 MHz 
1
H NMR of the product 
23a. 
 
H (500 MHz, 
D2O) 
Multiplicity 
2
JHF (Hz) 
3
JHF (Hz) 
3
JHH (Hz) Identity 
4.78 dd 49.9 - 3.4 3-H 
4.75 d - - 9.2 6-H 
3.97-3.90 m - 31.2* 9.7 and 3.4† 4-H 
3.88 t - - 9.7 5-H 
*Measured from the 395 MHz 
19
F NMR spectrum †Estimated coupling constants based on coupling 
constants observed for neighbouring protons. 
The predicted pyranose ring form of 23a was confirmed by NOE. The peak at 4.75 ppm 
(corresponding to 6-H) was irradiated and correlation was observed with the peak 
corresponding to 4-H and the peak corresponding to the protons of the propyl chain 
closest to the nitrogen (Figure 4.15). 
6-H 
5-H 
4-H 
3-H 
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Figure 4.15 - NOE spectrum of 23a provided evidence that the major equilibrium species was a 
pyranose ring. 
4.3.2.3 Application of 1H/19F HSQC-TOCSY in the characterisation of complex mixtures 
of equilibrium species 
 The product 23c existed as a mixture of equilibrium species, therefore it was 
difficult to confirm by 1H NMR the configuration of this product. Figure 4.16 shows the 
500 MHz 1H NMR spectrum of 23c, in which the peaks corresponding to the four 
equilibrium species overlap. The proton-fluorine vicinal coupling constants for each 
species were determined by 395 MHz 19F NMR spectroscopy which confirmed an axial-
equatorial relationship between 3-F and 4-H in the pyranose form, but no gave no 
indication of whether the 3-F or the 4-H was the axial substituent. It was therefore 
necessary to employ two-dimensional NMR techniques, which were carried out in 
collaboration with Dr. Tomas Lebl,* in order to deconvolute the spectra of the species. 
                                                     
*
 University of St. Andrews, UK 
4-H 6-H - irradiated propyl 1-H2 
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Figure 4.16 - Region of the 500 MHz 
1
H NMR spectrum of the diastereomer 23c.  
While the 1H NMR spectrum of 23c is very complicated, the 19F NMR spectrum of the 
HPLC-purified product has four clear peaks corresponding to each of the four 
equilibrium species. It was therefore decided to extract the 1H NMR spectrum of each 
of the equilibrium species using a two-dimensional 1H/19F experiment (1H/19F HSQC-
TOCSY). 
TOCSY (TOtal Correlation SpectroscopY) is a homonuclear two-dimensional technique 
in which cross-peaks between signals corresponding to nuclei in the same spin system 
are observed. HSQC (Heteronuclear Single Quantum Coherence spectroscopy) is a 
second two-dimensional technique that is used to evaluate coupling between protons 
and other nuclei.87 
Figure 4.17a shows the 4 possible equilibrium forms of 23c and Figure 4.17b shows the 
recorded 1H/19F HSQC-TOCSY spectrum. The vertical axis shows the four peaks in the 
19F NMR spectrum corresponding to each equilibrium species. By taking a slice through 
the centre of each row, it was possible to measure both the chemical shifts and the 
coupling constants of the proton peaks corresponding to each of the equilibrium 
species. The extracted 1H NMR spectra of the equilibrium species are shown in Figure 
4.17c. It should be noted that the integration of the peaks relates the efficiency with 
which magnetisation was transferred around the ring. 
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In order to observe correlation between 19F and the most distance protons, this 
techniques was complemented by recording the 1H/19F HMQC (Heteronuclear Multiple 
Quantum Coherence) spectrum (blue) which was overlaid onto the  1H/19F 
HSQC/TOCSY (red) (Figure 4.18) in order to show the cross-peaks corresponding to the 
protons furthest from the fluorine. The contour of the peaks in the HMQC does not 
have the same level of resolution as the HSQC/TOCSY spectrum, so no further 
information could be gained about coupling constants. 
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Figure 4.17 – Extraction of the individual 
1
H NMR spectra corresponding to each of the equilibrium species of 23c by  
1
H/
19
F HSQC-TOCSY.  a) Equilibrium forms of 23c. b) 
1
H/
19
F 
HSQC-TOCSY spectrum of the product of the reaction between DHOB and fluoropyruvate catalysed by E192N/T167V/S208V. The cross-peaks show the protons in the same spin 
system as each of the fluorine environments. c) Extracted 
1
H NMR spectra from the 
1
H/
19
F HSQC-TOCSY spectrum of the reaction between DHOB and fluoropyruvate.  
c) 
a) 
–190.5 ppm 
–194.5 ppm 
–201.9 ppm 
–207.4 ppm 
b) 
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Figure 4.18 - 
1
H/
19
F HSQC-TOCSY spectrum (red cross-peaks) overlaid with 
1
H/
19
F HMQC spectrum 
(blue cross-peaks) of the product 23c. The HMQC identifies cross-peaks which are weak in the HSQC-
TOCSY spectrum. 
 With all the information gathered together from the two-dimensional NMR 
experiments (Table 4.10), it was possible to assign the spectra and identify the 
structure of 23c by careful analysis of the coupling constants of the pyranose species. 
In the previously characterised pyranose species the geminal proton-fluorine coupling 
constants have always been measured at 49-50 Hz, therefore it was predicted that the 
pyranose species were those characterised by a peaks in the 19F NMR spectrum at        
–190.5 ppm (blue) and –201.9 ppm (yellow). Unfortunately, due to the complexity of 
the 1H NMR spectrum it was not possible to acquire a NOE spectrum to confirm this 
prediction. The configuration of DHOB dictated that 5-H and 6-H must be both axial, 
however the coupling constants measured between these two protons were quite 
small. Furthermore the proton-fluorine vicinal coupling constants of the pyranose 
species were surprisingly large. The deviation of the magnitude of the proton-proton 
coupling constants may be a consequence of flattening of the pyranose rings, perhaps 
due to an unfavourable 1,3-diaxial interaction between the C-4 hydroxyl and the C-2 
substituent. This may also explain why this diastereomer was observed as an 
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equilibrium mixture of ring forms because unfavourable steric interactions occur in all 
of the possible ring forms. 
Table 4.10 - Diagnostic chemical shifts and coupling constants of the equilibrium species of product 
23c from extracted 
1
H NMR spectra. 
 
F (395 MHz, 
D2O) /ppm
H (500 MHz, 
D2O) /ppm 
Multiplicity 
2
JHF /Hz 
3
JHF /Hz 
3
JHH /Hz Identity 
Major pyranose 
–190.5 
4.85 dd 49.7 - 4.8 3-H 
4.65 d - - 6.1 6-H 
4.39 dd - 22.4 3.7 4-H 
4.12 t - - 5.0 5-H 
Major furanose 
–194.5 
4.72 dd 44.2 - 1.7 3-H 
4.02 app. t - 5.9 7.4 4-H 
3.96 m - - - 5-H 
Minor pyranose 
–201.9 
5.03 dd 52.0 - 5.5 3-H 
4.57 d - - 7.2 6-H 
4.46 dt - 18.7 5.6 4-H 
3.95 t - - 6.4 5-H 
Minor furanose 
–207.4 
4.86 dd 48.1 - 7.3 3-H 
4.75 d - - 5.4 6-H 
4.30 td - 8.7 3.4 4-H 
4.18 dd - - 8.6 and 5.1 5-H 
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4.3.3 Summary of the products of the NAL-catalysed reaction of DHOB/ent-DHOB 
and fluoropyruvate 
 The products of the NAL catalysed reaction of DHOB/ent-DHOB and 
fluoropyruvate more difficult to characterise. The products of the ent-DHOB reactions 
with fluoropyruvate were less challenging to characterise as all three NAL variants gave 
predominantly one diastereomer, which existed as one major equilibrium species. By 
the application of separation techniques and informative two-dimensional NMR 
experiments, it was possible to identify and characterise the products of the DHOB 
reactions (summarised in Table 4.11). As previously observed for the reactions of 
AHOB, the (3R)-epimers are by far the most common as predicted in Section 4.1.2. 
Table 4.11 - Summary of the products of the NAL variant-catalysed reactions between DHOB and ent-
DHOB with fluoropyruvate. 
 
Aldehyde NAL variant Products observed 
Ratio of 
products 
a:b:c:d 
Ratio of products by 
configuration at C-3 and C-4 
(3R,4R):(3S,4S): 
(3R,4S):(3S,4R): 
DHOB 
E192N 23a and 23c 40:0:60:0 40:0:60:0 
E192N/T167V/S208V 23c 0:0:100:0 0:0:100:0 
E192N/T176G 23a, 23c and 23d 28:0:70:2 28:0:70:2 
ent-DHOB 
E192N ent-23a and ent-23d 8:0:0:92 0:8:92:0 
E192N/T167V/S208V 23d 0:0:0:100 0:0:100:0 
E192N/T176G ent-23a and ent-23d 10:0:0:90 0:10:90:0 
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4.4 Analysis of reactions of alternative substrates catalysed by NAL E192N 
variants by 296 MHz 19F NMR spectroscopy 
 The preparative-scale enzyme-catalysed reactions discussed previously have 
provided some information about the potential value of the NAL variants in the 
synthesis of fluorinated analogues of Neu5Ac, however many of the results are 
qualitative. In order to better understand the activity of the enzyme variants, further 
experiments were carried out in order to make direct comparison between the 
enzyme-catalysed reactions which can be quantified. Furthermore, in order to fully 
understand the diastereoselectivity of the NAL variants, it is important to analyse the 
kinetic ratios of products.  
In order to answer these questions, a series of reactions were carried out on a small 
scale and monitored by 296 MHz 19F NMR spectroscopy. The reactions were driven by 
excess aldehyde (5 molar equivalents). With fluoropyruvate as the limiting reagent, it 
was possible to calculate the conversion of fluoropyruvate to product at each time 
point over the course of 35 hours and plot the disappearance of fluoropyruvate and 
appearance of products over time. It was possible in this way to simultaneously 
compare the initial rates of reaction and evaluate the kinetic selectivity. The most 
constructive way to understand the stereocontrol imparted by the NAL-variants is to 
consider the absolute configuration of C-3 and C-4. The colour-coding used in 
presentation of the data throughout the following Sections is related to the 
configuration at C-3 and C-4 rather than pairs of enantiomers. 
4.4.1 Comparison of initial rates of enzyme catalysed reactions 
 In order to monitor the rate of the enzyme-catalysed reactions, a series of 
reactions were carried out in NMR tubes. In order for the NMR machine to lock, it is 
necessary to have a small amount of deuterated solvent in the NMR tube; however 
adding deuterium oxide to the buffer directly would have resulted in deuterium 
incorporation into the products. In order to overcome this problem, a sealed capillary 
tube containing deuterium oxide was placed inside the NMR tube so the deuterium 
oxide would not be in direct contact with the reaction mixture. 
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296 MHz 19F NMR spectra were recorded at suitable intervals over a period of 35 
hours. Figure 4.19 shows a stacked-plot of 5 time points taken from the reaction 
between DHOB and fluoropyruvate, catalysed by NAL E192N/T167V/S208V as an 
example. It is clear to see the intensity of the peaks corresponding to product 
(highlighted in blue) relative to fluoropyruvate (highlighted in orange) increased over 
time. The fluoropyruvate appeared as two triplets, this is because in an aqueous 
solution, the fluoropyruvate was in equilibrium between the ketone and hydrate form. 
 
Figure 4.19 – Time course of the reaction between DHOB and fluoropyruvate catalysed by 
E192N/T167V/S208V 
By measuring the relative integrals of reaction product (blue) compared to 
fluoropyruvate (orange) over time, it was possible to plot the appearance of product 
and disappearance of fluoropyruvate as shown in Chart 4.1a and the initial rates of 
reaction was calculated (Chart 4.1b). Time course reactions were carried out for each 
of the NAL-variant and aldehyde combinations and the results are shown in Table 4.12. 
(For full raw data sets, see Appendix 5) 
1 hr 5 min 
4 hr 13 min 
7 hr 24 min 
8 hr 19 min 
30 hr 38 min 
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Chart 4.1 - An example of a plot of the appearance of the product 23c of the NAL 
E192N/T167V/S208V-catalysed reaction of DHOB and fluoropyruvate and the disappearance of 
fluoropyruvate. The conversion was calculated from the relative integrals of the 296 MHz 
19
F NMR 
spectra recorded at suitable time intervals. a) Representation of the percentage disappearance of 
fluoropyruvate and the percentage appearance of product over the full reaction time. b) Linear points of 
the disappearance of fluoropyruvate. The initial gradient was used to calculate the initial rate of the 
reaction. In this reaction, the fluoropyruvate is disappearing at a rate of 27.7 nmol/min. For plots for all 
the combinations of NAL variants and aldehydes see Appendix 5. 
Table 4.12 - Calculated activity of the NAL variants towards the aldehyde analogues from the 
disappearance of fluoropyruvate.  
NAL variant Aldehyde 
Rate of disappearance 
of pyruvate  
/nmol min
–1 
Quantity of 
enzyme in the 
NMR tube /nmol 
Specific activity 
/min
–1
 
E192N 
DHOB 236 28.8 9.12 
ent-DHOB 13.3 28.8 0.46 
AHOB 30.25 28.8 1.05 
ent-AHOB 1.88 28.8 0.07 
E192N/T167V
/S208V 
DHOB 27.7 49.0 0.56 
ent-DHOB 0.76 25.9 0.03 
AHOB 0 - 0 
ent-AHOB 0 - 0 
E192N/T167G 
DHOB 3.15 52.7 0.06 
ent-DHOB 6.18 52.7 0.12 
AHOB 1.77 52.7 0.03 
ent-AHOB 1.52 52.7 0.03 
 
Chart 4.2 is a graphical representation of the data in Table 4.12. Most of the focus of 
discussion will be on the NAL variants E192N and E192N/T167V/S208V as the 
E192N/T167G variant is 35 times less active than the NAL E192N variant towards 
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AHOB and over 300 times less active than NAL E192N towards DHOB. The NAL E192N 
variant was found to be around 9 times more active towards DHOB compared to 
AHOB and the NAL E192N/T167V/S208V variant was found to be inactive towards 
AHOB. In the case of both NAL E192N and E192N/T167V/S208V, switching 
enantiomeric series resulted in a 15-20 fold decrease in activity.  
 
Chart 4.2 - Calculated specific activity of NAL variants towards the aldehyde analogues. Calculations 
based on the disappearance of fluoropyruvate, which was calculated by measuring relative integrals 
of 
19
F NMR spectra recorded at regular time intervals. Insert shows an enlargement of the lower levels 
of activity.  
The NAL E192N-catalysed reaction of AHOB and fluoropyruvate was carried out under 
identical conditions to the reactions of AHOB/ent-AHOB with pyruvate described in 
Section 3.2.1. Chart 4.3 shows the relative activities measured for these experiments 
which revealed that switching donor from pyruvate to fluoropyruvate resulted in a 4-
fold decrease in activity.  
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Chart 4.3 - Specific activities calculated for the reactions of the NAL E192N variant with AHOB/ent-
AHOB with pyruvate and AHOB with fluoropyruvate. (For data used to calculate these results, see 
Appendix 5) 
4.4.2 Determination of diastereoselectivity under kinetic control 
 It is not necessarily the case that the enzyme variants will display the same 
diasteroselectivity under kinetic conditions as under the preparative conditions 
described in Section 4.3.3. This became evident during the course of acquiring the data 
to measure the initial rates of reaction. For example, Figure 4.20 shows a selection of 
time points from the NAL E192N-catalysed reaction of AHOB and fluoropyruvate. In 
the preparative reaction conditions (Section 4.2.2) the product 57a was isolated in a  
98:2  excess over the 57d diastereomer, however under kinetic control, the 
diastereomers were observed in a 56:44 ratio 57a:57d. 
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Figure 4.20 – The reaction between AHOB and fluoropyruvate catalysed by NAL E192N was selective 
under the preparative conditions described previously but gave a mixture of products under kinetic 
control. 
In the case of reactions in which more than one diastereomer was formed, the ratio 
between the products was measured. The plot of the NAL E192N catalysed reaction 
between AHOB and fluoropyruvate is shown as an example in Chart 4.4. 
 
Chart 4.4 - An example of a plot of the appearance of enzyme reaction products (where two or more 
products are formed) and disappearance of fluoropyruvate generated from monitoring the enzyme 
catalysed reaction between the aldehyde analogues and fluoropyruvate. This example is the NAL 
E192N-catalysed reaction of AHOB and fluoropyruvate. 
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Table 4.13 shows the combined selectivity data for each combination of NAL variants 
and aldehyde analogues and the results are summarised in Chart 4.5. The two most 
prevalent colours on this chart are blue and pink which correspond to the two (3R)-
epimers of the enzyme reaction products. This result is in agreement with the QM/MM 
modelling studies discussed in Section 4.1.2.57 Surprisingly, the NAL E192N/T167G 
variant, which was evolved to favour attack of the si-face of the aldehyde in the 
reaction with DHOB and pyruvate, appears to be no longer selective in the reaction 
with DHOB and fluoropyruvate. Furthermore, the NAL E192N variant switched 
selectivity from favouring the product resulting from si-face attack of the aldehyde in 
reaction with DHOB and pyruvate, to favouring the product resulting from re-face 
attack of the aldehyde in reaction with DHOB and fluoropyruvate. 
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Table 4.13 – Kinetic ratio of the products of the reactions catalysed by the NAL variants. 
 
Aldehyde NAL variant 
Ratio of products 
a:b:c:d 
Ratio of products by 
configuration at C-3 and C-4 
(3R,4R):(3S,4S): 
(3R,4S):(3S,4R) 
DHOB 
E192N 41:0:52:7 41:0:52:7 
E192N/T167V/S208V 0:0:100:0 0:0:100:0 
E192N/T167G 7:0:90:2 7:0:90:2 
ent-DHOB 
E192N 9.5:0:0:90.5 0:9.5:90.5:0 
E192N/T167V/S208V 0:0:0:100 0:0:100:0 
E192N/T167G 24:0:0:76 0:24:76:0 
AHOB 
E192N 56:0:44:0 56:0:44:0 
E192N/T167V/S208V - - 
E192N/T167G 100:0:0:0 100:0:0:0 
ent-AHOB 
E192N 27:0:0:73 0:27:73:0 
E192N/T167V/S208V - - 
E192N/T167G 100:0:0:0 0:100:0:0 
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Chart 4.5 - Ratio of products of the kinetic controlled reactions of the NAL variants and DHOB and 
AHOB. The colour-coding corresponds to the relative configuration at C-3 and C-4. 
 
4.4.3 Evaluation of the value of NAL variants in the synthesis of fluorinated N-acetyl 
neuraminic acid analogues 
 In order for the enzyme-catalysed reactions evaluated within this thesis to be 
synthetically useful, it is important that the enzymes are active enough to give useful 
yields of product, with high diastereoselectivity. The kinetically controlled reactions 
made it possible to compare simultaneously activity and diastereoselectivity as 
illustrated in Chart 4.6. By comparing the reactions in this way, it has been shown that 
while the NAL E192N-catalysed reaction with DHOB was by far the most active 
enzyme-substrate combination, and so from a catalytic efficiency point of view the 
most suitable candidate for use in synthesis, the diastereoselectivity was very poor. 
However, there were three further enzyme-substrate combination which were much 
less active than the NAL E192N-catalysed reaction of DHOB, however did exhibit 
sufficient levels of activity and diastereoselectivity that they were considered to be 
good starting points for future development of improved NAL variants. 
The first of these potentially interesting reactions is the NAL E192N catalysed reaction 
of AHOB and fluoropyruvate. In the preparative scale reaction (Section 4.3.3), the 
reaction was completely selective for product 57a (98:2), however, under kinetic 
control, a mixture of the products 57a and 57d (56:44) was observed. It may be 
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possible to optimise the NAL E192N-catalysed reaction of AHOB to improve the yield 
and selectivity. The second interesting reaction is the NAL E192N/T167V/S208V 
catalysed reaction of DHOB and fluoropyruvate, which was found to be completely 
selective for the product 23c. Furthermore, the isolated yield in the preparative 
conditions of this reaction was 40%. Finally, the NAL E192N catalysed reaction of ent-
DHOB gave predominantly a single diastereomer ent-23d (d.r. 90:10). The NAL E192N 
variant was generally found to exhibit good activity with a broad range of substrates. 
  
Chart 4.6 - Activity and selectivity of NAL variant catalysed reactions of aldehyde analogues and 
fluoropyruvate. Insert is an expansion of the region 1.2 nmol min
-1
 nmol
-1
 and below. 
The NAL variants E192N/T167V/S208V and E192N/T167G have been engineered to be 
complementary and selective to give the diastereomers resulting from re-face and si-
face attack of the aldehyde respectively, in the reaction between DHOB and pyruvate. 
However, the diastereoselective variants were a factor of 10 less active compared to 
the NAL E192N variant.67 This initial high level of activity may account for why the NAL 
E192N variant is more tolerant to a broader range of substrates. Furthermore, 
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changing the donor from pyruvate to fluoropyruvate resulted in loss of 
diastereoselectivity in the case of the NAL E192N/T167G variant. 
4.5 Discussion of the observed activity and diastereoselectivity of the 
reactions of alternative substrates catalysed by NAL variants 
 The previous Sections have explained the experimental outcome of various 
reactions of NAL variants with aldehyde analogues and fluoropyruvate. In order to take 
these results forward and make suggestions about the future direction of this work, it 
is important to understand what has been learnt about the mechanism of NAL from 
these experiments. QM/MM modelling studies57and the crystal structures of saNAL in 
complex with fluoropyruvate63 were used to predict the selectivity the NAL variants 
might exhibit at the fluorine-bearing chiral centre (Section 4.1.2).  
Justifying the C-4 selectivity of the NAL variants is rather more difficult, as is explaining 
the decrease in activity observed in the reaction of fluoropyruvate compared to 
pyruvate. There are two factors to consider; firstly, the introduction of fluorine may 
have an effect on the active-site geometry, therefore resulting in a reduction in activity 
because the catalytic residues are no longer in the right position relative to the donor 
or acceptor. Alternatively, the electronegative nature of fluorine may cause the 
enamine of fluoropyruvate to be a poorer nucleophile in comparison to pyruvate and 
change the transition state energy barriers leading to formation of the (4R) and (4S)-
epimers. The NAL crystal structures may be used to evaluate whether the there are 
any structural differences between complexes of fluoropyruvate and complexes of 
pyruvate, however further QM/MM modelling studies would be required to evaluate 
the significance of the differences in electronic properties between pyruvate and 
fluoropyruvate. 
4.5.1 Evaluation of the predicted diastereoselectivity of NAL variants at the fluorine-
bearing chiral centre 
 At the beginning of this Chapter (Section 4.1.2), it was predicted that in the 
NAL-catalysed reactions of the aldehyde analogues and fluoropyruvate, the 
diastereomers with (3R) configuration would be formed preferentially. These 
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predictions were based on the crystal structure of fluoropyruvate in complex with NAL 
from S. aureus,63 which showed the fluorine preferentially forms the (Z)-enamine and 
the QM/MM modelling studies which showed that Y137 is responsible for proton 
transfer57 and is positioned above the "top" face of the Schiff-base (Figure 4.21). 
 
Figure 4.21 - Schematic representation of the aldehyde being attacked by the "top" face of the (Z)-
fluoroenamine. The Y137, which is responsible for mediating proton transfer, is above the "top" face 
of the Schiff-base complex. The reaction products therefore have the (3R) configuration. 
Chart 4.7 shows the (3R) verses (3S) selectivity observed for each of the NAL variant 
catalysed reaction of the aldehyde analogues and fluoropyruvate under kinetic control. 
In the vast majority of the experiments, the (3R)-epimers were seen as the major 
products, agreeing with the predictions made based on the structural and 
computational evidence. The only enzyme-substrate combination which goes against 
the expected C-3 selectivity is the NAL E192N/T167G catalysed reaction of ent-AHOB, 
however the NAL E192N/T167G variant is very inactive towards fluoropyruvate. 
  
Chart 4.7 - Representation of the ratio of products with (3R):(3S) configurations in the reactions 
between the aldehyde analogues and fluoropyruvate catalysed by NAL variants.  
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While in most cases, the (3R)-epimers were observed as the major products of the NAL 
variant-catalysed reactions of the aldehyde analogues and fluoropyruvate, there were 
some examples in which the (3S)-epimers were observed. However, were these 
products the result of reaction with the "bottom" face of the enamine, or reaction with 
the (E)-enamine? Figure 4.22 shows the crystal structure of the NAL E192N variant in 
complex with the THB inhibitor.66 From the surface view, it is possible to clearly see 
the cavity into which the inhibitor/aldehyde fits, and at the base of that pocket, the 
enamine is visible with the "top" face presented towards the cavity. Furthermore, the 
Y137 (gold) residue, which is believed to be responsible for proton transfer to the 
aldehyde oxygen, and the T167 (lilac) residue, which is believe to form a hydrogen 
bond with the aldehyde oxygen (and is therefore important in substrate recognition),57 
are both positioned above the "top" face of the enamine. From these observations it 
can be concluded that the aldehyde cannot be attacked by the "bottom" face of the 
enamine so the experiments in which the (3S)-epimers were observed resulted from 
attack from the "top" face of the (E)-enamine. 
 
Figure 4.22 - Crystal structure of NAL E192N in complex with the THB inhibitor (PDB 2WPB)
66
 
(K165/fluoropyruvate complex superimposed from the crystal structure of wild-type NAL from S. 
aureus)
63
. The Y137 (gold), S47 (yellow) and T167 (lilac) residues, which were predicted to be 
important in aldehyde recognition and catalysis, are all positioned above the "top" of the K165 Schiff-
base complex (pink). Furthermore, the shape of the binding pocket meant that the aldehyde entered 
the binding pocket onto the "top" of the enamine. a) Surface view shows the shape of the binding 
pocket and the "top" face of the enamine presented towards the cavity. b) Ribbon view shows more 
clearly the relative positions of the key catalytic residues and the K165 Schiff-base complex.  
In most cases, switching enantiomeric series did not change the selectivity at C-3 of the 
NAL variants and generally the (3R)-epimers were observed. The exception was the 
NAL E192N/T167G-catalysed reaction of ent-AHOB, which gave the (3S)-epimer, 
however the measured activity was very poor. Switching enantiomeric series 
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significantly decreased the activity of NAL variants, which may be due to binding 
efficiency. The enantiomer of THB has never been studied but it may be that it does 
not bind efficiently and is therefore is a poor inhibitor in comparison with THB. 
4.5.2 Structural evidence for reduced activity of the alternative donor 
 Switching from pyruvate to fluoropyruvate results in a drop in activity of the 
NAL variants in the reactions of the alternative substrates (Section 4.4.1) but also wild-
type NAL in the reaction with ManNAc.57 NAL from S. aureus (saNAL) has been 
crystallised in complex with fluoropyruvate.63 The saNAL is structurally very similar to 
the NAL from E. coli (ecNAL) (RMSD of 2.717 Å) which has been used throughout this 
thesis, so the observations in the crystal structures of saNAL are highly relevant to 
ecNAL. In order to rationalise the decrease in activity, it is important to know if 
switching from pyruvate to fluoropyruvate disrupts the local environment of the NAL 
active site.  
Figure 4.23 shows two crystal structures of wild-type saNAL superimposed, one in 
complex with pyruvate88 (pink) and one in complex with fluoropyruvate63 (cyan). This 
comparison was used to look for any differences in the overall structure of the protein 
caused by changing the donor from pyruvate to fluoropyruvate. Figure 4.23a shows 
the ribbon-type representation of the backbone of one subunit of saNAL. The 
backbone superimposes closely (RMSD of only 0.322 Å), so changing the donor 
apparently makes little difference to the tertiary structure of the protein. Figure 4.23b 
shows just the active-site, in particular the Schiff-base complex between K165 and the 
donor. Directed evolution identified T167 and S208 as important residues in control of 
configuration67 and the QM/MM modelling studies identified Y137, S47 and T167 as 
residues important in catalysis.57 As can be seen from the superimposed structures, 
there is very little difference in the relative positions of these key residues in the 
active-site and in particular, the position of the Schiff-base complex does not change 
significantly. Therefore, it is likely that the lower activity is brought about by the 
enamine of fluoropyruvate being a poor nucleophile in comparison to the enamine of 
pyruvate due to the electronegative character of fluorine. 
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Figure 4.23 - Overlaid crystal structures of wild-type NAL from S. aureus (saNAL) in complex with 
pyruvate (pink, PDB 4AH7)
88
 and fluoropyruvate (cyan).
63
 a) Ribbon view shows the overall protein 
structure of the saNAL is the same regardless of whether pyruvate or fluoropyruvate is bound, i.e. the 
introduction of the unnatural fluorinated ligand in place of the natural ligand has no effect on the 
tertiary structure of saNAL. b) Active site of saNAL showing the residues known to be important in 
catalysis and stereocontrol and the Schiff-base complex. The residues and the Schiff-base complex 
overlay closely, showing that in terms of the active-site geometry, introduction of the unnatural-
fluorinated ligand is only very subtly different to the natural ligand. 
4.5.3 Structural evidence for changes in selectivity of the alternative donor 
 In the reaction between DHOB and pyruvate, the product resulting from attack 
of the si-face of the aldehyde is the major product, however in the reaction between 
DHOB and fluoropyruvate, the product resulting from the attack of the re-face of the 
aldehyde is the major product. The binding mode of the aldehyde is known to be 
important in dictating the C-4 selectivity in the NAL-catalysed reaction.57 In order to 
look into potential structural differences in the active-site geometry in greater detail, 
the crystal structure of wild-type saNAL in complex with fluoropyruvate (cyan)63 was 
superimposed with the crystal structure of ecNAL E192N variant in complex with 
pyruvate and the THB inhibitor66 (pink) in the major (Figure 4.24a) and minor (Figure 
4.24b) binding modes. The key residues again appear to have very similar relative 
positions in the structure with pyruvate (pink) and the structure with fluoropyruvate 
(cyan), and there does not appear to be any significant difference in the positions of 
the key residues between the two binding modes. The differences in selectivity 
between pyruvate and fluoropyruvate most likely occur as a result of the electronic 
properties of fluoropyruvate, which may have a profound effect on the energy barriers 
to the transition states leading to the two C-4 epimers. 
a) b) 
Y137 
S208 
S47 
T167 
K165 
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Figure 4.24 - Overlaid crystal structures of wild-type NAL from S. aureus NAL (saNAL) in complex with 
fluoropyruvate
63
 (cyan) and NAL E192N variant from E. coli (ecNAL) in complex with pyruvate bound 
to the THB inhibitor (pink, PDB 2WPB).
66
 The positions of the important catalytic residues are only 
subtly different between the two structures, and there is no difference between the relative positions 
of the residues in the two binding modes of the THB inhibitor. There is no evidence that the possible 
binding modes of the aldehyde should be any different in the case of reactions of fluoropyruvate 
compared to the reactions of pyruvate. a) Major binding mode of the THB inhibitor (purple) b) Minor 
binding mode of the THB inhibitor (green). 
In Section 3.3.1, it was reasoned that the NAL E192N-catalysed reaction between 
AHOB and pyruvate was selective for the product resulting from si-face attack of the 
aldehyde because AHOB was unable to adopt the major binding mode seen in the 
crystal structure of the THB inhibitor bound to NAL E192N. Since the shape of the 
binding pocket was unchanged by changing the donor from pyruvate to 
fluoropyruvate, the argument that AHOB was more limited in terms of the binding 
modes it can adopt was equally valid in this case. Regardless of whether the donor 
used in the reaction is pyruvate or fluoropyruvate, the C-4 selectivity in the NAL 
catalysed reactions of AHOB was unchanged. This provides some evidence that the 
initial binding mode is still important in determining diastereoselectivity whether the 
donor is pyruvate or fluoropyruvate. 
 
Y137 
S208 
S47 
T167 
K165 
Y137 
S208 
S47 
T167 
K165 a) b) 
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Chapter 5 Conclusions and future outlook 
 
5.1 Overview and conclusions 
 This work primarily sought to evaluate the potential value of NAL variants in 
the synthesis of fluorinated analogues of N-acetyl neuraminic acid. This has been 
achieved by synthesis of a series of aldehyde analogues which have been used in the 
NAL variant-catalysed reaction with fluoropyruvate. The products were analysed by 19F 
NMR spectroscopy. Two-dimensional 1H/19F experiments were used in order to aid 
characterisation of the most complex reaction products. 
Chapter 2 outlined the development of a new synthetic route to access the new 
aldehyde substrate AHOB, which was used to further probe the activity and selectivity 
of the NAL variants. The route used to access AHOB was more modular in its approach 
compared to the previously developed routed employed in the synthesis of DHOB.65 
The new route utilising the lactone 33 could be modified to access further potential 
NAL substrates for example by utilising different reaction of  the lactone 3372, 80, 81, 89 or 
by introducing different functionalities later in the synthesis. 
Chapter 3 described the evaluation of the NAL variant-catalysed reactions of the new 
aldehyde AHOB in reaction with pyruvate compared to DHOB. It was found that while 
AHOB is significantly less active that DHOB, the selectivity at C-4 is greatly improved 
with only the product resulting from attack of the si-face of the aldehyde (the (4S)-
epimer) observed. The crystal structure of NAL E192N in complex with the THB 
inhibitor66 provided evidence that the selectivity may occur as a result of the AHOB 
adopting a binding mode similar to the minor binding mode of DHOB, which was found 
by QM/MM modelling studies to favour the formation of the (4S)-epimer.57 
Furthermore, the NAL E192N/T167V/S208V variant, which directs attack onto the re-
face of DHOB,67 was found to be inactive towards AHOB, which may provide some 
evidence of the mechanism of selectivity of the NAL variants, E192N/T167V/S208V and 
E192N/T167G. 
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Chapter 4 described the evaluation of the activity and selectivity of the NAL variant-
catalysed reactions of the aldehyde analogues and fluoropyruvate. The activity of the 
NAL variants towards fluoropyruvate was found to be lower compared to pyruvate. 
The crystal structure of saNAL63 provided no evidence which may explain this loss of 
activity, therefore it was concluded that the drop in activity was due to the enamine 
formed from fluoropyruvate being a poor nucleophile. The selectivity at the C-3 
position was found to be controlled by the preference for the fluoropyruvate-K165 
enamine complex to adopt the (Z)-configuration,57 which may be due to the gauche-
effect.35 The selectivity at the C-4 position was predicted to be controlled partially by 
the initial binding mode as evident by the observation that the si-face of AHOB, which 
is predicted to be restricted in terms of the binding modes it can adopt, is always 
attacked regardless of the donor. The C-4 selectivity of the DHOB reaction catalysed by 
NAL E192N switched with fluoropyruvate and was lost in the reaction catalysed by NAL 
E192N/T167G, which may be due to differences in the electronic properties of 
fluoropyruvate, resulting in changes in the energy profile of the reactions leading to 
the (4R) and (4S)-epimers. 
In conclusion, the work within this thesis has demonstrated that NAL variants may be 
used in the synthesis of fluorinated analogues of Neu5Ac with high levels of 
stereocontrol. The most promising examples, which may be used as a starting point for 
future development are outlined in Table 5.1. The examples were chosen based on 
superior enzyme activity (particularly in the case of entry 1), and in the cases of entries 
3 and 4, high levels of stereocontrol. However, further development is required in 
order to improve the activity of the NAL variants towards reactions of fluoropyruvate, 
for example by further directed evolution studies. 
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Table 5.1 - Summary of NAL-variant catalysed reaction between the aldehyde variants and 
fluoropyruvate which exhibited the greatest activity and diastereoselectivity. 
 
Entry NAL variant Aldehyde 
Specific activity
a
 
/nmolmin
-1
nmol
-1 
D.r (a:b:c:d)
b 
1 E192N DHOB 9.12 41:0:52:7 
2 E192N AHOB 1.05 56:0:44:0 
3 E192N ent-DHOB 0.46 9.5:0:0:90.5 
4 E192N/T167V/S208V DHOB 0.56 0:0:100:0 
a) Based on the activity calculated from the initial rate of the forward reaction (Section 4.4.1). b) Based 
on diastereoselectivity under kinetic control (Section 4.4.2) 
This work has also revealed some interesting insights into the mechanism of the C-4 
selectivity of the NAL variants and may have provided some evidence to validate the 
QM/MM modelling studies.57 When the diastereoselective NAL variants 
(E192N/T167V/S208V and E192N/T167G) were evolved, the mechanism of C-4 
selectivity was not understood67 and the diastereoselective variants have been found 
to lose their activity and diastereoselectivity when the substrate was changed. This is 
an example of one of the limitations of directed evolution in that ultimately, "you get 
what you screen for"90 and sometimes a bit more. The greater insight into the 
mechanism of stereocontrol of NAL, provided by the QM/MM modelling studies57 and 
validated experimentally within this work, may be used to direct the development of 
improved diastereoselective NAL variants with broader substrate specificity. 
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5.2 Future outlook 
5.2.1 Probing the proposed binding mode of new NAL substrates 
 The NAL E192N variant was found to only direct attack onto the si-face of 
AHOB regardless of the donor used. This was predicted to occur as a result of the 
binding mode of AHOB being more restricted in order to accommodate the N-acetyl 
group (Section 3.3.1). There is no crystallographic evidence to back up this hypothesis; 
however the basis for the proposed binding mode came from the crystal structure of 
the THB inhibitor bound in the active site of NAL E192N.66 In order to evaluate the 
possible binding modes of AHOB, the N-acetyl group was built onto the THB inhibitor 
in silico, however if the modified inhibitor 56 was synthesised (Figure 5.1), it could be 
crystallised with NAL E192N in order to provide an experimental comparison to back 
up the predictions made within this thesis. Furthermore, it was hypothesised that, 
based on the interaction observed between the C-7 hydroxyl group of Neu5Ac56 and 
the S208 residue, that the presence of a hydrogen-bond donor at position 208 may be 
important in stabilising the binding. If, in the crystal structure of the new inhibitor 56, 
it was found that the distance between the equivalent hydrogen-bond acceptor and 
S208 was comparable to the distance measured in the wild-type NAL, this may provide 
evidence to explain the lack of activity observed in NAL E192N/T167V/S208V towards 
AHOB. 
 
Figure 5.1 - Inhibitors related to substrates of the NAL variants. 
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5.2.2 Engineering NAL variants with greater activity towards fluorinated substrates 
 There is no evidence in the crystal structure of fluoropyruvate bound into the 
saNAL active-site63 to suggest why the introduction of fluorine results in a reduction in 
enzyme activity. The reason for the reduction in activity may be related to the energy 
barrier to the reactive species or to the transition state of the carbon-carbon bond 
forming reaction. There are two complementary approaches which could be used in 
order to improve the activity of NAL variants towards fluoropyruvate. 
The first approach would be to use QM/MM modelling studies, such as those used to 
study the reaction pathways of DHOB and pyruvate in NAL E192N.57 This may provide 
some insight into the difference in energy barriers in the carbon-carbon bond forming 
reaction with the enamine of fluoropyruvate compared to the enamine of pyruvate. 
The second approach is to use directed evolution to screen for NAL variants with 
greater activity towards fluoropyruvate.11 If a fluoropyruvate-selective variant were to 
be identified, this variant may then be studied using the QM/MM modelling 
techniques in order to understand why the new variant is more active towards 
fluoropyruvate. 
5.2.3 Optimisation of synthesis of N-acetyl neuraminic acid analogues 
 The yields achieved in the NAL variant-catalysed reactions were poor, 
particularly in the reaction of AHOB. It was seen that in the NAL E192N catalysed 
reaction of AHOB and fluoropyruvate, the conversion estimated by the 19F NMR 
spectrum before purification was much higher than the yield recorded after HPLC 
purification. Furthermore in the NAL E192N-catalysed reactions of DHOB, the reaction 
went to complete conversion as calculated from the 19F NMR spectrum, although this 
was not reflected in the isolated yields. It may therefore be possible with optimisation 
of the reaction conditions and the purification techniques to improve the isolated 
yields of products. 
This may be complemented by work carried out to engineer NAL variants which are 
more active towards fluoropyruvate. The drop in activity resulting from switching from 
pyruvate to fluoropyruvate was around four-fold in the NAL E192N-catalysed reaction 
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of AHOB, so by improving the activity of NAL variants towards fluoropyruvate, the 
isolated yield of the fluorinated Neu5Ac analogues may be improved. 
5.2.4 Design of new aldehyde substrates 
 Switching enantiomeric series of the aldehyde substrate resulted in a decrease 
in activity of the NAL variants of around 15-20 fold (Section 3.1.4 and 4.4.1).69 It would 
however be interesting to know whether switching the configuration of just one of the 
stereocentres of the aldehyde would also result in a similar decrease in activity. It may 
be that switching the configuration of one of the stereocentres is tolerated better than 
switching the other. Two further pairs of enantiomers could be synthesised as shown 
in Figure 5.2. These syn-diastereomers could be subjected to in the NAL variants-
catalysed reactions with pyruvate and fluoropyruvate in the same way as discussed for 
the anti-diastereomers in order to understand which NAL active-site interactions are 
the most important. 
 
Figure 5.2 - Potential new NAL substrate which may be used to probe which position is most critical in 
control of diastereoselectivity and enzyme activity. 
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Chapter 6 Materials and Methods and Experimental 
6.1 Biological Materials and Methods 
6.1.1 Buffers 
 The buffers used throughout this thesis are outlined in Table 6.1. Unless 
otherwise stated, the buffer components were dissolved in deionised water. The pH 
was adjusted by the addition of aqueous hydrochloric acid or sodium hydroxide. 
Table 6.1- Buffers used for protein purification, storage and enzyme catalysed reactions. 
Buffer/pH Component Concentration 
Washing - pH 7.4 
Tris.HCl 50 mM 
Imidazole 20 mM 
Sodium chloride 0.5 M 
Elution - pH 7.4 
Tris.HCl 50 mM 
Imidazole 0.5 M 
Sodium chloride 0.5 M 
Dialysis - Tris.HCl - 
pH 7.4 
Tris. HCl 50 mM 
Sodium chloride 50 mM 
Dialysis - Ammonium 
acetate - pH 7.4 
Ammonium acetate 20 mM 
Deuterated sodium 
phosphate - pH 7.4 
Disodium hydrogen 
phosphate 
15.5 mM 
Monosodium dihydrogen 
phosphate 
4.5 mM 
Sodium chloride 20 mM 
Deuterium oxide - 
 
6.1.1.1 Preparation of deuterated 20 mM sodium phosphate buffer: 
 Deuterated buffer was prepared by initially preparing a 50 ml solution of 20 
mM sodium phosphate buffer pH 7.4 (see Table 6.1) in water, which was then 
concentrated in vacuo. The residue was then dissolved in deuterium oxide (20 ml) and 
concentrated in vacuo. The process of re-dissolving in deuterium oxide and 
concentrating the residue was repeated a total of 5 times. The residue was then 
dissolved in deuterium oxide to a total volume of 50 ml. 
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6.1.2 Biological equipment 
6.1.2.1 2×TY Bacterial growth medium and bacterial strains and plasmids 
Bacterial cultures were grown in 2×TY medium. One litre of 2×TY medium contains 16 
g tryptone, 10 g yeast extract and 5 g NaCl. The pKnanA‐His6 plasmid, encoding NAL64 
was used and the bacterial strain used for high level protein expression was E. coli 
BL21 (DE3) (B F– dcm ompT hsdS(rB– mB–) gal λ(DE3)), purchased from Agilent 
Technologies, Cheshire, UK. The NAL variants were provided by Adam Daniels.57 
6.1.2.2 Enzymes 
L‐Lactate dehydrogenase from rabbit muscle was purchased from Roche, 
Mannheim, Germany. 
6.1.2.3 Chromatographic media 
Chelating Sepharose Fast Flow™ resin charged with Ni2+ was used for 
purification of His-tagged NAL and was purchased from Amersham Biosciences, 
Buckinghamshire, UK. Resins were stored in ethanol in 50 ml Falcon tubes without Ni2+ 
bound and were activated by decanting off the ethanol, washing with water then 
washing buffer (see Table 6.1). A 0.2 M NiCl2 aqueous solution was poured onto the 
resin which was placed on a roller at 4 °C for 1 hour. The NiCl2 solution was  decanted 
and the Ni2+-activated resin was washed twice with water then twice with washing 
buffer. 
6.1.2.4 Aseptic technique 
Standard aseptic techniques were used throughout. Sterilisation of media and 
heat resistant materials was carried out using an autoclave at 110 °C. Heat labile 
solutions were sterilised by filtration through 0.22 μm MiniSart® filters (Sartourius AG, 
Goettingen, Germany). 
6.1.2.5 Determination of pH 
The pH of buffer solutions was determined using a Jenway 3020 pH meter, 
calibrated according to the manufacturer’s instructions. 
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6.1.2.6 Spectrophotometry 
Absorbances were measured using a Kontron Instruments UVIKON 930 
spectrophotometer. 
6.1.2.7 Centrifugation 
Centrifugation was performed using a Beckman Coulter Avanti® J‐26 XP Series 
high‐performance centrifuge. Unless otherwise stated, centrifugation was performed 
at 4 °C. 
6.1.2.8 Cell lysis 
Cell lysis was carried out using a cell disruptor supplied by Constant Cell 
Disruption System, Nothants UK. The cells were lysed at 20 kpsi. 
6.1.2.9 Dialysis 
 NAL samples were dialysed against 50-100 times the volume of the relevant 
buffer for two 8-16 hr periods at 4 °C. Dialysis tubing (12‐14 kDa molecular weight 
cut‐off) was purchased from Medicell International Ltd., London, UK. 
6.1.2.10 Concentrating NAL 
Concentration of NAL solutions were carried out using 15 ml centrifuge filters 
(Regenerated cellulose 10 000 NMWL) purchased from Amicon Ultra – IS. Centrifuge 
filters were prepared by washing with water, followed by centrifugation (2187g, 10 
min) then three times with buffer (depending on which buffer the protein to be 
concentrated is dissolved into) followed by centrifugation (2187g, 10 min). The protein 
solution was then transferred to the filter and centrifuged (2187g) until the required 
volume/concentration was achieved. 
6.1.3 Purification of His Tagged NAL 
E. coli cells expressing the NAL E192N mutant85 (see Section 6.1.2.1) were 
grown in day cultures containing 5 ml 2xTY media, 5µl glycerol solution containing the 
E. coli cells and 5 µl of 100 mg/ml ampicillin solution for 6-8 hr at 37 °C. Day cultures 
were then transferred to night cultures, which were grown at 37 °C in 2×TY media 
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supplemented with 50 μg/ml ampicillin and 0.1 mM IPTG. The cells were harvested by 
centrifugation (9 000g, 20 min) and the pellet was re-suspended in washing buffer (see 
Table 6.1) using a homogeniser. The cells were lysed and the cell debris was collected 
by centrifugation (30 000g, 45 min). The supernatant was loaded onto chelating 
sepharose resin (pre-equilibrated with the wash buffer, see Section 6.1.2.3), in a 50 ml 
Falcon tube. The suspension was placed on a roller for 1 h. The suspension was then 
centrifuged (4000g, 5 min, 4 °C) and the supernatant was removed; washing buffer (30 
ml) was added to the resin and the suspension placed on a roller for 15 mins followed 
by centrifugation (4000g, 5 min). Contaminating proteins were removed by washing 
the resin a further 3 times with washing buffer (roll for 15 min, followed by 
centrifugation at 4000g for 5 min). Elution buffer (see Table 6.1) (30 ml) was added to 
the resin and placed on a roller for 1 hr. The suspension was centrifuged (4000g, 5 
min) and the eluted His-tagged NAL enzyme dissolved in the supernatant was 
decanted from the resin. The resin was then washed for a second time with elution 
buffer and rolled (15 mins) followed by centrifugation (4000g, 5 min) and the 
supernatant was collected. The eluted NAL was then dialysed (12 h, 4 °C) into Tris.HCl 
pH 7.4 dialysis buffer (see Table 6.1 and Section 6.1.2.9). The dialysis tubes containing 
eluted NAL were then transferred to fresh Tris.HCl pH 7.4 dialysis buffer and left to 
dialyse (4 h, 4 °C). The dialysed solution was then sterile filtered into Falcon tubes and 
stored at 4 °C. For longer-term storage, the NAL was dialysed into ammonium acetate 
buffer (see Table 6.1) and freeze-dried. Freeze-dried protein was re-dissolved into a 
suitable buffer depending on the experiment required. 
6.1.4 SDS-PAGE 
Protein purity was determined by SDS page. The composition of the running gel 
and stacking gel are given in Table 6.2 and the buffers are given in Table 6.3. The 
ladder was provided by Fermentas. Protein samples were mixed with sample buffer 
(1:1), heated to 100 °C for 3 min before loading onto the gel (20 l). The gel was 
stained (methanol (50% v/v), acetic acid (10% v/v), Coomassie Brilliant Blue (0.25% v/v) 
and water (39.75% v/v)) and destained (methanol (50% v/v), acetic acid (10% v/v), and 
water (40% v/v)). 
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Table 6.2– Composition of gels for SDS-PAGE 
Gel Component Quantity (µl) 
Running 
Acrylamide (30%) 7500 
1.5 M Tris-HCl 3750 
SDS (10%) 150 
Water 3500 
APS (Ammonium persulfate)  
(50 mg in 200 µl) (25%) 
50 
TEMED (Tetramethylethylenediamine) 5 
Stacking 
Acrylamide (30%) 625 
1.5 M Tris-HCl 625 
SDS (10%) 50 
Water 3650 
APS (Ammonium persulfate)  
(50 mg in 200 µl) (25%) 
50 
TEMED (Tetramethylethylenediamine) 5 
 
Table 6.3 - SDS buffers 
Buffer Component Quantity 
2 × SDS 
sample buffer 
Dithiothreitol 154 mg 
10% (w/v) SDS 2.0 ml 
Glycerol 1.0 ml 
1 M Tris.HCl (pH 6.8) 170 ml 
Water 1.63 ml 
0.2% (w/v) bromophenol blue 200 µl 
SDS running 
buffer 
Tris.HCl 3.0 g 
Glycine 14.4 g 
SDS 1.0 g 
-mercaptoethanol 0.14 ml 
water 1000 ml 
 
 
6.1.5 Measuring concentration of NAL 
 Concentration was determined by transferring 900 µl 100 mM Tris.HCl buffer 
(pH 7.4) into a 1 ml quartz cuvette (path length 1 cm) as a blank to calibrate the 
spectrometer. 100 µl dialysed NAL solution was added to the buffer and the 
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absorbance measured at 280 nm. The extinction coefficient of His6-tagged NAL is 
24870 M-1cm-1,91 which according to the Beer-Lambert Law (A=cl) gives a protein 
concentration of 1 mg/ml when A280 = 0.743. 
6.1.6 Measuring single point activity of NAL 
Activity was measured using the reverse-coupled assay by monitoring 
disappearance over 1 minute of NADH+ by UV-Vis spectroscopy at a wavelength of 340 
nm.64, 85 50 mM Tris.HCl buffer (pH 7.4) was used as a blank. To 50 mM Tris.HCl buffer 
(sufficient to make the final volume 1000µl) was added a solution of substrate (of 
known concentration in 50 mM Tris.HCl buffer, pH 7.4), NADH+ (0.2 mM), LDH (2 µl) 
and finally a solution of NAL (of known concentration in 50 mM Tris.HCl, pH 7.4). The 
final concentration of substrate and enzyme in the cuvette were 1.0 mM and 0.06 
mg/ml respectively. 
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6.2 General experimental 
Unless otherwise stated, all non-aqueous reactions were carried out under a 
nitrogen atmosphere. Solvents were evaporated under reduced pressure using a Büchi 
rotary evaporator attached to a vaccubrand PC2001 Vario diaphragm pump with the 
water bath set at 40 °C. Flash column chromatography was carried out using silica (35-
70µm) particles and thin layer chromatography was carried out using pre-coated 
aluminium plates. Ion exchange chromatography was carried out using Dowex® 1×8 
200-400 resin or Discovery SAX or SCX pre-packed cartridges. Ozone for ozonolysis was 
generated using a Welsbach generator at 0.4-0.6 psi. The machine was purged for at 
least 15 min before and after use with oxygen gas (0.4-0.6 psi) and the reaction 
mixture was also purged with oxygen (0.4-0.6 psi) before and after ozonolysis. Starch–
iodide paper was used to test that the quenching reaction of trioxolane intermediate 
by Me2S has gone to completion. Unless otherwise stated, petrol refers to petroleum 
ether (b.p. 40-60 °C) and ether refers to diethyl ether. NMR chemical shifts are quoted 
in parts per million (ppm) downfield of trimethylsilane and J coupling values are 
quoted in hertz (Hz). NMR spectra were recorded on Bruker Avance DPX 300, Avance 
500 or DRX 500 spectrophotometer and the spectra were processed using 
MestraReNova NMR processing software. Semi prep-HPLC of 23a, 23c and ent-23d was 
carried out on an Agilent Technologies 1200 series instrument. Optimum conditions for 
separation were found to be reverse-phase C18 Hyperclone column with a gradient 
elution 0:100 → 20:80 acetonitrile−TFA (0.1% v/v):water−TFA (0.1% v/v) over 30 min, a 
flow rate of 3.0 ml/min and an injection volume of 20 µl of a 23 -25 mg/ml of enzyme 
reactions product in water. Mass directed prep-HPLC was carried out by the University 
of Leeds HPLC services. HRMS was carried out by the University of Leeds Mass 
Spectrometer services using a Bruker MicrOTOF mass spectrometer. Melting points 
were recorded on a Reichert hot stage microscope and optical rotations (where 
provided) were recorded on a A.A-1000 Polarmeter or a Schmidt + Haensch Polartronic 
hr 532 polarmeter (units for     are 10
–1 deg cm2 g–1). 
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6.2.1 General method for ozonolysis 
 Unless otherwise stated, ozonolysis was carried out under the following 
conditions. The alkene was dissolved in methanol (0.1 mmol of alkene per 0.5 ml of 
MeOH), cooled to –78 °C, purged with O2 for at least 10 min and then exposed to 
ozone. Once a blue colour was observed, excess ozone was purged from the reaction 
with O2. Me2S (0.15 ml per 0.1 mmol of alkene) was added and the reaction was 
allowed to stir under nitrogen until all peroxides were quenched (starch-iodide paper). 
6.2.2 General method for monitoring NAL catalysed reactions by 500 MHz 1H NMR 
spectroscopy 
 For each experiment 0.1 mmol of alkene was cleaved by standard ozonolysis 
conditions. After quenching, the solution was transferred to an NMR tube and 
concentrated by blowing nitrogen over the solution to remove all volatile components. 
The NMR tube was then placed in a drying tube on the high-vacuum line over-night to 
remove all trace of volatile contaminants. A 1 M solution of sodium pyruvate in 20 mM 
deuterated sodium phosphate buffer pH 7.4 (see Section 6.1.1.1) (200 µl, 0.2 mmol) 
was added followed by NAL in 20 mM deuterated sodium phosphate buffer pH 7.4 
(500 µl). (NAL concentrations: E192N - 1.12 mg/ml, E192N/T167G - 1.59 mg/ml). The 
experiment was kept at room temperature and re-submitted for 500 MHz 1H NMR 
spectroscopy initially at 1 h intervals for the first 7 h, then at 3-6 h intervals thereafter 
up to 36 h. Conversions were calculated by comparing the relative integrals of the 
product peaks to the aldehyde peaks such that when the aldehyde peaks were no 
longer visible in the NMR spectrum the reaction was assumed to have gone to 
completion. 
6.2.3 General method for monitoring NAL catalysed reactions by 296 MHz 19F NMR 
spectroscopy 
 For each experiment 0.1 mmol of alkene was cleaved by standard ozonolysis 
conditions. After quenching the solution was transferred to an NMR tube and 
concentrated by blowing nitrogen over the solution to remove all volatile components. 
The NMR tube was then placed in a drying tube on the high-vacuum line over-night to 
remove all trace of volatile contaminants. A 1 M solution of sodium fluoropyruvate in 
50 mM Tris-HCl buffer pH 7.4 (20 µl, 0.02 mmol) was added followed by NAL in 50 mM 
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Tris.HCl buffer pH 7.4 (980 µl). (NAL concentrations: E192N - 1.00 mg/ml, 
E192N/T167V,S208V – 0.90 mg/ml, E192N/T167G - 1.82 mg/ml). A sealed capillary 
tube containing deuterium oxide was placed inside the NMR tube (Figure 6.1). The 
experiment was kept at room temperature and re-submitted for 296 MHz 19F NMR 
spectroscopy initially at 1 h intervals for the first 7 h, then at 3-6 h intervals thereafter 
up to 36 h. Conversions were calculated by comparing the relative integrals of the 
product peaks to the fluoropyruvate peaks such that when the fluoropyruvate peaks 
were no longer visible in the NMR spectrum, the reaction was assumed to have gone 
to completion. 
 
Figure 6.1 - NMR tube reaction set up for monitoring NAL-catalysed reactions by 296 MHz 
19
F NMR. 
Deuterium oxide is required for the machine to lock onto the signal but sealing the D2O inside a tube 
prevents it coming into contact with the reaction mixture. The electrical tape wrapped around the top 
of the capillary tube holds the tube in the centre of the NMR tube and prevents it from rattling. 
6.3 Experimental methods and characterisation 
2,3-O-Isopropylidene-D-ribono-1,4-lactone 2765 
 
Concentrated sulfuric acid (4 ml) was added to a solution of D-ribono-1,4-lactone (4.80 
g, 32.4 mmol) in acetone (250 ml) and stirred for 5 h 45 min. Solid sodium carbonate 
(20 g) was added and the solution was left to neutralise over night. The solution was 
dried (MgSO4), filtered and the solvent removed in vacuo to give a crude product 
which was recrystalised from petrol–EtOAc to give the lactone 2765 (4.61 g, 76%) as 
colourless prisms; m.p. 136.5-138 °C (EtOAc–petrol) [lit. 137-139 °C]; RF: 0.72 (EtOAc); 
Electrical tape 
Deuterium oxide 
inside a sealed 
capillary tube Reaction mixture 
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    ‒71.6 (c. 0.60 in chloroform) [lit. ‒66.0 (c. 1.0 in chloroform)]; H (400 MHz; 
CDCl3) 4.77 (1H, d, J 5.6, H-2), 4.72 (1H, d, J 5.6, H-3), 4.57 (1H, t, J 2.0, H-4), 3.99 (1H, 
dd, J 12.3 and 2.3, H-5A), 3.74 (1H, dd, J 12.3 and 1.7, H-5B), 1.98 (1H, s, OH), 1.41 (3H, 
s, MeA), 1.32 (3H, s, MeB); m/z  (ES) [MNa]
+ 211.0 (100%, [MNa]+). 
5-Deoxy-5-iodo-2,3-O-isopropylidene-D-ribono-1,4-lactone 2865 
 
 
Iodine (13.0 g, 51.0 mmol) was added to a solution of the lactone 27 (5.44 g, 24.0 
mmol), imidazole (5.00 g, 73.0 mmol) and triphenylphosphine (18.0 g, 69.0 mmol) in 
dry toluene (100 ml) and stirred under nitrogen at 75 °C for 30 min. The reaction was 
quenched with aqueous sodium thiosulfate (50 ml of a 1 M solution) then extracted 
with ethyl acetate (3 × 150 ml) and the combined organic layers were washed with 
brine (100 ml), dried (MgSO4), and the solvent removed in vacuo to give the crude 
product which was purified by flash column chromatography (gradient elution 5:95 → 
50:50 EtOAc–petrol) to give the iodo-lactone 2865 (5.39g, 75%) as colourless needles; 
m.p. 95-96 °C (EtOAc–petrol) [lit. 89.0-91.0 °C]; RF: 0.31 (4:1 petrol–EtOAc);     
   –27.2 
(c. 1.00 in chloroform) [lit. ‒33.1 (c. 1.05 in chloroform)]; H (300 MHz; CDCl3) 4.94 (1H, 
d, J 6.0, 2-H), 4.59-4.54 (2H, m, 3-H and 4-H), 3.36 (2H, d, J 6.1, 5-H), 1.41 (3H, s, MeA), 
1.33 (3H, s, MeB); HRMS Found: 320.9594, [C8H11IO4Na]
+ requires 320.9600. 
(2R, 3R)-2,3-O-Isopropylidene-pent-4-enoic acid 2965 
 
Zinc/copper couple (9.32 g) was added to a solution of the iodo-lactone 28 (5.32 g, 18 
mmol) in acetone–water (4:1) which was heated under reflux for 2 h. The reaction was 
cooled to room temperature then filtered through Celite®. The filtrate was evaporated 
under reduced pressure. The residue was dissolved in 97:3 CHCl3–formic acid (50 ml), 
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which was washed with brine (40 ml). The aqueous layer was then re-extracted with 
chloroform (3 × 50 ml). The combined organic phases were dried (MgSO4) and the 
solvent removed in vacuo to give the acid 2965 (2.48 g, 81%) as a colourless oil;  RF: 0.6 
(1:99 AcOH–EtOAc);     
   –13.6 (c. 1.00 in chloroform) [lit. −24.6 (c. 1.56 in 
chloroform)]; H (300 MHz; CDCl3) 5.80 (1H, ddd, J 17.1, 10.3 and 6.9, 4-H), 5.48 (1H, 
dd, J 17.1 and 1.1, 5-HA), 5.33 (1H, d, J 10.4, 5-HB), 4.86 (1H, app. t, J 7.2, 3-H), 4.71 (1H, 
d, J 7.4, 2-H), 1.64 (3H, s, MeA), 1.43 (3H, s, MeB). 
(2R,3R)-2,3-O-Isopropylidene-pent-4-enoic acid dipropylamine 3065 
 
Method 1 
A solution of the acid 29 (0.20 g, 1.16 mmol), dipropylamine (0.24 ml, 2.32 mmol) and 
triethylamine (1.29 ml, 9.28 mmol) in dry DMF (20 ml) was added over 8 h to a solution 
of 2-chloro-1-methyl-pyridinium iodine (1.19 g, 4.64 mmol) in dry DMF (40 ml) at 85 °C. 
The solution was stirred for a further 8 h, cooled to room temperature and diluted 
with ethyl acetate (60 ml) and water (150 ml). The layers were separated, and the 
aqueous phase was extracted with ethyl acetate (3 × 50 ml) and the combined organic 
phases were washed with brine (3 × 100 ml) and aqueous HCl (50 ml, 0.5 M), the 
solvent removed in vacuo and the product was purified by flash column 
chromatography (petrol–EtOAc 4:1) to give the protected dipropylamide 3065 (0.26 g, 
88%) as a pale yellow oil; RF: 0.31 (2:1, petrol–EtOAc);     
    –36.0 (c. 2.0 in 
chloroform) [lit. ‒28.6 (c. 0.91 in chloroform)]; H (500 MHz; CDCl3) 5.80 (1H, ddd, J 
17.2, 10.1 and 8.2, 4-H), 5.40 (1H, d, J 17.1, 5-HA), 5.25 (1H, d, J 10.2, 5-HB), 4.94 (1H, d, 
J 7.2, 3-H), 4.78 (1H, t, J 7.7, 2-H), 3.50 (3H, dt, J 13.3 and 7.8, propyl 1-HA), 3.14-2.96 
(3H, m, propyl 1-HB and propyl 1-H2), 1.67 (3H, s, MeA), 1.63-1.48 (4H, m, 2 × propyl 2-
H2), 1.41 (3H, s, MeB), 0.91 (3H, t, J 7.2, propyl 3-H3,A), 0.88 (3H, t, J 7.2, propyl 3-H3,B).  
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Method 2 
Diisopropylethylamine (DIPEA) (0.85 ml, 11.6 mmol), HCTU (2.41 g, 5.81 mmol) and 
dipropylamine (0.43 ml, 5.7 mmol) were added to a solution of the acid 29 (0.90 g, 
5.81 mmol) in dry DMF (50 ml) and stirred at room temperature for 18 h. The reaction 
was diluted with water (100 ml) and extracted with ethyl acetate (3 × 100 ml). The 
combined organic layers were washed with sat. aqueous sodium carbonate (2 × 50 ml) 
and brine (3 × 100 ml). Solvents were removed in vacuo and the crude product was 
purified by flash column chromatography (petrol–EtOAc (2:1) to give the protected 
diproylamide 3065 (0.43 g, 29%) as a pale yellow oil; Spectroscopically identical to that 
obtained previously. 
Method 3 
EDC (0.46 ml, 4.52 mmol), HOBt (0.60 g, 4.52 mmol) and dipropylamine (0.31 ml, 4.56 
mmol) were added to a solution of the acid 29 in EtOAc (160 ml) and stirred for 16 h. 
The reaction mixture was washed with water (160 ml) and the aqueous layer was 
extracted with EtOAc (2 × 120 ml). Combined organic layers were dried (MgSO4) and 
the solvent removed in vacuo and the residue was purified by flash chromatography 
(1:1 petrol–EtOAc) to give the protected dipropylamide 3065 (0.48 g, 62%) as a pale 
yellow oil; Spectroscopically identical to that obtained previously. 
(2R,3R)-2,3-Dihydroxy-N,N-dipropylpent-4-enamide 2465 
 
The protected diproylamine 30 (0.43 g, 1.68 mmol) was dissolved in a solution of 9:1 
trifluoroacetic acid–water (34 ml) and swirled for 2 min, the solvents were then 
removed in vacuo and the residue was purified by flash column chromatography 
(60:40 petrol–ethyl acetate) to give the diol 2465 (0.30 g, 84%) as colourless needles;  
m.p. 78.6-79.8 °C (EtOAc–petrol) [lit. 77.4-79.1 (CH2Cl2)]; RF: 0.17 (1:1, petrol–EtOAc); 
    
   22.2 (c. 0.90 in chloroform) [lit. 17.1 (c. 0.84 in chloroform)]; H (300 MHz; CDCl3) 
5.81 (1H, ddd, J 17.1, 10.5 and 5.8, 4-H), 5.34 (1H, dt, J 17.2 and 1.5, 5-HA), 5.25 (1H, dt, 
J 10.5 and 1.4, 5-HB), 4.45 (1H, dd, J 8.8 and 4.1, 2-H), 4.23 (1H, ddd, J 9.6, 5.5 and 4.2, 
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3-H), 3.71 (1H, d, J 8.78, 2-OH), 3.65-3.52 (1H, m, propyl 1-HA), 3.42-3.29 (1H, m, propyl 
1-HB), 3.22-3.10 (1H, m, propyl 1-HC), 3.11-2.99 (1H, m, propyl 1-HD), 3.06 (1H, d, J 
9.34, 3-OH), 1.73-1.47 (4H, m, 2 × propyl 2-H2), 0.94 (3H, t, J 7.4, propyl 3-H3,A), 0.90 
(3H, t, J 7.4, propyl 3-H3,B); m/z  (ES) [MNa]
+ 238 (100%, [MNa]+). 
(4S,5R,6R) and (4R,5R,6R)-7-(dipropylamino)-4,5,6-trihydroxy-2,7-dioxoheptanoate 
DPAH65 
 
The diol 24 (220 mg, 1.02 mmol) was subjected to general ozonolysis conditions 
described previously. Methanol was removed in vacuo and the crude mixture was re-
dissolved in 50 mM tris buffer (5.5 ml) to which sodium pyruvate (500 mg, 4.64 mmol) 
was added. The pH was adjusted to 7.4 by addition of NaOH (2 M) followed by addition 
of the NAL E192N variant (0.5 mg/ml in 50 mM tris buffer pH 7.4, 5 ml). The reaction 
was stirred for 24 hr then acidified to pH 3 with formic acid (2 M) and stirred for 30 
min. The pH was then adjusted to 7.4 with NaOH (2 M) followed by the addition of 
Bakers’ yeast (1.00 g) and the suspension was stirred for 16 h. The mixture was filtered 
through Celite® and the crude product was purified by Dowex® ion exchange (gradient 
elution 0 → 2 M formic acid in water) to give the sialic acid analogue DPAH65 (224 mg, 
72%, (4S):(4R) 75:25) as a pale yellow glass; H (500 MHz; D2O) 4.58 (1H, d, J 9.6, 6-H), 
3.95-3.87 (1H, m, 4-H), 3.60 (1H, t, J 9.5, 5-H), 3.46-3.28 (4H, m, 2 × propyl 1-H2), 3.26-
3.10 (4H, m, 2 × propyl 2-H2), 2.18 (1H, dd, J 13.2 and 5.0, 3-HA), 1.81 (1H, t, J 12.6, 3-
HB), 1.59-1.40 (6H, m, 2 × propyl 3-H3); m/z (ES) [MH]
+ 306.1 (100%, [MH]+). The 
characterisation data refers to the furanose ring form of the major diastereomer 
DPAH-a. See previous synthesis reports for full characterisation data for both 
diastereomers and both major and minor anomers and ring forms. The ratio of 
equilibrium species for the two diastereomers had previously been determined by 500 
MHz 1H NMR spectroscopy: (4S)-epimer - 46:33:14:7 and (4R)-epimer - 73:11:9:7.65 
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Di-p-anisylmethylamine 36a92 
 
4-4’-dimethoxybenzophenone (5.02 g, 20.7 mmol) and ammonium formate (7.72 g, 
112 mmol) were stirred under argon at 185 °C for 4 h. Anhydrous magnesium chloride 
(0.14 g, 1.44 mmol) and formamide (3.15 ml, 61.8 mmol) were added and stirred for a 
further 2 h at 185 °C. The mixture was cooled and diluted with dichloromethane (500 
ml), washed with water (200 ml) and the solvent was removed in vacuo. The residue 
was dissolved in HCl–methanol (1 M HCl, 55 ml) and heated under reflux for 2 h. 
Methanol was removed in vacuo and the residue was dissolved in water (50 ml) and 
extracted with toluene (50 ml). The aqueous fraction was made alkaline by the 
addition of NaOH (4 M) and extracted with toluene (3 × 50 ml). Combined organic 
layers were dried (MgSO4) and the solvent removed in vacuo. Purification by 
recrystalisation from diethyl ether gave the amine 36a92 as pale yellow crystals (2.38 g, 
47%). m.p. 55.5-57.5 °C (diethyl ether) [lit. 59.5-60.0 °C]; RF: 0.38 (10:90, MeOH–
CHCl3);  H (500 MHz; CDCl3) 7.27 (4H, d, J 7.3, 2 × aryl 1-H), 6.84 (4H, d, J 6.8, 2 × aryl 2-
H), 5.13 (1H, s, NH2-CH), 3.77 (6H, s, 2 × OMe), 1.71 (2H, s, NH2); HRMS Found: 
227.1072, [C15H15O2]
• requires 227.1067. 
(2R,3R)- and (2S,3S)-3-[bis(prop-2-en-1-yl)amino]pent-4-en-1,2-diol 31b 
 
Vinylboronic acid dibutylester (0.82 ml, 3.77 mmol) was added to a solution of DL-
glyceraldehyde (500 mg, 5.55 mmol) and diallyl amine (0.69 ml, 5.55 mmol) in 9:1 
CH2Cl2–HFIP (30 ml) which had been heated to reflux. The mixture was heated under 
reflux for 18 h before being cooled to room temperature and the solvent removed in 
vacuo and the residue was purified by flash column chromatography (10:90 MeOH–
CHCl3) to give the diallyl amine 31b (515 mg, 71%, d.r. >98:<2) as a yellow oil; RF: 0.43 
(10:90 MeOH–CH2Cl2); H (500 MHz; MeOH) 5.89-5.78 (3H, m, 4-H and 2 × allyl 2-H), 
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5.38 (1H, dd, J 10.3 and 2.1, 5-HA), 5.25-5.13 (5H, m, 5-HB and 2 × allyl 3-H), 3.83 (1H, 
dd, J 12.4 and 6.2, 2-H), 3.70 (1H, dd, J 11.0 and 5.6, 1-HA), 3.54 (1H, dd, J 11.0 and 6.4, 
1-HB), 3.40 (2H, dd, J 14.2 and 4.5, 2 × allyl 1-HA), 3.22 (1H, dd, J 9.1 and 7.7, 3-H), 2.94 
(2H, dd, J 14.2 and 8.0, 2 × allyl 1-HB); m/z (ES) [MH]
+ 198.1 (100%, [MH]+). 
N-[(3R,4R)- and N-[(3S,4S)-4,5-Dihydroxypent-1-en-3-yl]acetamide 3975 
 
Method 1 
Vinylboronic acid dibutylester (0.44 ml, 2.00 mmol) was added to a solution of DL-
glyceraldehyde (270 mg, 3.00 mmol) and the primary amine 36a (740 mg, 3.00 mmol) 
in 9:1 CH2Cl2–HFIP (30 ml) which had been heated to reflux. The mixture heated under 
reflux for 3 days before being cooled to room temperature and the solvent removed in 
vacuo to give the intermediate amine 31a. The residue was re-dissolved in 4:1 EtOH-
H2O (30 ml) to which TFA (1.3 ml) was added. This mixture was heated under reflux for 
18 h before being cooled to room temperature and the solvents removed in vacuo. The 
residue was re-dissolved in MeOH (20 ml) to which NaHCO3 (330 mg) and acetic 
anhydride (0.44 ml, 4.00 mmol) was added and the mixture was heated under reflux 
for 2 h. The mixture was cooled to room temperature, concentrated in vacuo and the 
residue purified by flash column chromatography (CH2Cl2–EtOH–NH4OH 85:13:2) to 
give the diol 3975 (122 mg, 38%, d.r. >98:<2) as a pale cream amorphous solid; RF: 0.14 
(85:13:2, CH2Cl2–EtOH–NH4OH); H (500 MHz; CDCl3) 8.09 (1H, s, NH), 5.95 (1H, ddd, J 
17.2, 10.4 and 6.7, 2-H), 5.24 (2H, m, 1-H2), 4.49 (1H, t, J 5.8, 3-H), 3.65 (1H, dd, J 10.8 
and 5.3, 4-H), 3.57 (1H, dd, J 11.4 and 4.5, 5-HA), 3.51 (1H, dd, J 11.4 and 6.4, 5-HB), 
2.01 (3H, s, acetyl CH3); C (75 MHz; CDCl3) 171.3 (acetyl C=O), 134.4 (1-C), 117.8 (2-C), 
73.5 (3-C), 62.9 (4-C), 53.9 (5-C), 23.3 (acetyl CH3); m/z (ES) [MNa]
+ 182 (100%, 
[MNa]+). 
 
Method 2 
A solution of the diallylamine 31b (295 mg, 1.5 mmol) in dry CH2Cl2 (10 ml) was added 
to a flask containing tetrakis(triphenylphosphine)palladium (34 mg, 0.03 mmol, 2 
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mol%) and N, N’-dimethylbarbituric acid (1.41 g, 9.00 mmol) which was heated to 35 °C 
and stirred under argon for 20 h, cooled to room temperature and concentrated in 
vacuo. The crude was dissolved in MeOH and NaHCO3 (1.01 g, 12 mmol) and acetic 
anhydride (0.18 ml, 1.88 mmol) were added and the mixture heated under reflux for 1 
h, cooled to room temperature, filtered and the filtrate was concentrated in vacuo. 
The crude residue was purified by flash column chromatography (CH2Cl2–EtOH–NH4OH 
85:13:2) to give the diol 3975 (224 mg, 91%) as a pale cream amorphous solid. 
spectroscopically identical to that obtained previously. 
 
(2S,3S) and (2R,3R)-3-Aminopent-4-ene-1,2-diol 41 
 
The diallylamine 31b (218 mg, 1.1 mmol) was dissolved in dry dichloromethane (10 ml) 
and transferred to a flame-dried flask containing tetrakistriphenylphosphine palladium 
(25 mg, 0.02 mmol) and N,N’-dimethylbarbituric acid (1.03 g, 6.6 mmol). The 
heterogeneous mixture was stirred at 30 °C for 20 h, the solvents was removed in 
vacuo and the crude mixture re-dissolved in methanol–water (2:1). HCl (2 M, 0.5 ml) 
was added and the mixture was purified by SCX ion exchange chromatography (5 g 
cartridge) eluting with methanol (50 ml) and NH4OH (35 % v/v, 10 ml). NMR revealed a 
mixture of the fully and partially allyl deprotected amine, which were separated by 
flash column chromatography (CH2Cl2–EtOH–NH4OH, 85:13:2) to give the amine 41 (89 
mg, 69%) as a yellow oil; RF: 0.09 (85:13:2, CH2Cl2–EtOH–NH4OH); H (500 MHz; 
MeOH) 5.94 (1H, ddd, J 17.4, 10.4 and 7.3, 2-H), 5.24 (1H, dd, J 17.3 and 1.36, 1-HB), 
5.18 (1H, dd, J 10.4 and 1.0, 1-HA), 3.63 (1H, dt, J 6.6 and 4.7, 4-H), 3.56 (2H, dd, J 5.8 
and 1.7, 5-H2), 3.40 (1H, dd, J 7.3 and 4.3, 3-H). 
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(4R,5R) and (4S,5S)-4-Ethenyl-5-(hydroxymethyl)-1,3-oxazolidin-2-one 42  
 
A solution of p-nitrophenyl chloroformate (615 mg, 3.05 mmol) in acetonitrile (1 ml) 
was added to a vigorously stirred solution of the amine 41 (143 mg, 1.22 mmol) and 
NaHCO3 (512 mg, 6.1 mmol) in 2:1 water–acetonitrile (4 ml) at 0 °C and stirred for 12 
h. The solvents were removed in vacuo and the remaining residue was extracted with 
methanol (3 × 20 ml), silica was added and the solvent removed in vacuo and the 
residue was loaded onto a column. (Gradient elution 1:99 MeOH–CHCl3 → 10:90 
MeOH–CHCl3) to give the oxazolidinone 42 (112 mg, 64 %) as a colourless amorphous 
solid; RF: 0.17 (9:1, CHCl3–MeOH); H (500 MHz; MeOH) 5.96 (1H, ddd, J 17.3, 10.3 and 
7.2, 2-H), 5.37 (1H, dt, J 17.1 and 1.2, 1-HB), 5.31 (1H, dt, J 10.3 and 1.1, 1-HA), 4.74 (1H, 
ddd, J 8.6, 6.2 and 4.7, 4-H), 4.50 (1H, app. t, J 8.0, 3-H), 3.70 (2H, dd, J 5.4 and 2.4, 5-
H); C (75 MHz; MeOH) 161.6 (C=O), 134.6 (2-C), 119.3 (1-C), 81.4 (4-C), 61.8 (5-C), 58.2 
(3-C); m/z (ES) [MNa]+ 166 (100%, [MNa]+); HRMS Found: 166.0491, [C6H9NO3Na]
+ 
requires 166.0475. 
(2S,3S,5S)-5-(Chloromethyl)-2,3-dimethoxy-2,3-dimethyl-1,4-dioxane 4472 
 
Butanedione (4.5 ml, 52.0 mmol), trimethylorthoformate (6.9 ml, 63.3 mmol) and (±) 
camphor sulfonic acid (1.09 g, 4.70 mmol, 10 mol%) were added to a solution of (S)-(-)-
3-chloro-1,2-propane diol (5.00 g, 45.2 mmol) in methanol (50 ml) and heated under 
reflux for 90 min. The reaction mixture was cooled to room temperature and 
triethylamine (0.7 ml) was added and the mixture allowed to stir at room temperature 
for a further 16 h. The reaction mixture was diluted with 1:1 sat. aqueous NaHCO3–
water (80 ml) and extracted with ether (3 × 80 ml). Combined organic fractions were 
washed with brine (80 ml), dried (MgSO4) and the solvent removed in vacuo to give the 
dioxane 4472 (6.10 g, 60%) as a pale yellow oil which was used without further 
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purification, however purification could be carried out by flash column 
chromatography (10:1 petrol–ether). RF 0.19 (1:10 ether–petrol)     
  : 158 (c. 1.40 in 
chloroform) [lit. 204 (c. 2.03 in chloroform)]; H (500 MHz; CDCl3) 4.08 (1H, dt, J 12.1 
and 5.6, 5-H), 3.62-3.57 (2H, m, 6-H), 3.50 (1H, dd, J 11.3 and 6.4, CH2ClA), 3.41 (1H, dd, 
J 11.1 and 6.4, CH2ClB), 3.30 (3H, d, J 1.1, OMeA), 3.27 (3H, d, J 1.1, OMeB), 1.30 (3H, d, J 
1.1, MeA), 1.29 (3H, d, J 0.9, MeB); HRMS Found: 247.0706, [C9H17ClO4Na]
+ requires 
247.0708. 
(2R,3R,5R)-5-(Chloromethyl)-2,3-dimethoxy-2,3-dimethyl-1,4-dioxane ent-4472 
 
(R)-(+)-3-chloro-1,2-propane diol (15.0 g, 135.6 mmol) was treated under the condition 
described for the enantiomer to give the dioxane ent-4472 (24.4 g, 80%) as a pale 
yellow oil which was used without further purification;     
  : ‒100.5 (c. 1.50 in 
chloroform) [lit. ‒204.1 (c. 2.03 in chloroform]. Spectroscopically identical to that 
obtained for the enantiomer. 
(5S,6S)-5,6-Dimethoxy-5,6-dimethyl-1,4-dioxan-2-one 3372 
 
Potassium tert-butoxide (4.98 g, 44.4 mmol) was added to a solution of the dioxane 44 
(5.00 g, 22.2 mmol) in THF (45 ml) and the mixture was heated under reflux for 80 min 
before being cooled to room temperature, diluted with water (50 ml) and extracted 
with ether (3 × 50 ml). Combined organic fractions were washed with brine (50 ml), 
dried (MgSO4) and the solvent removed in vacuo. The resulting alkene 45a was 
dissolved in dichloromethane (150 ml) and subjected to ozonolysis conditions at –78 °C 
until the reaction was seen to have gone to completion by the appearance of a 
permanent blue colour. The reaction was quenched at room temperature with 
dimethyl sulfide (10 ml) and stirred under nitrogen until testing with starch iodide 
paper revealed peroxides had been fully quenched, at which point the solvents were 
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removed in vacuo. Purification by flash column chromatography (10:1 petrol–ether) 
gave the lactone 3372 (1.23 g, 38%) as a pale yellow oil which solidified on cooling to 4 
°C; RF 0.17 (20:80 ether–petrol);     
  : 124.8  (c. 1.30 in chloroform) [lit. 213.3 (c. 0.83 
in chloroform)];  H (500 MHz; CDCl3) 4.28 (1H, d, J 17.8, 3-HA), 4.13 (1H, d, J 17.8, 3-
HB), 3.43 (3H, s, OMeA), 3.30 (3H, s, OMeB), 1.49 (3H, s, MeA), 1.38 (3H, s, MeB); HRMS 
Found: 213.0739, [C8H14O5Na]
+ requires 213.0733. 
(5R,6R)-5,6-Dimethoxy-5,6-dimethyl-1,4-dioxan-2-one ent-3372 
 
The dioxane ent-44 (15.0 g, 66.6 mmol) was treated as described for the enantiomer to 
give the lactone ent-33 (4.97 g, 40%) as a pale yellow oil which solidified on cooling to 
4 °C;     
  : -150.7 (c. 1.1 in chloroform) [lit. ‒212.1 (c. 1.07 in chloroform)]. 
Spectroscopically identical to that obtained for the enantiomer. 
(3R,5S,6S)-3-((R)-1'-Hydroxy-3'-methylbut-2'-enyl)-5,6-dimethoxy-5,6-dimethyl-1,4-
dioxan-2-one 49 
 
Lithium hexamethyldisilazide (1.0 M in THF, 7.89 ml, 7.89 mmol) was added to a 
solution of the lactone 33 (1.00 g, 5.26 mmol) in dry THF and stirred for 15 min at –78 
°C. 3-Methyl-2-butenal (0.61 ml, 6.32 mmol) was added and the mixture stirred for a 
further 10 min, followed by the addition of acetic acid (0.6 ml, 15.5 mmol). The 
mixture was allowed to warm to room temperature before being passed through a 
short plug of silica eluting with ether (125 ml). Solvents were removed in vacuo and 
the residue purified by flash column chromatography (40:60 ether−petrol) to give the 
alcohol 49 (1.22g, 85%, d.r. >98:<2) as a yellow oil; RF 0.11 (40:60 ether–petrol);     
  : 
145 (c. 0.20 in chloroform); max/cm
-1 (film) 3466, 1736, 1681; H (500 MHz; CDCl3) 5.49 
(1H, d, J 9.0, 2-H'), 4.76 (1H, dd, J 9.0, 3.0, 1-H'), 4.21 (1H, d, J 9.0, 3-H), 3.42 (3H, s, 
OMeA), 3.33 (3H, s, OMeB), 3.07 (1H, s, OH), 1.77 (3H, s, 4-H3'A), 1.72 (3H, s, 4-H3'B), 
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1.49 (3H, s, MeA), 1.44 (3H, s, MeB); C (75 MHz; CDCl3) 166.9 (2-C), 137.8 (3-C'), 121.4 
(2-C'), 104.8 (5-C or 6-C), 98.2 (5-C or 6-C), 74.6 (3-C'), 69.3 (1-C'), 50.1 (OMeA), 49.3 
(OMeB), 26.0 (4-C'A), 18.4 (4-C'B), 17.9 (MeA), 16.8 (MeB); HRMS Found: 297.132, 
[C13H22O6Na]
+ requires 297.1309.  
(3S,5R,6R)-3-((S)-1'-Hydroxy-3'-methylbut-2'-enyl)-5,6-dimethoxy-5,6-dimethyl-1,4-
dioxan-2-one ent-49 
 
The lactone ent-33 (2.00 g, 10.53 mmol) was treated as described for the enantiomer 
to give the alcohol ent-49 (2.63 g, 91%, d.r. >98:<2) as a yellow oil;     
  : −100.0 (c. 
1.00 in chloroform). Spectroscopically identical to that obtained for the enantiomer.  
(5S,6S,E)-3-(1'-hydroxy-3'-methylbut-2'-enylidene)-5,6-dimethoxy-5,6-dimethyl-1,4-
dioxan-2-one 50 
 
Lithium hexamethyldisilazide (1.0 M in THF, 15.7 ml, 15.7 mmol) was added to a 
solution of the lactone 33 (2.00 g, 10.5 mmol) in dry THF (48 ml) at  –78 °C and the 
mixture stirred for 10 min. 3-methyl-2-butenyl chloride (1.4 ml, 12.6 mmol) was added 
and the mixture stirred for a further 60 min. Acetic acid (1.2 ml, 21.0 mmol) was added 
and the mixture allowed to warm to room temperature before being passed through a 
short plug of silica eluting with ether (250 ml) and removing the solvents in vacuo. 
Purification by flash column chromatography (10:90 ether–petrol) to give the enol 50 
(0.13 g, 23%) as a colourless-pale yellow amorphous solid; RF 0.48 (40:60 ether–petrol) 
    
  : 100.7 (c. 0.7 in chloroform); max/cm
-1 (film) 3448, 1748, 1648; H (500 MHz; 
CDCl3) 11.69 (1H, d, J 1.6, OH), 6.19 (1H, d, J 1.3, 2-H'), 3.44 (3H, s, OMeA), 3.24 (3H, s, 
OMeB), 2.14 (3H, s, 4-H3'A), 1.94 (3H, s, 4-H3'B), 1.53 (3H, s, MeA), 1.49 (3H, s, MeB); C 
(75 MHz; CDCl3) 166.2 (2-C), 159.9(1-C’), 149.5 (3-C), 113.3 (2-C’), 104.2 (5-C or 6-C), 
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98.1 (5-C or 6-C), 50.7 (OMeA), 49.0 (4-C’A), 28.7 (4-C’B), 20.9 (OMeB), 17.5 (MeA) , 16.7 
(MeB). 
(5R,6R,E)-3-(1'-Hydroxy-3'-methylbut-2'-enylidene)-5,6-dimethoxy-5,6-dimethyl-1,4-
dioxan-2-one ent-50 
 
The lactone ent-33 (2.00 g, 10.5 mmol) was treated as described for the enantiomer to 
give the enol ent-50 (0.87 g, 30%) as a colourless-pale yellow amorphous solid;     
  : 
−103.1 (c. 0.6 in chloroform). Spectroscopically identical to that obtained for the 
enantiomer. 
Ethyl-3-(phenylselanyl)propanoate 6093 
 
Sodium borohydride (1.04 g, 27.6 mmol) was added to a vigorously stirred solution of 
diphenyl diselenide (3.74 g, 12 mmol) in ethanol (450 ml) at 0 °C which was warmed to 
room temperature once addition was complete. Caution: Hydrogen gas evolved. Once 
the solution became colourless (approx. 10-20 min – up to a further 1 g of sodium 
borohydride was added if the solution did not become colourless) ethyl-3-
chloropropionate was added and the mixture was heated to 60 °C and stirred for 6 h. 
The mixture was cooled to room temperature and water (15 ml) was added and 
approx. 75% of the ethanol was removed in vacuo. The remaining mixture was 
extracted with MTBE (3 × 100 ml), dried (MgSO4) and the solvent removed in vacuo. 
The residue was purified by automated column chromatography (gradient elution 99:1 
hexane–EtOAc  90:10 hexane–EtOAc) to give the ester 6093 (5.36 g, 87%) as a 
colourless-pale yellow oil; RF: 0.3 (5:95, MTBE–hexane); H (500 MHz; CDCl3) 7.54-7.50 
(2H, m, 2 × phenyl 3-H), 7.28-7.25 (3H, m, 2 × phenyl 2-H and phenyl 4-H), 4.13 (2H, q, J 
7.1, ethyl 1-H2), 3.10 (2H, t, J 7.5, 3-H2), 2.71 (2H, t, J 7.5, 2-H2), 1.25 (2H, t, J 7.1, ethyl 
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2-H2); HRMS Found: 259.0232, [C11H15O2
80Se]+ requires 259.0232 (isotope distribution 
as expected). 
3-(Phenylselanyl)propanoic acid 6193 
 
A solution of the ester 60 (7.00 g, 27.22 mmol) in THF (76.2 ml) was added to a 0.5 M 
aqueous solution of KOH (76.2 ml, 38.1 mmol) at 0 °C and stirred for 3 h. The reaction 
mixture was then extracted with MTBE (3 × 100 ml), and the aqueous layer acidified 
with conc. HCl(aq) and re-extracted with MTBE (3 × 100 ml). Combined organic layers 
from the second extraction were washed with brine (100 ml), dried (MgSO4) and the 
solvent removed in vacuo. Purification by recrystalisation from CH2Cl2 gave the acid 
6193 (4.05 g, 66%) as colourless prisms; m.p. 49.6-54.2 °C (CH2Cl2) [lit. 45.0-46.0 °C 
(CH2Cl2‒hexane)]; RF: 0.53 (50:90, MeOH–CHCl3); H (500 MHz; CDCl3) 7.53 (2H, dd, J 
6.5 and 3.1, 2 × phenyl 3-H), 7.31-7.24 (3H, m, 2 × phenyl 2-H and phenyl 4-H), 3.08 
(2H, t, J 7.4, 3-H), 2.77 (2H, t, J 7.4, 2-H). 
(3E,5S,6S)-3-[1’-hydroxy-3’-(phenylselanyl)propylidene]-5,6-dimethoxy-5,6-dimethyl-
1,4-dioxan-2-one 51 
 
A suspension of acid 61 (2.00 g, 8.80 mmol) in oxalyl chloride (1.49 ml, 17.6 mmol) was 
stirred at room temperature for 4 hr and the product was purified by distillation under 
vacuum (b.p. 175 °C, <0.1 mbar) to give acid chloride 48 as a colourless oil (1.93 g, 
89%) which was used immediately due to its instability. LHMDS (1.0 M in THF, 3.94 ml, 
3.94 mmol) was added to a solution of the lactone 33 (422 mg, 2.2 mmol) in dry THF 
(12 ml) which had been cooled to –78 °C and stirred for 15 min. The acid chloride 48 
(781 mg, 3.16 mmol) was then added to a solution and stirred for 1 h at –78 °C. Acetic 
acid (0.3 ml, 5.26 mmol) was added and the mixture warmed to room temperature 
then filtered through a short plug of silica, eluting with MTBE (40 ml) and the solvents 
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removed in vacuo. The residue was purified by automated column chromatography 
(gradient elution 10:90  40:60 MTBE–hexane) to give the enol 51 (575 mg, 65%, 1:1 
keto-enol) as a yellow oil. RF: enol - 0.2, keto - 0.08 (10:90, MTBE-hexane);     
  : 95.3 
(c. 0.20 in chloroform); Keto-enol ratio determined by separation of keto and enol 
forms by Biotage (see previously). 
H (500 MHz; CDCl3): 
enol - 11.32 (1H, s, OH), 7.58-7.46 (2H, m, 2 × phenyl 3-H), 7.28-7.23 (3H, m, 2 × phenyl 
2-H and phenyl 4-H), 3.43 (3H, s, OMeA), 3.15 (3H, s, OMeB), 3.12-3.04 (2H, m, 3-H'), 
2.84 (2H, t, J 8.0, 2-H'), 1.52 (3H, s, MeA), 1.41 (3H, s, MeB) 
keto - 7.57-7.48 (2H, m, 2 × phenyl 3-H), 7.31-7.18 (3H, m, 2 × phenyl 2-H and phenyl 4-
H), 4.67 (1H, s, H-3), 3.31 (3H, s, OMeA), 3.31 (3H, s, OMeB), 3.08 (2H, t, J 7.4, 3-H'), 
2.79 (2H, t, J 7.6, 2-H'), 1.46 (3H, s, MeA), 1.38 (3H, s, MeB) 
4-Nitro-N-[(2E)-3-phenylprop-2-en-1-ylidene]benzene-1-sulfonamide 34 
 
Borontrifluoro diethyletherate (194 µl, 1.58 mmol, 8 mol%) was added to a refluxing 
solution of 4-nitrobenzenesulfonamide (4.00 g, 19.8 mmol) and cinnamaldehyde (2.49 
ml, 19.8 mmol) in dry toluene (113 ml). Caution: Effervescence occurs on addition of 
boron trifluoro diethyletherate. The solution was heated under reflux for 3 days, 
cooled to room temperature and the solvent removed in vacuo. The residue was 
triturated from EtOAc to give the imine 34 (5.50 g, 88%) as a dark brown solid; RF: 0.3 
(20:80, EtOAc–petrol); H (500 MHz; CDCl3) 8.86 (1H, d, J 9.5, 1-H), 8.38 (2H, d, J 8.9, 2 
× nosyl 3-H), 8.18 (2H, d, J 8.9, 2 × nosyl 3-H), 7.62-7.57 (3H, m, 2 × phenyl 3-H and 3-
H), 7.51-7.42 (3H, m, 2 × phenyl 2-H and phenyl 4-H), 7.01 (1H, dd, J 15.8, 9.5, 2-H); C 
(75 MHz; CDCl3) 173.1 (1-C), 156.0 (3-C), 150.5 (nosyl-1-C or nosyl 4-C), 144.4 (nosyl-1-
C or nosyl 4-C), 133.9 (phenyl 1-C), 132.3 (phenyl 4-C), 129.3 (nosyl 2-C or nosyl 3-C), 
129.2 (2 × phenyl 2-C), 129.0 (2 × phenyl 3-C), 124.34 (nosyl 2-C or nosyl 3-C), 124.31 
(2-C); HRMS Found: 317.0592, [C15H13N2O4S]
+ requires 317.0591. 
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N-[(1’R,2’E)-1’-[(2R,5S,6S)-5,6-Dimethoxy-5,6-dimethyl-3-oxo-1,4-dioxan-2-yl]-3’-
phenylprop-2’-en-1’-yl]-4-nitrobenzene1’-sulfonamide 35 
 
Lithium hexamethyldisilazide (1.0 M in THF, 2.4 ml, 2.4 mmol) was added to a solution 
of the lactone 33 (300 mg, 1.6 mmol) in THF (5 ml) at –78 °C and stirred for 15 min. A 
solution of the imine 34 (500 mg, 1.6 mmol) in THF (10 ml) was added to the enolate 
solution and the reaction stirred for 1 h at –78 °C before being quenched with acetic 
acid (0.4 ml) and filtered through a short plug of silica, eluting with ether. The solvents 
were removed in vacuo and the resulting crude material was purified by flash column 
chromatography (20:80 EtOAc–petrol). The excess p-nosyl sulfonamide was removed 
by dissolving the residue in chloroform, filtering under vacuum and concentrating the 
filtrate in vacuo to give the lactone 35 (643 mg, 79%, d.r. 83:17) as a sticky yellow-
orange solid; RF: 0.43 (1:1, petrol–EtOAc);     
  : 92.9 (c. 0.50 in chloroform); max/cm
-1 
(film) 3271, 3106, 2951, 1748, 1530, 1450; H (500 MHz; CDCl3) 8.15 (2H, d, J 8.8, 2 × 
nosyl 2-H), 7.98 (2H, d, J 8.7, 2 × nosyl 3-H), 7.23-7.20 (3H, m, 2 × phenyl 3-H and 
phenyl 4-H), 7.09-7.05 (2H, m, 2 × phenyl 2-H), 6.32 (1H, d, J 16.0, 3-H'), 5.82 (1H, d, J 
7.2, NH), 5.80 (1H, dd, J 16.0 and 9.2, 2-H'), 4.55-4.49 (1H, m, 1-H'), 4.39 (1H, d, J 3.1, 2-
H), 3.32 (3H, s, OMeA), 3.20 (3H, s, OMeB), 1.45 (3H, s, MeA), 1.43 (3H, s, MeB); C (75 
MHz; CDCl3) 165.9 (3-C'), 149.7 (nosyl 4-C), 146.4 (nosyl 1-C), 135.2 (phenyl 1-C), 135.1 
(3-C'), 128.8 (2 × nosyl 3-C), 128.6 (2 × phenyl 3-C and phenyl 4-C), 126.3 (2 × phenyl 2-
C), 124.1 (2 × nosyl 2-C), 122.3 (2-C'), 105.4 (6-C), 98.6 (5-C), 73.6 (2-C), 58.6 (1-C'), 50.2 
(OMeA), 49.5 (OMeB), 17.7 (MeA), 16.8 (MeB); HRMS Found: 529.1260, 
[C23H26N2O9SNa]
+ requires 529.1251. The diastereomeric ratio was determined by the 
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relative integration of the peaks at 4.55-4.49 (1H, m, 1-H’maj) and 4.68-4.60 (1H, m, 1-
H’min) in the 500 MHz 1H NMR spectrum. 
N-[(1’S,2’E)-1’-[(2S,5R,6R)-5,6-Dimethoxy-5,6-dimethyl-3-oxo-1,4-dioxan-2-yl]-3’-
phenylprop-2’-en-1’-yl]-4-nitrobenzene1’-sulfonamide ent-35 
 
The lactone ent-33 (2.70 g, 14.2 mmol) was treated as described for the enantiomer to 
give the lactone ent-35 (6.52 g, 91%, d.r. 83:17) as a sticky yellow-orange solid;     
  : 
−39.8 (c. 1.30 in chloroform). Spectroscopically identical to that obtained for the 
enantiomer. 
(2R,3R,4E)-2-Hydroxyl-3-[(4-nitrobenzene)sulfonamide]-5-phenyl-N,N-dipropylpent-
4-enamide 53 
 
Trimethylaluminium (2.00 M in hexane, 1.0 ml, 2.00 mmol) was added to a solution of 
dipropylamine (273 µl, 2.00 mmol) in dry CH2Cl2 (5 ml) and stirred at room 
temperature for 15 min. The lactone 35 (0.50 g, 1.00 mmol) was dissolved in the 
minimum amount of CH2Cl2 and added to the stirred solution of Me2AlNPr2 and the 
mixture was warmed to 40 °C, stirred for 2 h, cooled to room temperature and quench 
by addition of 1 M HCl(aq) (1 ml). Caution: addition of HCl results in a vigorous 
effervescent reaction. The reaction mixture was extracted with CH2Cl2 (3 × 30 ml), 
dried (Na2SO4) and the solvent removed in vacuo. The residue was dissolved in 1:1 
MeCN–water (50 ml) to which TFA (1.2 ml) was added and the mixture stirred at room 
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temperature for 24 h, poured into EtOAc, separated and the aqueous layer extracted 
with EtOAc (2 × 30 ml). Combined organic layers were dried (MgSO4) and the solvent 
removed in vacuo. Purification by flash column chromatography (30:70 EtOAc–petrol) 
to give the sulfonylamide 53 (324 mg, 88%) as a dark orange/yellow solid; RF: 0.37 (1:1, 
petrol-EtOAc); m.p. 121-123 °C (petrol–EtOAc);     
  : 45 (c. 0.80 in chloroform); 
max/cm
-1 (film) 3203, 2969, 1645, 1532; H (500 MHz; CDCl3) 8.13 (2H, d, J 8.5, 2 × 
nosyl 2-H), 7.99 (2H, d, J 8.5, 2 × nosyl 3-H), 7.20 (3H, s, 2 × phenyl 2-H and phenyl 4-H), 
7.05-6.96 (2H, m, 2 × phenyl 3-H), 6.12 (1H, d, J 15.9, 5-H), 5.64 (1H, dd, J 15.8 and 8.1, 
4-H), 4.16 (1H, d, J 2.1, 2-H), 4.29 (1H, d, J 8.1, 3-H), 3.61-3.51 (1H, m, propyl 1-HA), 
3.37-3.27 (1H, m, propyl 1-HB), 3.25-3.14 (1H, m, propyl-1-HC), 3.03-2.90 (1H, m, propyl 
1-HD), 1.71-1.55 (2H, m, propyl 2-H2,A), 1.51-1.40 (2H, m, propyl 2-H2,B), 0.94 (3H, t, J 
7.3, propyl 3-H3,A), 0.82 (3H, t, J 7.3, propyl 3-H3,B); C (75 MHz; MeOD) 172.4 (1-C), 
151.0 (nosyl 4-C), 148.8 (nosyl 1-C), 137.2 (phenyl 1-C), 135.2 (phenyl 5-C), 129.7 (2 × 
phenyl 2-C), 129.5 (2 × phenyl 3-C), 129.1 (phenyl 4-C), 127.3 (2 × nosyl 3-C), 125.2 (2 × 
nosyl 2-C), 124.2 (4-C), 72.3 (2-C), 60.7 (3-C), 50.3 (propyl 1-CA), 49.1 (propyl 1-CB), 23.4 
(propyl 2-CA), 21.8 (propyl 2-CB), 11.7 (propyl 3-CA), 11.4 (propyl 3-CB); HRMS Found: 
476.1862, [C23H30N3O6S]
+ requires 476.185. 
 
(2S,3S,4E)-2-Hydroxyl-3-[(4-nitrobenzene)sulfonamide]-5-phenyl-N,N-dipropylpent-
4-enamide ent-53 
 
The lactone ent-35 (3.00 g, 5.93 mmol) was treated as described for the enantiomer to 
give the sulfonylamide ent-53 (2.19 g, 78%) as a dark orange/yellow solid;     
  : −48.7 
(c. 1.7, CHCl3). Spectroscopically identical to that obtained for the enantiomer. 
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(2R,3R,4E)-3-Amino-2-hydroxy-5-phenyl-N,N-dipropylpent-4-enamide 54 
 
Thiophenol (300 µl, 2.97 mmol) and 1,8-diazabicycloundec-7-ene (600 µl, 3.96 mmol) 
were added to a solution of the sulfonylamide 53 (470 mg, 0.99 mmol) in MeCN (4 ml) 
and stirred at room temperature for 16 h. The reaction mixture was concentrated in 
vacuo and purified by flash column chromatography (gradient elution 5:95 EtOH–
CH2Cl2  5:5:90 sat. NH3 in MeOH–EtOH–CH2Cl2) to give amine 54 (255 mg, 89%) as a 
pale yellow viscous oil; RF: 0.18 (5:95, EtOH–CH2Cl2);     
  : 55.1 (c. 0.90 in chloroform); 
max/cm
-1 (film) 3277, 2965, 1638; H (500 MHz; CDCl3) 7.34-7.20 (5H, m, 2 × phenyl 2-
H, 2 × phenyl 3-H and phenyl 4-H), 6.52 (1H, d, J 15.9, 5-H), 6.12 (1H, dd, J 15.9 and 7.9, 
4-H), 4.60 (1H, d, J 3.2, 2-H), 3.88 (2H, s, NH2), 3.82 (1H, dd, J 7.7 and 2.8, 3-H), 3.60-
3.51 (1H, m, propyl 1-HA), 3.39-3.31 (1H, m, propyl 1-HB), 3.20-3.12 (1H, m, propyl 1-
HC), 3.01-2.93 (1H, m, propyl-1-HD), 1.63-1.54 (2H, m, propyl 2-H2A), 1.52-1.45 (2H, m, 
propyl 2-H2B), 0.90 (3H, t, J 7.4, propyl-3-H3A), 0.93 (3H, t, J 7.4, propyl 3-H3B); C (75 
MHz; CDCl3) 171.0 (1-C), 133.2 (5-C), 128.9 (phenyl 1-C), 128.5 (2 × phenyl 2-C), 127.9 
(phenyl 4-C), 126.6 (2 × phenyl 3-C), 126.0 (4-C), 70.2 (2-C), 56.8 (3-C), 48.8 (propyl 1-
CA), 47.6 (propyl 1-CB), 22.1 (propyl 2-CA), 20.7 (propyl 2-CB), 11.4 (propyl 3-CA), 11.1 
(propyl 3-CB); HRMS Found: 291.2067, [C17H27N2O2]
+ requires 291.2067. 
 
(2S,3S,4E)-3-Amino-2-hydroxy-5-phenyl-N,N-dipropylpent-4-enamide ent-54 
 
The sulfonylamide ent-53 (2.00 g, 4.21 mmol) was treated as described for the 
enantiomer to give amine ent-54 (1.06 g, 88%) as a dark orange/yellow viscous oil; 
    
  : −30.5 (c. 1.20 in chloroform). Spectroscopically identical to that obtained for the 
enantiomer. 
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(2R,3R,4E)-3-Acetamido-2-hydroxy-5-phenyl-N,N-dipropylpent-4-enamide 24 
 
A solution of the amine 54 (225 mg, 0.77 mmol), NaHCO3 (520 mg, 6.16 mmol) and 
acetic anhydride (0.11 ml, 1.16 mmol) in methanol (5 ml) was heated under reflux for 1 
h before being cooled to room temperature, filtered and the solvent removed in 
vacuo. Purification by flash column chromatography (80:20 EtOAc–petrol) to give the 
dipropylamide 24 (228 mg, 89%) as a pale yellow/colourless amorphous solid; RF: 0.16 
(80:20, EtOAc–petrol);     
  : 29.1 (c. 1.30 in chloroform); max/cm
-1 (film) 3234, 1628; 
H (500 MHz; CDCl3) 7.32-7.27 (4H, m, 2 × phenyl 2-H and 2 × phenyl 3-H), 7.24-7.20 
(1H, m, phenyl 4-H), 6.53 (1H, d, J 15.9, 5-H), 6.36 (1H, d, J 8.4, NH), 6.05 (1H, dd, J 15.9 
and 7.2, 4-H), 4.85-4.81 (1H, m, 3-H), 4.59 (1H, d, J 2.2, 2-H), 3.68-3.56 (2H, m, propyl 
1-H2,A), 3.30-3.23 (1H, m, propyl 1-HB), 3.01-2.94 (1H, m, propyl 1-HC), 2.06 (3H, s, 
acetyl CH3), 1.70-1.60 (2H, m, propyl 2-H2,A), 1.57-1.47 (2H, m, propyl 2-H2,B), 0.97 (3H, 
t, J 7.4, propyl 3-H3,A), 0.85 (3H, t, J 7.4, propyl 3-H3,B); C (75 MHz; CDCl3) 170.4 (amide-
C=O), 169.8 (acetyl C=O), 136.2 (phenyl 1-C), 134.0 (5-C), 128.6 (2 × phenyl 2-C), 128.0 
(phenyl 4-C), 126.6 (2 × phenyl 3-C), 122.5 (4-C), 70.3 (2-C), 53.7 (3-C), 48.4 (propyl 1-
CA), 47.5 (propyl 1-CB), 23.4 (acetyl CH3), 22.1 (propyl 2-CA), 20.7 (propyl 2-CB), 11.4 
(propyl 3-CA), 11.0 (propyl 3-CB); HRMS Found: 333.2165, [C19H29N2O3]
+ requires 
333.2173. 
 
(2S,3S,4E)-3-Acetamido-2-hydroxy-5-phenyl-N,N-dipropylpent-4-enamide ent-24 
 
The amine ent-54 (1.39 g, 4.8 mmol) was treated as described for the enantiomer to 
give the dipropylamide ent-25 (0.88 g, 56%) as a pale yellow/colourless amorphous 
solid;     
  : −34.4 º (c. 0.90 in chloroform). Spectroscopically identical to that obtained 
for the enantiomer. 
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(4R,5R,6R)-7-(Dipropylamino)-5-acetamido-4,6-dihydroxy-2,7-dioxoheptanoate 55a 
 
The dipropylamide 24 (150 mg, 0.4 mmol) subjected to general ozonolysis conditions 
described previously. Methanol was removed in vacuo and the crude mixture was re-
dissolved in 50 mM tris buffer (5 ml) to which sodium pyruvate (88 mg, 0.8 mmol) was 
added. The pH was adjusted to 7.4 by addition of NaOH (2 M) followed by addition of 
the NAL E192N variant (1 mg/ml in 50 mM tris buffer pH 7.4, 1 ml). The reaction was 
stirred for 24 h then acidified to pH 3 with formic acid (2 M) and allowed to stir for 30 
min. The pH was then adjusted to 7.4 with NaOH (2 M) followed by the addition of 
baker’s yeast (200 mg) and stirred for 16 h. The mixture was filtered through Celite® 
and the crude product was purified by Dowex® ion exchange (gradient elution 0 → 2M 
formic acid in water) to give the sialic acid analogue 55 (57 mg, 41 %, d.r. >98:<2) as a 
pale yellow glass; H (500 MHz; D2O) 4.83 (1H, d, J 10.3, 6-H), 4.11 (1H, td, J 11.2, 10.9 
and 4.5, 4-H), 4.00 (1H, t, J 10.2, 5-H), 3.59-3.50 (2H, m, propyl 1-H2,A), 3.29-3.22 (1H, 
m, propyl 1-HC), 3.03-2.96 (1H, m, propyl 1-HD), 2.35 (1H, dd, J 13.1, 4.5, 3-Heq), 1.88 
(3H, s, acetyl-CH3), 1.99-1.92 (1H, m, 3-Hax), 1.68-1.57 (2H, m, propyl 2-H2,A), 1.53-1.43 
(2H, m, propyl 2-H2,B), 0.87 (3H, t, J 7.4, propyl 33,A), 0.83 (3H, t, J 7.4, propyl 3-H3,B); C 
(75 MHz; D2O) 174.0 (acetyl C=O), 172.1 (1-C), 169.0 (7-C), 95.9 (2-C), 68.0 (6-C), 65.7 
(4-C), 54.1 (5-C), 49.9 (propyl 1-CB), 48.7 (propyl 1-CA), 38.7 (3-C), 22.1 (propyl 2-CA), 
21.9 (acetyl-CH3), 20.0 (propyl 2-CB), 10.5 (propyl 3-CB), 10.2 (propyl 3-CA); HRMS 
Found: 345.1682, [C15H25N2O7]
- requires 345.1667. The product was isolated as a single 
diastereomer which exists as one pyranose ring form as determined by 500MHz 1H 
NMR. 
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(4R,5S,6S) and  (4S,5S,6S) -7-(Dipropylamino)-5-acetamido-4,6-dihydroxy-2,7-
dioxoheptanoate ent-55 
 
The dipropylamide ent-25 (100 mg, 0.3 mmol) subjected to general ozonolysis 
conditions described previously. Methanol was removed in vacuo and the crude 
mixture was re-dissolved in 50 mM tris buffer (3.5 ml) to which sodium pyruvate (66 
mg, 0.6 mmol) was added. The pH was adjusted to 7.4 by addition of NaOH (2 M) 
followed by addition of the NAL E192N variant (0.8 mg/ml in 50 mM tris buffer pH 7.4, 
4 ml). The reaction was stirred under nitrogen for 24 h. The reaction was acidified to 
pH 3 with formic acid (2 M) and allowed to stir for 30 min. The pH was then adjusted to 
7.4 with NaOH (2 M) followed by the addition of Bakers’ yeast (150 mg) and stirred for 
16 h. The mixture was filtered through Celite® and the crude product was purified by 
Dowex® ion exchange (gradient elution 0 → 2M formic acid in water) to give the sialic 
acid analogue ent-55 as a pale yellow glass, which was then further purified by mass 
directed HPLC. (9 mg, 9%, (4S):(4R) 76:24); H (500 MHz; D2O)
* 5.03 (1H, d, J 10.6, 6-
H4S,maj), 5.00 (1H, d, J 9.6, 6-H4S,min), 4.75 (1H, d, J 10.2, 6-H4R), 4.23 (1H, dd, J 10.6 and 
3.1, 5-H4S), 4.12 (1H, t, J 3.0, 4-H4S), 4.04-4.06 (1H, m, 4-H4R), 3.94 (1H, t, J 10.2, 5-H4R), 
3.57-3.47 (2H, m, 2 × propyl 1-H2,A
4S), 3.42-3.33 (2H, m, propyl H-12
4R), 3.23-3.16 (1H, 
m, propyl 1-HC
4S), 3.07-2.99 (1H, m, propyl 1-HC
4R), 2.97-2.90 (1H, m, propyl 1-HD
4S), 
2.26 (1H, dd, J 13.1 and 4.5, 3-Heq
4R), 2.17-2.15 (1H, m, 3-Heq
4S,maj), 2.12-2.09 (1H, m, 3-
Heq
4S,min), 2.01-1.93 (1H, m, 3-Hax
4S), 1.90 (3H, s, acetyl CH3
4R), 1.90-1.89 (1H, m, 3-Hax
4R) 
1.19 (3H, s, acetyl CH3
4S), 1.62-1.52 (2H, m, propyl 2-H2,A), 1.46-1.52 (2H, m, propyl 2-
H2,B), 0.83 (3H, t, J 7.4, propyl 3-H3,B), 0.78 (3H, t, J 7.4, propyl 3-H3,B) C (75 MHz; D2O) 
174.0 (acetyl C=O4R), 173.3 (acetyl C=O4S), 172.0 (1-C4R), 169.6 (7-C4S), 169.0 (7-C4R), 
95.9 (2-C4R), 95.3 (2-C4S), 68.8 (6-C4S,min), 68.0 (6-C4R), 65.4 (4-C4R), 64.5 (4-C4S), 64.4 (6-
C4S,maj), 54.1 (5-C4R), 49.7 (propyl 1-CA,
4S), 49.5 (5-C4S), 49.4 (2 × propyl 1-C4R), 48.5 
                                                     
*
 Superscript abbreviations in NMR characterisation data: 4S and 4R refer to the 
diastereomer, and maj and min refer to the major and minor anomer. When 
unspecified, assume that the peak described both of the diastereomers/anomers. 
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(propyl 1-CB,
4S), 39.0 (3-C4S,min), 38.7 (3-C4R), 36.4 (3-C4S,maj), 22.1 (acetyl CH3,
4R), 21.9 
(acetyl CH3,
4S), 21.8 (propyl 2-CA), 19.9 (propyl 2-CB), 10.4 (propyl 3-CB), 10.2 (propyl 3-
CA); HRMS Found: 346.1718, [C15H26N2O7]
- requires 346.174; The diastereomeric ratio 
was determined by comparison of the relative integrals of the peaks at 4.12 (1H, t J 
3.0, 4-H4R) and 4.04-4.06 (1H, m, 4-H4S) The major diastereomer ent-55b was observed 
as 60:40 mixture of anomers, which was determined by comparison of the peaks for 6-
H in the 500 MHz 1H NMR spectrum. The minor diastereomer ent-55a was observed as 
a single anomer and was found to be spectroscopically identical to the enantiomer 
55a.  
6.3.1 General method for synthesis of fluorinated sialic acid analogues 
 The alkene was cleaved under standard ozonolysis condition (see Section 
6.2.1). Methanol was removed in vacuo and the crude mixture was re-dissolved in 50 
mM tris buffer (1.2 ml per 0.1 mmol aldehyde) to which sodium fluoropyruvate (0.5-1 
eq.) was added. The pH was adjusted to 7.4 by addition of NaOH (2 M) followed by 
addition of the NAL variant (in 50 mM tris buffer, 2-4 mg per 0.1 mmol aldehyde). The 
reaction was allowed to stir under nitrogen for 24 h. The mixture was frozen, thawed 
and filtered through Celite® and the product was isolated by ion exchange 
chromatrography using Dowex® resin (gradient elution 0 → 2 M formic acid in water) 
or SAX resin cartridges (gradient elution 0 → 2 M formic acid in MeOH) 
(3R,4S,5S,6R)-7-(dipropylamino)-3-fluoro-4,5,6-trihydroxy-2,7-dioxoheptanoate 23b  
 
Reaction was carried out as described in the general experimental Section 6.3.1 using 
the alkene 24 (222 mg, 1.03 mmol), sodium fluoropyruvate (88 mg, 0.69 mmol) and 
the NAL E192N/T167V/S208V variant. The crude product was purified by ion exchange 
to give the fluorinated sialic acid analogue 23b (90 mg, 41%, d.r. >98:<2) as a yellow 
glass. Purification by reverse-phase HPLC, retention time 31.0 min; H (500 MHz, D2O) 
5.03 (1H, dd, 2JHF 52.0, 
3JHH 5.5, 3-H
min,pyran), 4.86 (1H, dd, 2JHF 48.1, 
3JHH 7.3, H-3
min,furan), 
4.85 (1H, dd, 2JHF 49.7, 
3JHH 4.8, 3-H
maj,pyran), 4.75 (1H, d, 3JHH 5.4, 6-H
min,furan), 4.72 (1H, 
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d, 2JHF 44.2, H-3
maj,furan), 4.65 (1H, d, 3JHH 6.1, 6-H
maj,pyran), 4.57 (1H, d, 3JHH 7.2, 6-
Hmin,pyran), 4.46 (1H, dd, 3JHF 18.7, 
3JHH 5.6, 4-H
min,pyran), 4.39 (1H, dd, 3JHF 22.4, 
3JHH 3.7, 4-
Hmaj,pyran), 4.30 (1H, td, 3JHH 7.7 and 3.4, H-4
min,furan), 4.18 (1H, dd, 3JHH 8.6 and 5.1, H-
5min,furan), 4.12 (1H, t, 3JHH 5.0, 5-H
maj,pyran), 4.02 (1H, app. t, 3JHH 7.4, H-4
maj,furan), 3.96 
(1H, m, H-5maj,furan), 3.95 (1H, dd, 3JHH 6.4, 5-H
min,pyran); 3.43-2.99 (4H, m, 2 × propyl 1-
H2), 1.58-1.37 (4H, m, 2 × propyl 2-H2), 0.99-0.66 (6H, m, 2 × propyl 3-H3); F (395 MHz, 
D2O) –190.5 (d, 
2JHF 50.5, 
3JHF 24.0, 3-F
maj,pyran), –194.5 (d, 2JHF 43.7, 
3JHF 4.7, 3-F
maj,furan), 
–201.9 (d, 2JHF 53.1, 
3JHF 18.7, 3-F
min,pyran), –207.4 (d, 2JHF 48.5, 
3JHF 10.1, 3-F
min,furan);* 
m/z (ES) [MH]+ 324.1 (100 % [MH]+). The fluorinated sialic acid analogues 23b was 
observed as a mixture of equilibrium ring forms (pyranose and furanose), which both 
existed as major and minor anomers with a ratio of 37:29:23:11 major pyranose to 
minor pyranose to major furanose to minor furanose. The ratio of equilibrium species 
was determined by analysis of the 395 MHz 19F NMR spectrum and the reaction was 
seen to be completely diastereoselective under the reaction conditions to within the 
sensitivity of 395 MHz 19F NMR spectroscopy. The 1H NMR spectrum was indirectly 
obtained by 19F/1H HSQC-TOCSY. 
 
                                                     
*
 Superscript abbreviations in NMR characterisation data: maj and min refer to the 
major and minor anomer and pyran and furan refers to the pyranose and furanose ring 
form. When unspecified, assume that the peak described both of the anomers/ring 
forms. 
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(3R,4S,5S,6R)-7-(dipropylamino)-3-fluoro-4,5,6-trihydroxy-2,7-dioxoheptanoate 23b NMR spectra 
1H/19F-HSQC-TOCSY Extracted 1H-NMR spectra 
 
 
 
 
 
–190.5 
–194.5 
–201.9 
–207.4 
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(3R,4S,5S,6R) and (3R,4R,5S,6R)-7-(dipropylamino)-3-fluoro-4,5,6-trihydroxy-2,7-
dioxoheptanoate 23  
 
Reaction was carried out as described in the general experimental Section 6.3.1 using 
the alkene 24 (314 mg, 1.58 mmol), sodium fluoropyruuvate (202 mg, 1.58 mmol) and 
the NAL E192N variant. A mixture of products 23b and 23a (171 mg, 33%, 23b:23a 
60:40) were isolated by ion exchange as a yellow glass. Purification by reverse-phase 
HPLC: 23a retention time 28.7 min, 23b retention time 31.0 min. The spectroscopic 
data for the product 23b was found to be identical to that described previously. The 
product 23a was observed as 92:8 mixture of anomers of a pyranose ring and the 
spectroscopic data is presented as follows; H (500 MHz, D2O) 4.78 (1H, dd, 
2JHF 49.9 
3JHH 3.4, 3-H), 4.57 (1H, d, 
3JHH 9.2, 6-H), 3.97-3.90 (1H, m, 4-H), 3.88 (1H, t, 
3JHH 9.7, 5-
H), 3.42-3.08 (4H, m, 2 × propyl 1-H2), 1.58-1.38 (4H, m, 2 × propyl 2-H2), 0.78-0.68 (6H, 
m, 2 × propyl 3-H3);  F (395 MHz, D2O) –206.0 (1F, dd, 
2JHF 49.9, 
3JHF 32.5, 3-F
maj), –
216.8 (1F, dd, 2JHF  51.4 , 
3JHF 32.8, 3-F
min); m/z (ES) [MH]+ 324.1 (100 % [MH]+). The 
ratio of diastereomers was determined by analysis of the 395 MHz 19F NMR spectrum.  
(3R,4S,5R,6S)-7-(dipropylamino)-3-fluoro-4,5,6-trihydroxy-2,7-dioxoheptanoate ent-
23d 
 
Reaction was carried out as described in the general experimental Section 6.3.1 using 
the alkene ent-24 (202 mg, 0.93 mmol, supplied by Thomas Harman), sodium 
fluoropyruvate (119 mg, 0.93 mmol) and the NAL E192N/T167V/S208V variant. The 
crude product was isolated by ion exchange to give the fluorinated sialic acid analogue 
ent-23d (155 mg, 52%, d.r. >98:<2) as a colourless glass. One pyranose ring form was 
observes as a single anomer. H (500 MHz, D2O) 4.62 (1H, d, 
3JHH 9.7, 6-H), 4.60 (1H, dd, 
2JHF 49.3 
3JHH 9.3, 3-H), 3.95 (1H, dt, 
3JHF 13.3 
3JHH 9.4, 4-H), 3.78 (1H, t, 
3JHH 9.5, 5-H), 
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3.42-3.12 (4H, m, 2 ×  propyl 1-H2), 1.60-1.39 (4H, m, 2 × propyl 2-H2), 0.83-0.70 (6H, 
m, 2 × propyl 3-H3);  F (395 MHz, D2O) –199.8 (1F, dd, 
2JHF 49.3, 
3JHF 13.3, 3-F); m/z (ES) 
[MH]+ 324.1 (100 % [MH]+). The reaction was found to be completely 
diastereoselective under the conditions described to within the sensitivity of 395 MHz 
19F NMR spectroscopy. 
(3R,4R,5S,6R)-7-(dipropylamino)-5-acetamido-3-fluoro-4,6-dihydroxy-2,7-
dioxoheptanoate 57a 
 
Reaction was carried out as described in the general experimental Section 6.3.1 using 
the alkene 25 (100 mg, 0.3 mmol), sodium fluoropyruuvate (38 mg, 0.3 mmol) and the 
NAL E192N variant. The product was purified first by Dowex® ion exchange then mass 
directed HPLC to give the fluorinated sialic acid analogue 57 (5.3 mg, 5%, 57a:57d 
98:2). The product 57a was observed as mixture of anomers in a 97:3 ratio. H (500 
MHz; D2O) 4.95 (1H, dd, 
2JHF 49.0, 
3JHH 2.1, 3-H
min), 4.90 (1H, dd, 2JHF 49.2, 
3JHH 2.2, 3-
Hmaj), 4.84 (1H, d, 3JHH 10.0, 6-H
min), 4.83 (1H, d, 3JHH 10.0, 6-H
maj), 4.23 (1H, t, 3JHH 9.9, 
5-Hmaj), 4.22 (1H, t, 3JHH 9.9, 5-H
min), 4.17 (1H, ddd, 3JHF 29.1, 
3JHH 10.9 and 2.2, 4-H
min), 
4.16 (1H, ddd, 3JHF 29.1, 
3JHH 10.9 and 2.2, 4-H
maj), 3.55-3.43 (2H, m, propyl 1-H2,A), 
3.25-3.18 (1H, m, propyl 1-HC), 3.00-2.93 (1H, m, propyl 1-HD), 1.91 (3H, s, acetyl-CH3), 
1.62-1.51 (2H, m, propyl 2-HA), 1.48-1.39 (2H, m, propyl 2-HA), 0.81 (3H, t, 
3JHH 7.7, 
propyl 3-HA), 0.78 (3H, t, 
3JHH 7.5, propyl 3-HA); C (75 MHz; D2O) 174.1 (acetyl-C=O), 
170.8 (1-C), 168.7 (7-C), 95.4 (2-C), 89.7 (d, 1JCF 178.0, 3-C), 67.6 (6-C), 66.9 (5-C), 66.8 
(4-C), 49.8 (propyl 1-CA), 48.7 (propyl 1-CB), 22.1 (propyl 2-CA), 21.9 (acetyl-CH3), 20.1 
(propyl 2-CA), 10.5 (propyl 3-CB), 10.3 (propyl 3-CA); F (296 MHz, D2O) –199.2 (1F, dd,
 
2JHF 49.3, 
3JHF 10.4, 3-F
3S4R), –207.8 (1F, dd, 2JHF 49.0, 
3JHF 29.1, 3-F
3R4R,min), –218.5 (1F, 
dd, 2JHF 50.2, 
3JHF 28.8, 3-F
3R4R,maj).* HRMS Found: 363.1565, [M]-H+ requires 363.1573. 
                                                     
*
 Superscript abbreviations in NMR characterisation data: “3R4R” and “3S4R” refer to 
the 57a and 57d diastereomers respectively. “maj” and “min” refer to the major and  
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The ratio of anomers and diastereomers was determined by analysis of the 296 MHz 
19F NMR. The product 57d could not be characterised by 1H NMR or 13C NMR so the 
configuration was predicted by correlation of the 19F NMR spectroscopy data with a 
related product (product ent-23d) with the same relative configuration. 
 
                                                                                                                                                           
minor anomer. When unspecified, assume that the peak described both of the 
anomers. Only 296 MHz 19F NMR has been used to characterise the product 57d. 
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Appendix 1 - Synthesis of non-commercial available reagents 
A1.1 Synthesis of primary amine used in the Petasis reaction 
 The primary amine 36a, used in the Petasis reaction described in Section 2.3.2, 
was synthesised by melting 4-4’-dimethoxybenophenone 58 with ammonium formate, 
followed by the addition of magnesium chloride and formamide. Refluxing in acidic 
methanol and recrystalisation from diethyl ether gave the primary amine 36a in a 47% 
overall yield (Scheme A:1).92 
 
Scheme A:1 - Synthesis of the primary amine 36a used in the optimisation of the Petasis reaction 
described in Section 2.3.2. 
A1.2 Optimisation of the synthesis of the selanyl acid chloride 
 Synthesis of the selanyl acid chloride used in the Claisen reaction of the lactone 
33 (Section 2.3.3) was synthesised in three steps from the chloro ester 59. The 
conversion of the chloro ester 59 to the selanyl-ether 60 was carried out as described 
in the literature by reaction with the phenylselanide dimer under reducing conditions 
to give the intermediate ester 60 in an 86% yield.93 However, hydrolysis of the ester 
resulted in cleavage of the carbon-selenium bond under the conditions described in 
the literature.93 The reaction conditions were optimised with the aid of analytical 
HPLC, which was calibrated with a sample of known concentration of the selanyl-ether 
60, the acid 61 and diphenyldiselanide 62. By using the analytical HPLC it was possible 
to follow the reactions under various conditions and monitor the rate of conversion to 
the acid and the rate of decomposition. Table A:1 show the conditions screened along 
with both the conversion to the acid 61 after 90 minutes and the decomposition to 
diphenyldiselanide 62 after 90 minutes. Chart A:1 shows the plots of disappearance of 
selanyl-ether 60 (blue) and the appearance of the acid 61 (green) and 
diphenyldiselanide 62 (red). Increased reaction temperatures and higher 
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concentrations of ester 60 resulted in a faster rate of decomposition. However, very 
low concentrations of ester 60 also favoured decomposition. The optimised condition 
for synthesis of the acid 61 were found to be potassium hydroxide in 1:1 THF–water 
with the temperature careful controlled in a jacketed vessel at 0 °C to prevent the 
elimination of diphenyldiselenide 62. 
Table A:1 - Optimisation of the conditions for the hydrolysis of ester 60 
 
Reaction 
number 
Solvent 
Temp 
/°C 
Initial 
concentration 
of 60/mg ml
-1 
Conversion to 
61 after 90 
min % 
Decomposition to 
62 after 90 min % 
1 
EtOH–water 
(98:2) 
0 4 1.5 30.0 
2 
Water–THF 
(1:1) 
22 46.3 55.2 27.7 
3 
Water–THF 
(1:1) 
22 23.1 51.4 24.7 
4 
Water–THF 
(1:1) 
0 46.3 43.5 19.8 
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― selenyl-ether 60                 ― acid 61                        ― diphenyldiselanide 62 
Chart A:1 - Optimisation of the hydrolysis of the ester 60 to give the acid 62, while reducing the 
decomposition to diphenyldiselanide. 
Scheme A:2 outlines the optimised conditions for the synthesis of the acid chloride 48. 
The acid chloride 48 was synthesised by reacting the acid 61 with oxalyl chloride, 
followed by distillation.94 The acid choride 48 was used immediately in the Claisen 
reaction with the lactone 33 (Section 2.3.3) 
 
Scheme A:2 - Synthesis of non-commercially available reaction partners of  the lactone 33 1) 
Optimised synthesis of the selanyl acid chloride 48 used in the Claisen reaction with the lactone 33. 
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A1.3 Synthesis of the imine used in the Mannich reaction 
 The imine 34 (see Section 2.3.3) was synthesised in a single step from 
cinnamaldehyde 63 and p-nitrobenzene sulfonamide 64 in refluxing toluene with 
catalytic boron trifluoride etherate. The resulting imine 34 was triturated from ethyl 
acetate and isolated in 78% yield (Scheme A:3). 
 
Scheme A:3 - Synthesis of non-commercially available reaction partners of the lactone 33 2) Synthesis 
of the imine 34 used in the Mannich reaction with lactone 33 
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Appendix 2 - Unsuccessful reduction of enol products 50 and 51 
 Section 2.3.3 described a selection of examples of reactions of the lactone 33. 
One example was a Claisen-type condensation between the lactone 33 and two 
different acid chlorides 47 and 48. Literature precedent80 suggested that it ought to be 
possible to reduce the resulting enol 50/51 to the alcohol (Scheme A:4), however no 
suitable conditions were found. 
 
Scheme A:4 - Unsuccessful reduction of Claisen-type condensation products 50 and 51. 
Table A:2 outlines all of the reduction conditions attempted for enol 50 and 51. Entry 1 
and Entry 9 replicate the conditions described in the literature.80 In the case of the 
enol 50 (Entry 1), the conjugate reduction product was formed in a complex mixture 
with starting material and decomposition by-products. In the case of the enol 51 (Entry 
9), a complex mixture with no evidence of enol reduction was formed.  
Entries 2-8 are all variations of Luche conditions, where CeCl3 is used as an additive 
with sodium borohydride as the reducing agent. Luche conditions are known to 
selectively reduce ,-unsaturated ketones to give allyl alcohols.95 In all cases either a 
complex mixture was formed or no reaction was observed. Some success was 
observed when the reaction was cooled to –78 °C (Entries 6 and 7), but still only a very 
small quantity of product was observed and the purity was very poor. It was predicted 
that the reason for difficulty in carrying out the reduction was that, even under Luche 
conditions, conjugate reduction was taking place.  
In an attempt to avoid the problem of conjugate reduction, the enol 51 was 
synthesised with the intention that the selanyl-ether functional group would act as a 
"masked" double bond, which would allow the required double bond functionality to 
be revealed later.82 However, the enol 51 also proved difficult to reduce and in most 
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cases, no reaction took place or a complex mixture was observed. This was most likely 
due to the decomposition. 
  
Appendix 
 
164 
 
Table A:2 - Reduction conditions attempted for enol-lactones 50 and 51 
Entry Enol 
Reducing 
agenta-e and 
additives 
Solvent Temp /°C 
Time 
/h 
Comments 
1 50 NBu4BH4
a CH2Cl2 0 to RT 5.25 
Conjugate 
reduction 
product 
observedf 
2 50 
NaBH4
b, 
CeCl3.7H2O 
MeOH–CH2Cl2 
1:1 
– 70 to – 30 1 
Complex 
mixturef 
3 50 K-selectrideb THF – 78 120 No reactiong 
4 50 
NaBH4
c, 
CeCl3.7H2O 
MeOH RT 0.6 
No product 
observedh 
5 50 
NaBH4
c, 
CeCl3.7H2O 
MeOH 
– 70 to  
– 30 
4 
No product 
observedf 
6 50 
NaBH4
d, 
CeCl3.7H2O 
MeOH – 78 4 
<4% yield of 
impure 
productf 
7 50 
NaBH4
a, 
CeCl3.7H2O 
MeOH – 78 to RT 72 
<10% yield of 
impure 
productf 
8 50 
NBu4BH4
a, 
CeCl3.7H2O 
MeOH–CH2Cl2 
1:1 
– 78 72 
Complex 
mixturef 
9 51 NBu4BH4
a CH2Cl2 0 to RT 5.25 
Complex 
mixturef 
10 51 NaBH4
e EtOH 0 3 
Complex 
mixturef 
11 51 
NaBH4
d, 
CeCl3.7H2O 
MeOH – 78 - No reactiong 
12 51 NBu4BH4
d CH2Cl2 0 5 No reaction
g 
13 51 NBu4BH4
d CH2Cl2 – 78 4 No reaction
f 
14 51 NaBH4
d EtOH – 78 1.5 No reactionf 
15 51 NaBH4
d EtOH 0 1.5 
Complex 
mixturef 
a-e) Equivalents of reducing agent used. Where an additive was used, equimolar equivalents of reducing 
agent and additive were used. a) 2.2 equivalents b) 1.5 equivalents c) 1.0 equivalents d) 1.1 equivalents 
e) 2.0 equivalents f) By analysing the 
1
H-NMR spectrum of the crude product g) No reaction was 
observed by TLC h) No product observed by LC-MS 
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Appendix 3 - Monitoring the reaction between aldehyde variants and 
pyruvate by 500 MHz 1H NMR spectroscopy 
 The following Section is the data used to determine the kinetic selectivity of the 
NAL variants towards AHOB and pyruvate (Section 3.1.4). The NAL variant-catalysed 
reactions between AHOB and pyruvate were monitored by 500 MHz 1H NMR 
spectroscopy. Chart A:2 represents the calculated conversions at each time point in 
the NAL E192N-catalysed reaction of AHOB and pyruvate. 
 
Chart A:2 - Representation of the percentage disappearance of AHOB and appearance of diastereomer 
55a calculated from the relative integrals measured at a series of time points in the NAL E192N-
catalysed reaction of AHOB and pyruvate. 
The conversion in the NAL E192N-catalysed reaction of ent-AHOB and pyruvate was 
made more challenging because the reaction was very slow, so the decomposition of 
ent-AHOB made it difficult to reliably measurement the reaction rate. A series of time 
points from the 500 MHz 1H NMR spectroscopy time-course is shown in Figure A:1, and 
it is possible to see that the peaks corresponding to AHOB are decomposing faster 
than the peaks corresponding to product ent-55b (highlighted in green) are appearing. 
After ozonolysis of the aldehyde precursor ent-25, there is always a small amount of 
benzaldehyde remaining, which does not participate in the enzyme reaction. The peaks 
corresponding to benzaldehyde are highlighted in purple. The contaminating 
benzaldehyde was therefore used as an internal standard in order to estimate the loss 
of AHOB due to decomposition. The full time-course data is shown in Chart A:3. 
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Figure A:1 - Illustration of the change in intensity of the peaks corresponding to ent-AHOB (red) and 
the product of the NAL E192N-catalysted reaction ent-55b (green) over time by 500 MHz 
1
H NMR 
spectroscopy.  Decomposition was estimated by measuring by using the peaks corresponding to the 
benzaldehyde by-product (purple) as an internal standard. 
 
 
Chart A:3 - Representation of the percentage disappearance of ent-AHOB and appearance of 
diastereomer ent-55b calculated from the relative integrals measured at a series of time points in the 
NAL E192N-catalysed reaction of ent-AHOB and pyruvate. 
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Appendix 4 - 19F NMR spectra from the reactions of AHOB and 
fluoropyruvate 
 The following Section shows the 296 MHz 19F NMR used in the characterisation 
of the products of the NAL-catalysed reaction of AHOB and fluoropyruvate (Section 
4.2.2). Figure A:2 shows the 296 MHz 19F NMR spectra of the products after ion 
exchange purification for the reaction between  AHOB and fluoropyruvate catalysed by 
NAL E192N (Figure A:2a) and E192N/T167G (Figure A:2b) and between ent-AHOB and 
fluoropyruvate catalysed by NAL E192N (Figure A:2c) and E192N/T167G (Figure A:2d). 
The first thing to note is that, as would be expected from the conversions recorded in 
Section 4.2.1 (Table 4.2), most of the samples are very weak and the fluoropyruvate 
peak (highlighted in orange) dwarfs the doublet of doublets (highlighted in red or 
green) and the reaction products are difficult to distinguish from the noise. Across the 
four reactions, two different products are identified, one characterised by a peak at  –
207.9 ppm (red) and a second at –200.9 ppm (green). Upon HPLC purification, a peak 
at –218.5 ppm was identified, which corresponded to the minor anomer of the product 
characterised by the peak at –207.9 ppm. 
 
Figure A:2 – 296 MHz 
19
F NMR of products isolated after ion exchange of the reactions between 
fluoropyruvate and AHOB/ent-AHOB catalysed by the NAL variants. The conversion is low in all cases 
so there is a large peak for fluoropyruvate (highlighted orange) however two different diastereomers 
were identified as diagnostic doublet of doublets at –207.9 ppm (red) and –200.9 ppm (green) a) 
AHOB catalysed by E192N b) AHOB catalysed by E192N/T167G c) ent-AHOB catalysed by E192N d) ent-
AHOB catalysed by E192N/T167G 
b) 
c) 
d) 
a) 
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Appendix 5 - Monitoring the reaction between aldehyde variants and 
fluoropyruvate by 296 MHz 19F NMR spectroscopy 
 The following Sections show the data used to calculate initial rates of NAL-
catalysed reaction of the aldehyde analogues and fluoropyruvate and the 
diastereoselectivity of the enzymes. (For the initial rates see Section 4.4.1 and for the 
calculated kinetic ratios see Section 4.4.2) The NAL variant-catalysed reactions 
between the aldehyde analogues and fluoropyruvate were monitored by 296 MHz 19F 
NMR spectroscopy. The main body of the thesis shows two examples of the plots of 
conversion of fluoropyruvate and appearance of fluorinated product 23 and 57 over 
time. These plots were used to calculate the initial rates of reaction and the kinetic 
ratio of products. The following plots show the conversions calculated from relative 
integrals for all of the combinations of NAL variants and aldehyde analogues.  
A5.1 Reactions of AHOB/ent-AHOB and fluoropyruvate 
 
Chart A:4 - A plot of the appearance of the products of the NAL E192N -catalysed reaction of AHOB 
and fluoropyruvate and the disappearance of fluoropyruvate. The conversion was calculated from the 
relative integrals of the 296 MHz 
19
F NMR spectra recorded at suitable time intervals. a) 
Representation of the percentage disappearance of fluoropyruvate and the percentage appearance of 
product over the full reaction time. b) Linear points of the disappearance of fluoropyruvate. The initial 
gradient was used to calculate the initial rate of the reaction. In this reaction, the fluoropyruvate is 
disappearing at a rate of 30 nmol/min. 
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Chart A:5 - A plot of the appearance of the product of the NAL E192N/T167G-catalysed reaction of 
AHOB and fluoropyruvate and the disappearance of fluoropyruvate. The conversion was calculated 
from the relative integrals of the 296 MHz 
19
F NMR spectra recorded at suitable time intervals. a) 
Representation of the percentage disappearance of fluoropyruvate and the percentage appearance of 
product over the full reaction time. b) Linear points of the disappearance of fluoropyruvate. The initial 
gradient was used to calculate the initial rate of the reaction. In this reaction, the fluoropyruvate is 
disappearing at a rate of 1.8 nmol/min. 
 
Chart A:6 - A plot of the appearance of the products of the NAL E192N-catalysed reaction of ent-AHOB 
and fluoropyruvate and the disappearance of fluoropyruvate. The conversion was calculated from the 
relative integrals of the 296 MHz 
19
F NMR spectra recorded at suitable time intervals. a) 
Representation of the percentage disappearance of fluoropyruvate and the percentage appearance of 
product over the full reaction time. b) Linear points of the disappearance of fluoropyruvate. The initial 
gradient was used to calculate the initial rate of the reaction. In this reaction, the fluoropyruvate is 
disappearing at a rate of 1.9 nmol/min. 
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Chart A:7 - A plot of the appearance of the product of the NAL E192N/T167G-catalysed reaction of 
ent-AHOB and fluoropyruvate and the disappearance of fluoropyruvate. The conversion was 
calculated from the relative integrals of the 296 MHz 
19
F NMR spectra recorded at suitable time 
intervals. a) Representation of the percentage disappearance of fluoropyruvate and the percentage 
appearance of product over the full reaction time. b) Linear points of the disappearance of 
fluoropyruvate. The initial gradient was used to calculate the initial rate of the reaction. In this reaction, 
the fluoropyruvate is disappearing at a rate of 1.5 nmol/min. 
A5.2 Reaction of DHOB/ent-DHOB and fluoropyruvate 
  
Chart A:8 - A plot of the appearance of the products of the NAL E192N-catalysed reaction of DHOB and 
fluoropyruvate and the disappearance of fluoropyruvate. The conversion was calculated from the 
relative integrals of the 296 MHz 
19
F NMR spectra recorded at suitable time intervals. a) 
Representation of the percentage disappearance of fluoropyruvate and the percentage appearance of 
product over the full reaction time. b) Linear points of the disappearance of fluoropyruvate. The initial 
gradient was used to calculate the initial rate of the reaction. In this reaction, the fluoropyruvate is 
disappearing at a rate of >263 nmol/min. 
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Chart A:9 - A plot of the appearance of the product of the NAL E192N/T167V/S208V-catalysed 
reaction of DHOB and fluoropyruvate and the disappearance of fluoropyruvate. The conversion was 
calculated from the relative integrals of the 296 MHz 
19
F NMR spectra recorded at suitable time 
intervals. a) Representation of the percentage disappearance of fluoropyruvate and the percentage 
appearance of product over the full reaction time. b) Linear points of the disappearance of 
fluoropyruvate. The initial gradient was used to calculate the initial rate of the reaction. In this reaction, 
the fluoropyruvate is disappearing at a rate of 28 nmol/min. 
 
Chart A:10 - A plot of the appearance of the products of the NAL E192N/T167G-catalysed reaction of 
DHOB and fluoropyruvate and the disappearance of fluoropyruvate. The conversion was calculated 
from the relative integrals of the 296 MHz 
19
F NMR spectra recorded at suitable time intervals. a) 
Representation of the percentage disappearance of fluoropyruvate and the percentage appearance of 
product over the full reaction time. b) Linear points of the disappearance of fluoropyruvate. The initial 
gradient was used to calculate the initial rate of the reaction. In this reaction, the fluoropyruvate is 
disappearing at a rate of 3.2 nmol/min. 
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Chart A:11 - A plot of the appearance of the products of the NAL E192N-catalysed reaction of ent-
DHOB and fluoropyruvate and the disappearance of fluoropyruvate. The conversion was calculated 
from the relative integrals of the 296 MHz 
19
F NMR spectra recorded at suitable time intervals. a) 
Representation of the percentage disappearance of fluoropyruvate and the percentage appearance of 
product over the full reaction time. b) Linear points of the disappearance of fluoropyruvate. The initial 
gradient was used to calculate the initial rate of the reaction. In this reaction, the fluoropyruvate is 
disappearing at a rate of 13 nmol/min. 
 
Chart A:12 - A plot of the appearance of the product of the NAL E192N/T167V/S208V-catalysed 
reaction of ent-DHOB and fluoropyruvate and the disappearance of fluoropyruvate. The conversion 
was calculated from the relative integrals of the 296 MHz 
19
F NMR spectra recorded at suitable time 
intervals. a) Representation of the percentage disappearance of fluoropyruvate and the percentage 
appearance of product over the full reaction time. b) Linear points of the disappearance of 
fluoropyruvate. The initial gradient was used to calculate the initial rate of the reaction. In this reaction, 
the fluoropyruvate is disappearing at a rate of 0.76 nmol/min. 
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Chart A:13 - A plot of the appearance of the products of the NAL E192N/T167G-catalysed reaction of 
ent-DHOB and fluoropyruvate and the disappearance of fluoropyruvate. The conversion was 
calculated from the relative integrals of the 296 MHz 
19
F NMR spectra recorded at suitable time 
intervals. a) Representation of the percentage disappearance of fluoropyruvate and the percentage 
appearance of product over the full reaction time. b) Linear points of the disappearance of 
fluoropyruvate. The initial gradient was used to calculate the initial rate of the reaction. In this reaction, 
the fluoropyruvate is disappearing at a rate of 6.2 nmol/min. 
A5.3 Rate of NAL E192N catalysed reaction: Pyruvate Vs fluoropyruvate 
 Chart A:14a and b show the data used to compare the initial rate of the NAL 
E192N-catalysed reaction of AHOB and pyruvate with AHOB and fluoropyruvate (see 
Section 4.4.1). 
 
 
Chart A:14 - Comparison of the rate of reaction of AHOB with pyruvate Vs fluoropyruvate. AHOB was 
the limiting reagent. a) Linear points of the disappearance of AHOB in the reaction with pyruvate. The 
initial gradient was used to calculate the initial rate of the reaction. In this reaction, the AHOB 
disappeared at a rate of 161 nmol/min. b) Linear points of the disappearance of AHOB in the reaction 
with fluoropyruvate. The initial gradient was used to calculate the initial rate of the reaction. In this 
reaction, the AHOB disappeared at a rate of 22 nmol/min. 
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